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Abstract

The Nova paraneoplastic antigens are neuron-specific RNA-binding proteins that are

essential for neuronal viability and participate in the control of alternative splicing. In
this study, the yeast two-hybrid system is used to isolate Nova-interacting proteins. A
novel RNA-binding protein named brPTB is identified, that is closely related to the polypyrimidine tract-binding protein (PTB) and is ennched in the brain at the mRNA and
protein levels. brPTB interacts with Nova proteins in vitro and in vivo. Splicing assays
in kidney epithelial cell lines show that brPTB inhibits the effect of Noval in the
inclusion of alternatively spliced exons in two target pre-mRNAs: glycine receptor oc2
subunit (GlyRa2) and GABAA receptor y2 subunit (GABAARy2). Furthermore, in the
case of GlyRoc2, brPTB binds to a site adjacent to Noval in a 90 nucleotide fragment of
intronic RNA upstream of the alternatively spliced exon, but with an affinity more than
10-fold lower than Noval. When the brPTB site is mutated, binding is abolished and the
inhibitory effect on Noval-dependent exon inclusion disappears. In addition, it is shown
that the inhibitory effect of brPTB on Noval splicing does not occur in neuronal cells.
These results suggest that brPTB is a tissue-restricted RNA-binding protein that
specifically interacts with Nova and inhibits its ability to activate exon selection. Nova
proteins localize in distinct nuclear foci, but fail to co-localize with any of the known
proteins that occupy sub-nuclear structural domains. Both endogenous and transfected
brPTB and Nova proteins co-localize in these foci in neuroblastoma cell lines but not in
non-neuronal cells. A model is proposed whereby alternative splicing and nuclear
localization mediated by Nova and brPTB are linked as the consequence of their protein
interaction in specific cell types.
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Introduction

R N A - b i n d i n g proteins a n d R N A - b i n d i n g

domains

In eukaryotic cells, the path of RNA molecules, from DNA transcribed in the nucleus
protein synthesized in the cytoplasm, encompasses a multitude of steps, including

capping, polyadenylation, splicing, editing, nuclear export, localization, translat

stability and, finally, turnover. The existence of these separate biochemical stages in the
metabolism of RNA provides the distinct opportunity for regulation at different levels
and with broad outcomes. The effectors of these processes are RNA-binding proteins

(RBPs) consisting of diverse families of proteins that mediate their actions through direct
binding to RNA targets.
Amino acid sequence analysis and phylogenetic data on a plethora of existing
RBPs has resulted in the recognition of numerous sub-families, each with distinct
features most notable of which are the various RNA-binding motifs (Burd and Dreyfuss,
1994). More recently, structural information has provided concrete evidence for the
mechanism of RNA binding and its implications in the proposed functional role of these
proteins. A review of RBP families and their most prominent members is therefore
warranted before any detailed examination of their cellular function. An informative way
to categorize these RBPs is based on the amino acid sequence similarities and predicted
functional significance of their RNA-binding motifs (Burd and Dreyfuss, 1994; Varani
and Nagai, 1998).

R R M - t y p e RNA-binding proteins
Newly transcribed RNAs in the nucleus, called heterogeneous nuclear RNAs (hnRNAs),
exist in complexes with proteins, forming heterogeneous nuclear ribonudeoprotein
particles (hnRNPs; Dreyfuss et al., 1993; Matums et al., 1993). Early studies have

identified a number of proteins involved in the assembly of these particles and ha
determined, albeit crudely, the sequence requirements for their RNA binding by

ribohomopolymer binding assays (Dreyfuss et al., 1988; Swanson and Dreyfuss, 1988).

Comparisons of the sequence and overall structural organization of different hnRNP
proteins established common motifs that were hypothesized to bind RNA, and led to

identification of the RNA Recognition Motif (RRM) that, since then, has been recogn

as the most prevalent RNA-binding domain (Swanson et al.. 1987; Siomi and Dreyfuss
1997).
The RRM motif was first identified as a repeated domain in the sequence of the
hnRNP protein Al and the polyadenylate binding protein (PABP; Adam et al., 1986).

Each RRM (also called RNP, for ribonudeoprotein motif) consists of 80-100 amino ac

that comprises of a secondary structure with two a helices and four (3 sheets sepa

loops of variable length (Nagai et al., 1990). The amino acid sequences of the firs

third fi sheets constitute the most conserved elements of the RRM and have been na
RNP2 and RNP1, respectively (Burd and Dreyfuss, 1994; see also Figure 2). The
remainder of the RRM domain contains many conserved hydrophobic residues that are

thought to mediate proper folding but play a small role in actual RNA-binding spec

(Birney et al., 1993). The sequence specificity of RNA-binding and, ultimately, the
function of these RRM-containing proteins have been shown to differ substantially

below). Nevertheless, the evolutionary conservation of several residues and their similar
secondary structure suggested that these proteins share common folding properties
similar protein-RNA interface features (Kenan et al., 1991).
When the crystal structure of the first RRM domain was solved (from the splicing
factor U1A snRNP), it was found that the highly conserved RNP2 and RNP1 segments

form (3 sheets that lie juxtaposed and exposed to solvent, available for contact w
molecules (Nagai et al., 1990). Co-crystal structures of the RRM domains from this
other proteins bound to RNAs (with or without intramolecular base-pairing) have

determined the specific characteristics of RNA-protein recognition and have provid

insight into the mechanism guiding sequence-specific RNA binding (Oubridge et al.,
1994; Handa etal., 1999).
From these and other studies, a general model for RNA binding by RRM domains

has emerged that involves a general recognition of the RNA molecule by the charged
aromatic amino acid residues of RNP2 and RNP1, and a more sequence-specific
interaction with the variable loop element before RNP1 (Burd and Dreyfuss, 1994).

Added complexity and specificity can be achieved when proteins that contain more t

one RRM domains (such as the translation regulator PABP, the splicing factor U2AF6
and the hnRNP protein Al) require their contiguous RNA-binding motifs for proper
recognition of the same RNA molecule (Nietfeld et al. 1990; Zamore et al., 1992).

Interestingly, other proteins that contain multiple RRMs may bind distinct RNA tar

with each RNA-binding domain and perform different functions. For instance, the U1
snRNP protein has been shown through UV cross-linking and immunoprecipitation

assays to bind to the Ul snRNA through the first RRM and to a polyadenylation signa

via its second R R M , suggesting that it plays a role in both splicing and polyadenylation
and perhaps providing a link between the two processes (Lutz and Alwine, 1994).
Members of the RRM-type of RBPs include a variety of proteins with different
RNA-binding specificities and diverse functions in RNA metabolism. For example,
hnRNP Al contains two RRM domains and has been shown to influence 5' splice site
selection in vitro (Ge and Manley, 1990; Mayeda and Krainer, 1992). Furthermore, it

been suggested to compete with another RRM-containing protein (ASF/SF2) that favor
more proximal 5' splice sites. These results have also been verified by in vivo

overexpression/RT-PCR splicing assays (Caceres et al., 1994). Sex lethal is a Droso

RRM-containing protein that activates a female-specific splicing switch by binding

polypyrimidine tract upstream of a repressed exon. This is hypothesized to block t

binding of another RRM protein, U2AF65, an essential splicing activator that is no
to activate the lower-affinity female-specific site (Valcarcel et al., 1993).
The hnRNP I protein, also known as the polypyrimidine tract binding protein

(PTB), was first identified as a protein that binds the polypyrimidine tract that t

precedes 3' splice sites and was later recognized as an hnRNP protein (Garcia-Blan

al., 1989; Ghetti et al., 1992). It contains four RRM domains that have been sugges
play different roles in RNA-binding, dimerization and splicing repression (Gil et
1991; Patton et al., 1991; reviewed in Wagner and Garcia-Blanco, 2001). In vitro

splicing assays and immunodepletion experiments have implicated PTB in the control

alternative splicing through a mechanism that possibly involves repression of 3' s

sites via competition with U2AF65 for binding, similar to the one proposed for Sex
(Singh et al., 1995; reviewed in Valcarcel and Gebauer, 1997; see below).

Thus, the interplay between various R R M proteins on specific R N A targets and,

more importantly, the competition for binding of these RNAs has been shown to regu

various processes such as alternative splicing and polyadenylation. This underscor
biological significance of the RRM domain in regulating RNA-binding and mediating

control of RNA processing and calls for more studies that would clearly identify t

specific sequence requirements and understand the pathophysiology behind disorders
involving mutations in RRM proteins that result in aberrant RNA-binding.

KH-type RNA-binding proteins

The first member of this sub-family of RNA-binding proteins was the hnRNP K protei
whose amino acid sequence revealed three similar domains that were named KH motifs
(for hnRNP K Homology; Siomi et al., 1993a). Sequence comparisons identified other

KH-type RBPs including the product of the fragile X/mental retardation gene (FMRP;

Siomi et al., 1993b), the paraneoplastic neurologic disease antigens Noval and Nova
(Buckanovich et al., 1993; Yang et al., 1998) and the yeast splicing factor Mer-1

(Nandabalan et al., 1993). Most of these proteins have one to three KH motifs conta
approximately 70 amino acids each, with a core Gly-X-X-Gly sequence, conserved

hydrophobic residues and a variable loop (Burd and Dreyfuss, 1994). Until recently,
for the function of KH-containing proteins in the binding of RNA had been limited

consisted mostly of in vitro assays (Siomi et al., 1993b; Ashley et al., 1993; Sio
1994; Buckanovich et al., 1996; Yang et al., 1998). Mutations of highly conserved

residues in the KH domain impaired RNA binding ability in vitro (Siomi et al., 199
have been associated with human disease (De Boulle et al., 1993).

Structural data on the K H motif came first from N M R spectroscopy studies on the

vigilin protein and showed the globular KH domain to contain three antiparallel (3

on one face backed by three a helices on the other (Musco et al., 1996). Further an
of the structures of single KH domains from FMRP, Nova, and hnRNP K, supported the

conclusion that the RNA-protein interface is most likely located in the loop betwe

first two helices that contains the strongly conserved tetrapeptide GXXG (Musco et

1997; Baber et al., 1999; Lewis et al., 1999). Definitive evidence for this interac

provided by the co-crystal structure of the third Nova2 KH domain in association w

single stem loop RNA molecule (Lewis et al., 2000). These studies showed that, unli

the (3 sheet of the RRM motif, it is an a/(3 platform flanked by the invariant GXX

of the KH domain that recognizes and binds RNA. Furthermore, the residue mutated i
severe form of fragile X/mental retardation disease is predicted by this analysis

the hydrophobicity of the cc/(3 platform and alter the RNA-binding properties of F
Even though they are not as numerous as the RRM-type RBPs, KH-containing

proteins have often been implicated in human disease. Whether their function is ab
by mutations (FMRP) or autoantibodies (Nova), there has been evidence linking the

specific defect in RNA-binding of these proteins to the underlying disease (De Bou

al., 1993; Siomi et al., 1994; Buckanovich et al., 1996; Jensen et al, 2000a; Lewi
2000). KH-type proteins must therefore play significant roles in RNA biology that,

perturbed in some human disorders, can cause distinct phenotypes that are likely t
provide more clues for the biological function of these proteins in vivo.
Sequence similarities between the KH-type RBP Sam68 (see below), a female
germ-cell specific tumor-suppressor gene from Caenorhabditis elegans named GLD-1

and the shrimp G R P 3 3 protein prompted the identification of the K H motif-containing
GSG (for GRP33/Sam68/GLD-1) super-domain (Jones and Schedl, 1995). Mutations in

a conserved residue of the KH domain in GSG eliminate the tumor-supressor function
GLD-1 and implicate RNA-binding in this function as well as in oogenesis for which

GLD-1 is essential (Jonas and Schedl, 1995). The cloning of the cDNA for the splici

factor SF1 identified it as another member of this sub-family of KH-type RBPs (Arn
et al., 1996).

Other RNA-binding domains

Several other motifs have been described that can bind RNA and characterize additi

sub-families of RBPs. The arginine-rich motif (ARM) is, as the name suggests, a sho
domain (10-20 amino acids) of mostly arginine residues (Burd and Dreyfuss, 1994).
Described mostly in viral proteins, this domain is thought to recognize RNA as an

(Lazinski et al., 1989; Tan et al., 1993). The role of arginine residues in these p

RNA interactions is thought to be two-fold: increasing the non-specific binding of
through their positive charges while forming specific hydrogen bonds. The HIV Rev
Tat proteins which contain this domain, have been implicated in diverse functions
concerning RNA metabolism such as trans-activation of transcription and export of

unspliced viral RNA (Malim et al., 1989). Surprisingly, the same motif can assume t
different conformations during RNA-binding: the Rev ARM binds as an a helix while

Tat peptide is a fi sheet and yet they both penetrate the major groove of their re
RNA targets (Puglisi et al., 1995).

The R G G box is an RNA-binding domain that was first described in h n R N P U

(Kiledjian and Dreyfuss, 1992; Puglisi et al., 1992). It contains 20 to 25 amino ac
closely spaced arginine-glycine-glycine (RGG) repeats that assume a (3 spiral

conformation (Ghisolfi et al., 1992; Burd and Dreyfuss, 1994). Curiously, most prot
that contain an RGG box (such as hnRNP Al, FMRP, and Nucleolin) also contain other
RNA-binding domains, most often an RRM motif, suggesting that perhaps the RGG box

is not involved in sequence specific RNA binding, but rather facilitates binding b
domains.
Other RNA-binding domains that have been described, but not yet adequately
characterized, include the double stranded RNA-binding motif (DSRM), the zinc
finger/knuckle motif and the cold shock domain (Burd and Dreyfuss, 1994; Siomi and
Dreyfuss, 1997). Recently, it has also been proposed that the homeodomain of the

Drosophila protein bicoid, usually involved in DNA binding and transcription activ
can also bind the 3' UTR of RNA and act as a translational repressor (Dubnau and
Struhl, 1996).

Functions of RNA-binding proteins

As mentioned above, the processing of RNA molecules, from heterogeneous nuclear
RNAs (hnRNAs or pre-mRNAs) to mature transcripts ready to be translated in the

ribosome, involves many steps that are regulated by RBPs. The effect of RBPs on the
metabolism of RNA is a consequence of direct binding which can alter the RNA's

structural conformation, affect its localization pattern, facilitate or impede its
to regulatory molecules (including other proteins), and control its stability.

Consequently, R B P s play a crucial role in the post-transcriptional control of gene

expression and thus of cellular processes in general (Siomi and Dreyfuss, 1997). Ma

of the varied functions of RBPs are coupled to preceding or subsequent events in t
lifecycle of the RNA molecule hence providing continuity and an added opportunity

control and regulation. The functions of RBPs will be reviewed here in a sequentia
manner, as the transcript moves from the nucleus to the cytoplasm.

Transcription and mRNA processing

Even though the general transcription factors are DNA-binding proteins, the role p

by RNA-binding proteins in the control of transcription (and especially its termin

significant and has been mostly recognized through the study of retroviral RBPs an

function in trans-activation and anti-termination (e.g. the HIV protein Tat and th
N protein, respectively; Rees et al., 1996; Su et al., 1997; Legault et al., 1998).

analysis of the function of these RBPs is not in the scope of this thesis. Instead

of RBP functions in transcription will be limited to recent intriguing findings th

evidence for the spatial, temporal and functional linkage of transcription to mRNA

processing (collectively defined as the biochemical reactions that transform newly

synthesized pre-mRNA to mature mRNA, including 5' capping, splicing of introns and
cleavage and polyadenylation).
Reports have shown that mRNA processing in vivo occurs co-transcriptionally

(Beyer and Osheim, 1988; Bauren et al., 1998). The carboxy-terminal domain (CTD) of
RNA polymerase II (RNA pol II) has emerged as a leading candidate in mediating the

coupling of all three major mRNA processing reactions to transcription, but the pr
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mechanism for this remains unknown (McCracken et al., 1997). In agreement with this

hypothesis, the CTD domain contains tandem peptide repeats that have been proposed

mediate protein-protein interactions and are the regulatory target of phosphorylat
kinases (Komarnitsky et al., 2000; Schroeder et al., 2000).
The activation of the c-Src kinase during mitosis has been shown to result in the

interaction with and phosphorylation of a KH-type RBP named Sam68 (Fumagalli et al
1994; Taylor and Shalloway, 1994). Sam68 is a functional homologue of the HIV
protein Rev since dominant negative mutants of Sam68 block the transactivation of
containing transcripts (Rev Response Element; Reddy et al., 1999). Phosphorylation
Sam68 abolishes its RNA-binding activity and its ability to act as a Rev homologue

(Derry et al., 2000). This suggests that the regulation of transcription and pre-mR

processing is linked to signal transduction pathways, highlighting the fact that R

binding proteins may play crucial roles in the response of the cell to external st
The mRNA processing reactions (capping, splicing and polyadenylation) are

thought to be interdependent, but all three can be separately stimulated by the RN

CTD (Fong and Bentley, 2001). Furthermore, different domains of the CTD and specifi

interactions with other RBPs or protein complexes (e.g. the cleavage stimulation f

CstF) have been proposed to be responsible for this effect (Fong and Bentley, 2001)
a domain of RNA pol II, the CTD is uniquely positioned during RNA transcription to

mediate and couple subsequent processing reactions (Roberts et al., 1998). Apart fr

physical location in the protein complex on transcribed RNA, its ability to intera

other proteins enables the CTD to attract other RBPs, such as members of the SR fa
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of splicing factors, to transcription sites in the nucleus where splicing can occur
concurrently (Yuryev et al., 1996; Misteli and Spector, 1999; see below).
The enzymatic complexes regulating and affecting 5' capping and 3' cleavage and

polyadenylation of the pre-mRNA are quite large and involve many factors including
many RNA-binding proteins that are not going to be discussed here (for reviews see

Colgan and Manley, 1997; Bentley, 1998; Shatkin and Manley, 2000). It is of interes

note however, that accumulating data on these processes point to the interpretatio
they do not occur independently of each other and are instead part of an intricate
regulation pattern that ensures the correct processing of the mRNA on all fronts.

example, splicing factors have also been shown to regulate polyadenylation by bind

intronic enhancer sequences (Lou et al., 1996; Lou et al., 1998). Furthermore, RBPs
involved in processing seem to be involved in the regulation of other, downstream

in the metabolism of mRNA. The proteins mediating 5' capping are members of the cap

binding complex (CBC) and have recently been shown to interact with the nuclear po

of the translation initiation factor eIF4G and possibly facilitate the transfer of

the cytoplasm for efficient translation (Fortes et al., 2000; McKendrick et al., 200

Splicing

Given that splicing concerns the physical joining of discontinuous exons in eukary

pre-mRNAs, it is expected that RNA-binding proteins will play a crucial role in th
process. The basal splicing machinery of the cell consists of small nuclear RNAs

(snRNAs) and a number of associated RBPs resulting in the formation of five comple
(Ul, U2, U4, U5 and U6 snRNPs, for small nuclear ribonudeoprotein particles) that
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associate with newly synthesized pre-mRNA in an orderly way (reviewed in Staley and
Guthrie, 1998; Smith and Valcarcel, 2000; Hastings and Krainer, 2001). In addition,

spliceosome, as it is assembled on the new transcript, will eventually contain a m
of non-snRNP RBPs such as members of the SR family (named for their common motif

rich in serine and arginine residues), the U2 auxiliary factor (U2AF), splicing fac
(SF1; also known as branch point binding protein, BBP) and others.
Despite the fact that introns can vary substantially in size and sequence, they
maintain several conserved motifs, most prominently dinucleotides in their 5' and

(splice donor and acceptor site, respectively), a polypyrimidine tract, and a branc

adenosine. These motifs are recognized by components of the splicing machinery: Ul
snRNP binds to the 5' splice site; U2AF is composed of two subunits, U2AF65 and

U2AF35, which bind to the polypyrimidine tract and the 3' splice site, respectively
binds to the branch point adenosine. This forms the commitment complex which, with
the addition of U2 snRNP and ATP, becomes the pre-spliceosome. In turn, the
recognition of the pre-spliceosome by the U5-U4-U6 tri-snRNP results, after

rearrangements, in the fully-competent spliceosome. Furthermore, the interaction of

snRNP with the 5' splice site enhances the recognition and splicing of the upstrea

splice site, a result that helped establish the idea behind the exon definition mo

(Robberson et al., 1990; Kuo et al., 1991). This model predicts that protein-protei

interactions across the exon facilitate the recognition of the upstream 3' and dow
5' splice sites and help "define" the exon and mark it for splicing.
Alternative (as opposed to constitutive) splicing concerns exons that for various
reasons are not always included in the mature mRNA. These include cassette exons,
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mutually exclusive exons and the existence of alternative splice sites (5' or 3').
Particular intronic or exonic sequences besides the splice sites (which in these cases
usually have weak consensus) are the cis-acting elements responsible for the regulation of
alternative splicing and can function positively (enhancers) or negatively (repressors or
silencers). These sequences have been therefore defined as intronic or exonic splicing
enhancers or silencers (ISE, ESE, ISS and ESS). Successful splicing events in this case
are characterized by the interplay of general splicing factors (e.g. snRNPs) with specific
regulatory factors (trans-acting enhancer or repressor factors of splicing).
The SR proteins are a family of RBPs that have been grouped together by their
similarity in structural organization and function in pre-mRNA splicing (Zahler et al.,
1992, Fu, 1995). They contain at least one RRM-type RNA-binding domain in their Nterminus and a C-terminal domain characterized by multiple arginine-serine dipeptide
repeats (RS domain) which can mediate protein-protein interactions. The role of the SR
proteins is proposed to be in forming bridging interactions between essential splicing
factors recognizing different splice sites. For example, the SR proteins ASF/SF2 and
SC35 interact with Ul snRNP and the heterodimer U2AF through their RS domains,
thereby forming a complex across the intron and facilitating the necessary
transesterification reactions that will join the two exons (Wu and Maniatis, 1993; Kohtz
et al., 1994). In concert with this, SR protein-bound enhancer elements can activate weak
3' splice sites supporting a role for SR proteins in stabilizing U2AF binding (Buvoli et
al., 1997). Alternatively, the interactions between SR proteins (perhaps recruited by
specific exonic elements) and splice site-bound general factors could favor exon
definition (Smith and Valcarcel, 2000; see above).
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Thus, S R proteins can function both as general splicing factors (in bridging splice
sites; see above) and as specific splicing enhancers (dependent on the binding of ciselements). For example, ASF/SF2 has been described to function as a sequence-specific
splicing enhancer in alternative splicing (see below), but also as a general factor in
constitutive splicing as the interaction with Ul snRNP and U2AF would imply. The
latter is supported by experiments in a tet-inducible system that have shown ASF/SF2 to
be an essential gene for cell viability and required for alternative splicing, that cannot
rescued by other SR proteins (Wang et al., 1996). Importantly, the RS domain is
responsible for mediating the enhancer sequence-dependent splicing function of SR
proteins and it can be uncoupled from its function in general splicing (Graveley and
Maniatis, 1998). In conclusion, SR proteins can play important roles in alternative
splicing as they are recruited to regulated exons directly by intronic or exonic ciselements (Lavigueur et al., 1993; Sun et al., 1993) or indirectly through protein-protein
interactions with other trans-acting splicing factors (Lynch and Maniatis, 1996).
In this way, they can also function in the coupling of splicing to previous
biochemical processes in RNA metabolism (e.g. transcription). The SR proteins
ASF/SF2 and 9G8 stimulate splicing of an exon in the fibronectin pre-mRNA in vivo,
through an exonic splicing enhancer sequence (ESE). Significantly, promoter swapping
experiments and mutational analysis of cis-acting elements have shown that successful
splicing regulation by SR proteins in this transcript depends on promoter structure,
suggesting that interactions between RNA pol II and the promoter could regulate
alternative splicing by influencing SR proteins (Cramer et al., 1999). Recent experiments
have shed light on the molecular mechanism behind this coupling by showing that a
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novel transcriptional activator termed p52 co-localizes with ASF/SF2 and their
interaction modulates alternative splicing in vitro and in vivo (Ge et al., 1998).
Another large family of RBPs that has been implicated in the regulation of

alternative splicing are the hnRNP proteins. This hypothesis is consistent with th

specific localization in the nucleus and their early binding of hnRNA. The hnRNP A

protein was found to have the opposite effect from ASF/SF2 in 5' splice site selec

vivo (Caceres et al., 1994). However, this was the result of overexpression experim

with minigene constructs in HeLa cells and the two proteins were not tested in the
experiment to prove antagonism. Nevertheless, they are in agreement with previous
vitro mRNA splicing data where addition of hnRNP Al counteracts the specific
stimulatory effect of ASF/SF2 (Mayeda and Krainer, 1992; Sun et al., 1993). The

positive effect of ASF/SF2 is thought to be mediated by stimulating the binding of

snRNP to the 5' splice site (Eperon et al., 1993). While the molecular mechanism of

splicing repression by hnRNP Al has not been elucidated, it has been shown to depe
on splicing silencer sequences (Blanchette and Chabot, 1999; Caputi et al., 1999;

Gatto-Konczak et al., 1999). In these studies, in vivo splicing assays using minige

constructs from a variety of alternatively spliced transcripts were performed in s

cell lines and the effect of co-transfected hnRNP Al and/or ASF/SF2 was measured b
RT-PCR. Recent data support a similar interaction between hnRNP Al and ASF/SF2 in

the control of 3' splice site choice as well (Bai et al., 1999). The effect on both

splice site choice by these proteins lends support to the exon definition model an

suggests a role for constitutive splicing factors in the regulation of tissue-spec
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alternative splicing, perhaps through slight variations in their levels or modifications (see
below).
The hnRNP I/PTB protein binds CU-rich sequences in the polypyrimidine tract of

introns and was for that reason hypothesized to be involved in constitutive splici

(Garcia-Blanco et al., 1989; Patton et al., 1991). However, since then, PTB has been
found to mediate the repression of exon inclusion through the binding of intronic

silencer (ISS) elements in a number of alternatively spliced mRNAs including c-src
(Chan and Black, 1997), o-actinin (Southby et al, 1999), fibroblast growth factor

receptor-2 (Carstens et al., 2000), a-tropomyosin (Gooding et al., 1998), (3-tropomy

(Mulligan et al., 1992), and GABAA receptor y2 subunit (Ashiya and Grabowski, 1997).
Mutation of the PTB sites within the different ISSs results in reduced binding in
reverses exon repression in vivo (Gooding et al., 1994; Perez et al., 1997a; Chou
2000). Furthermore, PTB-mediated exon repression can be abolished in vitro by
competition with exogenous RNAs (Ashiya and Grabowski, 1997; Chan and Black,

1997) or immunodepletion of PTB (Southby et al, 1999; Chou et al., 2000) and can be
reconstituted by adding back recombinant PTB protein (Ashiya and Grabowski, 1997;
Southby et al, 1999; Chou et al., 2000).
These results, together with its presumed ubiquitous protein distribution, have
prompted the suggestion that PTB is a universal splicing repressor of weak exons
(Wagner and Garcia-Blanco, 2001). However, PTB is unlikely to act independently of

other factors in exon repression for a number of reasons. First, PTB is expressed i

tissues where some of these exons are included in the mature mRNA. The first event
which a role for PTB in splicing repression was described involved an exon in the
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tropomyosin pre-mRNA (Mulligan et al, 1992) that was not included in non-muscle cells

(Guo et al., 1991). Second, the presence of exogenous PTB binding sites is not suff

for the repression of heterologous exons (Lin and Patton, 1995; Perez et al., 1997
Gooding et al., 1998). Third, additional silencer sequences and presumably the

corresponding trans-acting RBP factors are required for the repression of some exo
(Del Gatto-Konczak et al., 1999; Carstens et al., 2000). In addition, PTB has been

isolated as part of a multi-protein complex associated with some of these regulato

elements (Chan and Black, 1997; Grossman et al., 1998; Chou et al., 2000). Finally,

data exists for the requirement of PTB as a splicing repressor in vivo. Studies of
out and transgenic mice (if viable) will likely settle the questions of where PTB

actually expressed, whether it is an essential splicing factor, and what its exact
the splicing of a number of target pre-mRNAs.
The observation that the intronic binding sites for PTB sometimes overlap those

for U2AF (Lin et al., 1995; Singh et al., 1995) has resulted in the hypothesis tha

mechanism of splicing repression by PTB involves the competition for binding sites
general splicing factors, similar to the mechanism described for the action of the
Drosophila RBP Sex lethal (Valcarcel et al., 1993; see below). However, in most of

regulated exons mentioned above there is no such overlap. Another proposed model f

the function of PTB takes advantage of the existence of multiple PTB sites in most

these transcripts, often located in both introns flanking the repressed exon (Pere

1997a; Southby et al., 1999; Carstens et al, 2000; Chou et al., 2000). Together wit

evidence that PTB can multimerize (Perez et al., 1997b; Oh et al., 1998), it is pla

that RNA-binding on specific ISSs and protein-protein interactions of multiple PTB
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monomers across the exon results in its repression, possibly by inhibiting the accessibility

of ESEs (Chou et al., 2000; Wagner and Garcia-Blanco, 2001). A similar model has be

proposed for the action of hnRNP Al on the regulation of an alternative exon in it

transcript (Blanchette and Chabot, 1999). In this case however, binding of multiple

in the flanking introns by hnRNP Al results in the inclusion of the downstream exon
A novel family of RBPs that have recently been described to regulate cell-specific
alternative splicing are the CELF protein (CUG-BP and ETR-3-Like Factors; Ladd et
2001). CUG-binding protein (CUG-BP), the first homologue of this family, was

identified due to its ability to bind CUG-triplet repeats and was recognized to ha
similar structure to hnRNP proteins (Timchenko et al., 1996). CUG-BP has been
implicated in the pathogenesis of myotonic dystrophy (DM), possibly through its
regulation of the alternative splicing of the cardiac troponin T (cTNT) pre-mRNA

(Philips et al., 1998). Elav-Type RNA binding protein 3 (ETR-3) is similar in seque
to CUG-BP and has also been shown to bind CUG-triplet repeats (Lu et al., 1999).
Members of the CELF family have been shown to be differentially expressed in a

developmentally-regulated way and to bind in vitro to muscle-specific splicing enh
sequences (MSEs) present in introns flanking an alternatively spliced exon in the

pre-mRNA (Ladd et al., 2001). Furthermore, it was shown that members of this family
activate MSE-dependent exon inclusion in a cTNT minigene in vivo, and that ETR-3

protein expression differences during development correlate with exon usage in cTN

splicing. This suggests that the regulation of alternative splicing could be the r

competition and/or synergism among many RBPs that function as a complex (see below)
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Overall, S R

and h n R N P proteins have been k n o w n to act as enhancers or

repressors in the alternative splicing of numerous transcripts, including their own in some
autoregulatory cases (Smith and Valcarcel, 2000). The exact mechanism for this function
is not known but has been proposed to be mediated by the binding of specific cis-acting
RNA elements (exonic or intronic splicing enhancers and silencers). Future studies
including biochemical and structural analyses of the RNA-protein interactions,
determination of the domains involved in protein-protein interactions and genetic studies
(such as knock-out and transgenic animals) will help elucidate the molecular mechanism,
the likely RNA targets and the biological significance of the function of RBPs in splicing.
One of the most significant consequences of alternative splicing in the biology of
a complex organism is the spatial and temporal differential processing of mRNAs and the
generation thereby of diverse proteins from the same transcript. This would suggest that
the regulation of alternative splicing can be modulated in a tissue- or developmental
stage-specific manner. Several mechanisms have been proposed to this effect including
variations in the relative concentrations of general splicing factors, post-translational
modifications, and the existence of tissue-, cell- or developmentally-restricted splicing
factors (Lopez, 1998). One of the best studied examples of this is the hnRNP-like protein
Sex lethal (Sxl) of Drosophila melanogaster that is exclusively present in female flies and
sets up a sex-specific splicing pattern of downstream effector genes in the sexual
determination pathway (Boggs et al., 1987; Bell et al., 1988). In the case of the
transformer mRNA, this is thought to occur by the binding of Sxl to the polypyrimidine
tract thus forcing the essential splicing factor U2AF to activate a lower-affinity female
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specific splice site (Valcarcel et al., 1993). A similar mechanism has been proposed for
the splicing inhibition by Sxl of another RNA target, msl-2 (Merendino et al., 1999).
This result, together with the proposed competition between U2AF65 and PTB on
the polypyrimidine tract, would suggest that a fundamental characteristic of alternative

splicing is the existence of splice sites with different affinities and that the regulation
exon inclusion or exclusion depends on binding competition by splicing factors. The
default splicing pattern would then be one that includes exons with the strongest splice
sites (i.e. closest to the consensus for binding by the general splicing factors). On the
other hand, the inclusion of regulated exons (which contain weaker splice sites) will
depend on the balance between enhancer and silencer elements and the actions of the
RBPs that recognize them. This interplay between multiple RBP factors would require
the formation of large complexes on the pre-mRNA in a regulated and orderly way.
Examples of this can be found in the study of alternative splicing in Drosophila
development where the P-element transposase is only produced in germline cells (Laski

et al., 1986). In somatic cells, the retention of intron 3 in the P element transcript resul
in the production of a transposase inhibitor and requires a regulatory sequence in exon 3
(an exonic splicing silencer, ESS). This ESS is bound by numerous trans-acting factors
including Ul snRNP, the Drosophila hnRNP protein hrp48, and the P-element somatic
inhibitor protein (PSI), a germ-cell specific KH-type RBP that functions in splicing
repression (Siebel et al., 1992; Siebel et al., 1994). The mechanism of splicing inhibition
in this complex is not clear but is known to involve an interaction between PSI and Ul
snRNP (Labourier et al., 2001). Furthermore, transcriptional repression of the P-element
promoter results in reduced splicing of intron 3 in a negative autoregulatory feedback

loop, and provides additional evidence for the coupling of splicing to transcription
(Roche et al., 1995).
Another example is provided by the Drosophila gene doublesex where femalespecific processing of exon 4 requires a purine-rich exonic splicing enhancer (ESE). This
element is bound by an RBP complex including the RS domain-containing Tra and Tra2
proteins, and the Drosophila homologues of the SR proteins ASF/SF2 and 9G8
(Heinrichs and Baker, 1995; Lynch and Maniatis, 1996). The assembly of this complex
is cooperative, depends on Tra and is thought to activate splicing by stabilizing U2AF
binding. Two human homologues of Tra-2 have been identified as the first mammalian
RBPs that are sequence-specific splicing activators without being essential splicing
factors since HeLa cell extracts that are lacking Tra2 proteins can still function in
constitutive splicing (Tacke et al., 1998).
It is likely though that the paradigms established in Drosophila concerning
alternative splicing are not entirely accurate in mammals where the existence of all-ornothing splicing patterns is improbable due to the complexity, number and density of
cells. Instead, models that have been proposed to explain the mechanism of splicing
regulation in mammalian cells suggest that an interplay is at work between positive and
negative trans-acting factors and between constitutive splicing factors and sequence- or
cell- specific proteins. This results in promoting exon selection (positive regulation) or
repressing exon inclusion (negative regulation) according to the relative levels of the
factors involved which interact with the pre-mRNA as a complex (Grabowski, 1998).
These complexes are a testament to the intricate balance of power between competing
signals that will eventually lead to the inclusion or not of an exon.

~>~>

T h e reasons for the existence of such a complex system of regulation in
mammalian cells are multifaceted (Smith and Valcarcel, 2000). First, there are more
genes and splicing events (compared to lower organisms) that would require many single,
dedicated, transcript-specific splicing factors. In the model described above, the same
proteins in different combinations can achieve regulation of multiple transcripts. Second,
since there are various RBPs involved in splicing regulation, there will have to be
numerous binding sites for them on the pre-RNA. In some cases, these cis-acting signals
are not the best consensus sequences for binding and only provide for weak protein-RNA
interactions. Consequently, recognition of the RNA and successful splicing will depend
on the interaction of multiple elements and allows for an additional layer of control.
Finally, multiple splicing components provide for sensitive responses to varying levels of
any of these proteins as well as to the signals that regulate them and produce differences
in splicing patterns that are better attuned to environmental cues or developmental
requirements.
However, even in this model, the requirement for some tissue- or cell-specific

factors remains, whether it is in the actual splicing regulator that exists in different le
among various cell types or in other regulatory proteins (such as kinases) that in turn

affect the post-translational state of splicing factors. A lot of work on alternative splic
regulation in mammalian systems has concentrated in the nervous system where the
functional diversification of proteins resulting from differential mRNA processing can be
advantageous in allowing neurons to transmit and respond to specific electrical or
chemical signals and mediate information processing through plasticity, learning and
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memory. The regulation of alternative splicing by R B P s in the nervous system will be
discussed below.

Nuclear export and shuttling
In addition to altering its structural characteristics, RBPs can provide the RNA
with localization and targeting signals. Many RBPs have been shown to move between
the nucleus and the cytoplasm through the nuclear pore complex (NPC) and it is

reasonable to assume that this transport affects the localization pattern of bound

(reviewed in Nigg, 1997; Nakielny and Dreyfuss, 1999). The fact that different clas
RNA molecules use distinct and non-overlapping mechanisms of nuclear export

(Jarmolowski et al., 1994), together with the existence of several components of th

that seem to recognize assorted signals on the transported proteins (Yang et al., 2

suggest that there are multiple layers of control and varying degrees of regulatio
nuclear transport of protein and mRNA. For both nuclear import and export, many

peptide signal sequences and their corresponding receptors have been identified, a

molecular mechanisms for the trafficking of proteins (many of them RBPs) through t
NPC have begun to be elucidated.
The best characterized peptide sequence guiding nuclear import (called a nuclear
localization signal, NLS), is the mono- or bi-partite NLS that contains one or two

of positively charged residues, respectively (exemplified by the SV40 T antigen an
nucleoplasmin sequences). NLS sequences are bound by the importin (3 receptor that

mediates nuclear entry (Gorlich et al., 1995). Other co-factors (such as RanGDP; se
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below) are required for this process and many more signal-receptor pairs have been
identified (Nakielny and Dreyfuss, 1999).
Since mRNA is synthesized in the nucleus and must be transported out to the
cytoplasm, a more in-depth review of some relevant facts about the nuclear export
mRNA ribonudeoprotein particles (mRNPs) and the shuttling of some RBPs is

appropriate. Various elements on the mRNA seem to influence its nuclear export. Th

5' cap and the associated cap-binding complex (CBC) proteins stimulate nuclear exp

(Izaurralde et al., 1992; Visa et al., 1996). Also, the existence of unspliced intro
mRNA prevents its export into the cytoplasm and provides a mechanism for the
prevention of improper translation of unprocessed messages (see below). The most

important mediator of mRNA export, however, is the binding by RBPs and the specific
peptide signals that they contain.
Insight into the function of RBPs in the export of RNA came from the study of
retroviruses and their regulated export of intron-containing RNAs. The HIV protein

was the first RNA-binding protein identified to contain a nuclear export signal (N

consisting of a short leucine-rich peptide (Fischer et al., 1995; Wen et al., 1995)
was found to interact with and use the cellular receptor protein Crml for nuclear
(Fornerod et al., 1997; Stade et al., 1997). Crml associates with RanGTP (a small,
bound GTPase providing energy for the transport) and the NES sequence in a manner

is inhibited by leptomycin B in vivo, an observation that has allowed the identifi
many Rev-like RNA export pathways (reviewed in Izaurralde and Mattaj, 1995; Stutz
and Rosbash, 1998).

The discovery that some h n R N P proteins are able to shuttle between the nucleus

and the cytoplasm has led to the identification of shuttling or bi-directional sig
provide information for both the import and export of the protein (Pinol-Roma and

Dreyfuss, 1992; Michael et al, 1995; Lee et al., 1996b). Specifically, the hnRNP pr
Al has been shown to shuttle due to the M9 sequence, a domain of approximately 40

amino acids rich in glycine and aromatic residues (Michael et al., 1995). The recep

the M9 signal has been identified as the transportin protein, which differs from t

importin family of receptors and acts independently of the import pathway of prote
containing classical NLS sequences (Pollard et al., 1996).
The hnRNP K protein also contains a bi-directional shuttling domain that has
been named KNS (for hnRNP K Nuclear Shuttling domain) and differs from both the
classical NLS domain and the M9 sequence of hnRNP Al (Michael et al., 1997). This

domain has been shown, in competition assays with saturating levels of other signa

mediate the import of hnRNP K protein independently of importin or transportin pro

and suggests that the KNS domain utilizes a novel import pathway, one that possibl
does not require soluble factors.
Surprisingly, the hnRNP K protein also contains a classic bi-partite NLS

sequence, whose deletion does not impair nuclear localization since the KNS is abl

mediate nuclear import (Michael et al., 1997). In contrast to hnRNP Al, the nuclear

localization of full length hnRNP K protein does not depend on RNA pol II function.

However, when a construct of the hnRNP K protein lacking the classic NLS domain was

tested in the presence of actinomycin D (a transcription inhibitor), it was found t
nuclear import became transcription dependent (Michael et al., 1997). This would
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suggest a role for h n R N P proteins A l and K in the nuclear export of m R N A s and the
existence of a waste-preventing mechanism blocking their re-import into the nucleus in
the absence of active transcription. In the latter case, the function of hnRNP proteins in
the nucleus mediating RNA export would not be required, but their contribution to
cytoplasmic processes could be useful (see below).
These results, together with previous observations on the shuttling of other
hnRNPs suggest different functions for these proteins according to their localization and
shuttling patterns (Pinol-Roma and Dreyfuss, 1991). hnRNPs C and U do not shuttle and
localize to the nucleus by virtue of their classic NLS in a transcription-independent
manner. hnRNPs Al and I lack a classic NLS, shuttle, and their nuclear localization is
transcription-dependent. Finally, hnRNP K contains both a classic NLS and a shuttling
domain and its nuclear localization becomes transcription-dependent only in the absence
of the classic NLS. This organization hints at the existence of at least two distinct
pathways for the nuclear import of these proteins that are under differential regulation
depending on whether the proteins function in the export of mRNA. The prediction
would be that hnRNPs Al and I mediate RNA export while hnRNP K does so only when
its classical NLS domain is masked, perhaps through protein-protein interactions or other
associations that result in conformational changes in the protein.
It is becoming increasingly clear, therefore, that the export of mRNA from the
nucleus, where it was synthesized and processed, to the cytoplasm, where it will be
translated, is mediated by RBPs and occurs in ribonudeoprotein (RNP) complexes. The
fact that these RBPs have other functions in the metabolism of RNA, strongly suggests
that nuclear transport does not occur independently of preceding events or without
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influencing subsequent ones. Earlier evidence had shown that the nucleocytoplasmic

transport of some RBPs depends on transcription, as described above (Pinol-Roma an
Dreyfuss, 1991; Pinol-Roma and Dreyfuss, 1992; Lee et al., 1996b).
More recent reports have linked mRNA nuclear export to pre-mRNA processing

(Huang and Carmichael, 1996; Luo and Reed, 1999; Brodsky and Silver, 2000; Daneholt

2001) and splicing (Kataoka et al, 2000; Le Hir et al, 2000a; Zhou et al., 2000; Hu

and Steitz, 2001; Le Hir et al., 2001; Luo et al., 2001). In the latter case, RBPs p

means by which to imprint newly spliced transcripts with information that will fol

them to the cytoplasm and perhaps regulate downstream events (Matsumoto et al. 199

Le Hir et al., 2000b). These RBPs that associate with mRNAs only as a consequence o
splicing events have been referred to as the exon-exon junction complex (EJC) and

include the splicing factors SRml60, DEK and RNPS1, the shuttling protein Y14 and t
mRNA export factor REF/Aly.
Since some of the hnRNP proteins that play a role in splicing are also able to

shuttle between the nucleus and the cytoplasm (e.g. hnRNP Al), it has been suggest
that they may associate with RNA transcripts during earlier biochemical steps and

or guide it through subsequent events (Kataoka et al, 2000; Mili et al., 2001; Zen
et al., 2001). While the two modes of RNA export (via an hnRNP particle or through
splicing-dependent mRNP complexes with EJC proteins) may seem to be competing,

they can provide additional regulatory steps for the cell or allow it to identify,

example, intron-containing transcripts and retain them in the nucleus (reviewed in

and Magni, 2001). In support of this model, protein components of the EJC have been
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found to belong to or interact with proteins of the m R N A surveillance machinery (Kim et
al., 2001b; Lykke-Andersen et al., 2001; see below).
Other proteins that have been shown to shuttle and could mediate the export of
bound mRNAs include the HuR protein (also known as HuA), a member of the Hu
family of paraneoplastic antigens (Fan and Steitz, 1998a). The shuttling domain of

which lacks a classical NLS, was named HNS (for HuR Nuclear Shuttling sequence) an

exhibits similarity to the M9 domain of hnRNP Al in its sequence composition as we
in regulating nuclear localization in a transcription-dependent fashion. However,

function of HuR and the proposed consequence of its shuttling most likely concerns
role in the stability of bound mRNA and will be discussed later. Another RBP that
been shown to shuttle between the nucleus and the cytoplasm and has been proposed

be involved in the regulation of RNA stability is the hnRNP D protein (Loflin et a

1999). In addition, members of the SR family of proteins have been shown to shuttle

could play a role in the export of RNA (Caceres et al., 1998). Indeed, two shuttlin
proteins have been shown recently to promote the nuclear export of intronless RNA

could provide the necessary adaptor function for molecules not exposed to EJC prot
or bound by hnRNP protein during splicing (Huang and Steitz, 2001).

Cytoplasmic localization

The specific localization of mRNAs in the cytoplasm is an important means by which

achieve spatially regulated protein synthesis and its aftermaths during developmen
beyond (Bandziulis et al., 1989; Curtis et al, 1995; Mohr and Richter, 2001). Most

signals on the mRNA controlling cytoplasmic localization have been identified in t
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untranslated region (UTR) and are bound by R B P s that mediate this process (Jansen,
2001). Significantly, many of these RBPs have been found to belong to the hnRNP

family and support a general model for the function of these proteins in the cytop

after binding their mRNA targets in the nucleus and mediating their export (Shyu a
Wilkinson, 2000).
Several mechanisms for the localization of mRNA in the cytoplasm have been

described. Active transport of bound mRNA by RBPs, presumably through interactions

with motor proteins and the cytoskeleton, occurs with some hnRNP proteins suggesti

that the cytoplasmic localization of transcripts depends on previous, nuclear event

These processes have been visualized in Drosophila embryos and Xenopus oocytes, an

the proteins involved show homology to mammalian hnRNPs (Cote et al., 1999; Lall e
al., 1999). Other mechanisms for the selective cytoplasmic localization of mRNA
involve localized stabilization of transcripts (as observed for a Drosophila heat

protein; Bashirullah et al., 1999) or local trapping of the RNA (as is the case wi
Staufen RBP anchoring bicoid message in Drosophila; St. Johnston et al., 1991).
The zipcode-binding protein (ZBP-1) is an interesting RBP that contains RNA-

binding domains of both the KH- and RRM-type (Ross et al., 1997). It was identified
a protein that binds the 3'UTR "zipcode" element of (3-actin mRNA that had been
previously shown to be necessary for the correct cytoplasmic localization of that
transcript in fibroblasts (Kislauskis et al., 1994). ZBP-1 is highly homologous to
protein named Vera (or VglRBP), which has been shown to mediate the specific

cytoplasmic localization of a Xenopus mRNA (Deshler et al., 1997; Havin et al., 199

While Vera is thought to mediate the association of its bound mRNA with microtubul
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(Elisha et al., 1995), the localization of (3-actin m R N A by ZBP-1 requires the presence of

microfilaments (Sundell and Singer, 1991; Ross et al., 1997). Furthermore, the sequ

elements recognized by these two homologous proteins on the 3' UTR of their respec

mRNA targets are radically different. These results suggest that proteins of simil
sequence and structure can not only have different binding specificities but also

different cellular machineries to achieve cytoplasmic localization. A related func

RBPs concerns the facilitation of local actin polymerization, possibly in order to
anchor mRNA molecules in the cytoplasm (Zhao et al., 2001).
Functional associations between the endoplasmic reticulum (ER) and RBPs

responsible for the cytoplasmic localization of mRNA have also been described. The

Xenopus protein Vera co-fractionates with ER membranes (Deshler et al., 1997), whil
the mammalian homologue of the Drosophila RBP Staufen co-localizes with the rough

ER and co-sediments with polysomes (Marion et al., 1999). Furthermore, specific sig
on RNAs are responsible for their localization to specific ER subdomains (Choi et
2000). These results suggest that cytoplasmic localization of mRNA and association
particular sub-domains of the ER is mediated by RBPs and specifies an important

mechanism for the eventual localization of proteins to different cellular compartm
In contrast to nuclear transport, little is know about the exact molecular
mechanism and the peptide signals responsible for the movement and the correct
cytoplasmic localization of RBPs and, consequently, of bound mRNAs. Recently,

functional interactions between RBPs and motor proteins that could mediate movemen

across the cytoskeleton have been reported. Deletion of the microtubule motor prot

kinesin I in Drosophila germ cells results in the specific absence of Staufen prot
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oskar m R N A (whose cytoplasmic localization is dependent on intact Staufen function)

from the posterior pole (Brendza et al., 2000). Importantly, this mislocalization w
corrected by the addition of a wild type kinesin I transgene.
The RBP Swallow is required for the correct localization of the bicoid mRNA to

the anterior pole of the Drosophila oocyte (Nusslein-Volhard et al., 1987). In a re
study, the anterior localization of Swallow protein was found to require an intact

microtubule network with correct polarity (Schnorrer et al., 2000). Using yeast-two

hybrid screens, Swallow was found to interact with the motor protein dynein with w

it co-immunoprecipitates in ovarian extracts. Furthermore, in transgenic flies car

deletion of the Swallow peptide domain that interacts with dynein, Swallow protein

not localize to the anterior pole (Schnorrer et al., 2000). Even though the localiz
bicoid mRNA in these mutants was not tested, these results suggest an important

functional interaction between RBPs that are responsible for mRNA localization and
motor proteins of the cytoskeleton. As mentioned above, specific requirements for
microtubules and microfilaments have also been established for the cytoplasmic
localization of Vg-1 and (3-actin mRNAs, respectively.

Additionally, in budding yeast, the localization of the cell fate determinant Ashl

to the presumptive daughter nucleus occurs at the level of the mRNA and depends on

presence of its 3' UTR and an intact actin cytoskeleton (Takizawa et al., 1997). Pr

protein interactions between a novel family of RBPs (the She proteins) have been s

in this case to be important for the tethering of Ashl mRNA to the Myo4p myosin mot

protein and could explain the requirement for both the 3'UTR and the actin cytoske

for proper localization of this message (Bohl et al., 2000; Long et al., 2000). Ano
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novel R B P named Loci that binds double stranded R N A , has been shown to also be
required for efficient localization of Ashl mRNA (Long et al., 2001). Surpnsingly,

localization of this protein is exclusively nuclear, suggesting again that previou
events are necessary for the cytoplasmic localization of RNA and highlighting the

importance of cross-talk between nucleus and cytoplasm and the crucial role that R
play in mediating this communication.

Translation control, stability and turnover
The mRNP complexes involved in translation initiation, elongation and termination

well characterized and will not be considered here. However, a couple of interesti

instances involving the regulation of translation and its coupling to other events

mRNA metabolism (especially cytoplasmic localization and nuclear transport) have b
reported to involve several RBPs, particularly members of the hnRNP family.
The hnRNP protein A2 has been implicated in the translational regulation of the

mRNA for myelin basic protein (MBP) in vivo (Kwon et al., 1999). Specifically, hnRN

A2 enhances the translation of a heterologous transcript that includes a particula
sequences from the 3' UTR of MBP mRNA. Coupled with the described function of

hnRNP A2 in shuttling and the cytoplasmic localization of this transcript (Munro e

1999; see below) these results place hnRNP A2 in the forefront of an integrated ro
the metabolism of target mRNAs. The function of other shuttling hnRNP proteins in

regulation of translation has also been described. The hnRNP proteins Al and I/PTB

have been shown to mediate cap-dependent translation (Svitkin et al., 1996), and hn

I/PTB has also been implicated in the regulation of cap-independent translation i
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transcripts (Kaminski et al., 1995). Also, h n R N P C, even though considered to be a

mostly nuclear protein, has been associated with the binding of an internal riboso
entry site (IRES; Sella, 1999).
Another example of the involvement of hnRNP proteins in translation control
concerns hnRNPs K and E. These proteins have been affinity purified from rabbit

reticulocytes using a particular sequence in the 3'UTR of the erythroid 15-lipoxyg

gene (LOX) called the differentiation control element (DICE; Ostareck et al., 1997)

element had previously been shown to be responsible for the translational silencin

LOX mRNA until the final steps of reticulocyte maturation (Ostareck-Lederer et al.
1994). More recent evidence has suggested that the mechanism of silencing by DICE
and hnRNPs K and E entails the inhibition of joining by the 60S ribosomal subunit

formation of the 80S subunit at the AUG start codon (Ostareck et al., 20001). Moreo

the regulation of this translational silencing is mediated through the phosphoryla

hnRNP K by the extracellular-signal-regulated kinase (ERK). This phosphorylation is

necessary both for the cytoplasmic localization of hnRNP K and its ability to sile
translation of DICE-containing mRNAs (Habelhah et al, 2001).
Several lines of evidence suggest that the regulation of mRNA translation is

coupled to the stability and turnover of the transcript. For example, interactions

translation initiation factors and decapping enzymes have been proposed to arbitra

decision on whether the transcript will undergo translation or degradation (Schwar

Parker, 2000; Vilela et al., 2000). Additionally, the poly(A)-binding protein (PABP)

been hypothesized to provide a link between translation and mRNA decay by being pa

of a complex bound to an RNA instability element (Grosset et al, 2000). Another pro
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identified in this complex is h n R N P D which had been previously implicated in m R N A

stability and highlights again the centrality of hnRNP proteins in mRNA metabolism
(Loflin et al., 1999).
The Hu proteins are a family of proteins that have been identified as target

antigens in paraneoplastic encephalomyelitis/sensory neuropathy (Szabo et al., 1991
They consist of at least four homologous members each with three RRM-type RNAbinding motifs (HuA through D; Okano and Darnell, 1997). They are similar to the

Drosophila proteins Sex lethal and Elav that have been implicated in the regulatio

determination and neuronal development, respectively, possibly through the control

alternative splicing (Robinow et al., 1988; Valcarcel, 1993; Koushika et al., 2000)
proteins have been shown to bind AU-rich elements (AREs) in the 3'UTR of mRNAs and

have been hypothesized to play a role in the stability and degradation of ARE-cont

messages (Fan et al., 1997; Jain et al., 1997; Myer et al., 1997; Fan and Steitz, 1

Ford et al., 1999). Moreover, transfection of HuB results in increased steady-state
of the mRNA encoding for neurofilament M protein and induces the formation of

neurites in cell culture (Antic et al., 1999). However, it is not known whether the

increased level of message was due to increased stability or translation initiatio

Furthermore, the specific details of this binding and the exact mechanism by which
proteins affect mRNA translation and/or stability have not yet been discerned.
A novel function of RBPs emerging from recent reports has been the prevention

of unspliced transcripts from exiting the nucleus and the regulation of nonsense-m
decay of such mRNAs that do cross the nuclear membrane into the cytoplasm. This is

particularly interesting since one of the prototype RBPs with a role in RNA transp
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the H J V protein Rev which actually mediates nuclear export of unspliced, viral m R N A s .
After the initial observation that splicing mutants in the yeast allowed pre-mRNA

mistakenly transported to the cytoplasm (Legrain and Rosbach, 1989), current work h
focused on the role of specific RBPs in nonsense-mediated mRNA decay and the

functional coupling of this surveillance process to previous events (i.e. splicing
successful result of splicing (witnessed by the occurrence of exon-exon junctions

formation of the EJC) serves as both a mediator of mRNA nuclear export (see above)

a marker for the mRNA surveillance machinery of the cell in order to avoid nonsens

mediated decay of the mature transcript in the cytoplasm. RBPs in the EJC (such as
and RNPS1) were found to interact with the mRNA surveillance machinery (hUpf
complex) and mediate its function (Kim et al., 2001a; Lykke-Andersen et al, 2001).
Taken together, the evidence described in the preceding sections point out the

multiple functions of many RBPs and especially the hnRNP proteins. This suggests t

individual hnRNP proteins could be trans-acting factors that bind their mRNA targe

shortly after or concurrently with transcription, participate in their splicing an

processing reactions, guide them through nuclear export and mediate their cytoplas

localization and selective translation. A striking example is provided by the hnRN
I/PTB protein that has been implicated in the control of mRNA splicing, poly(A)
cleavage, nuclear export, cytoplasmic localization and translation (Valcarcel and

Gebauer, 1997; Moreira et al., 1998; Cote et al., 1999; Gosert et al., 2000; see abo

Thus, hnRNP proteins provide a strong model for the integrated function of RBPs an

distinct opportunity for the regulation of RNA metabolism in multiple, linked step
and Wilkinson, 2000).
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R N A - b i n d i n g p r o t e i n s in t h e n e r v o u s s y s t e m

The particular functions of RBPs in the nervous system will be considered in the c

of two processes on the elucidation of which significant progress has been made re

and which constitute the focus of this thesis, namely the regulation of alternativ

and the trafficking and localization of RBPs and mRNA, particularly at the synapse
Neuronal functions of RBPs will also be considered as those emerge from the study
neurologic diseases, especially neurodegeneration.

Neuron-specific alternative splicing

The regulation of the inclusion of alternatively spliced (cassette) exons in the n

system has furthered our understanding of the general aspects of alternative splic

well as the particular tissue- or cell-specific factors and processes that are req

tyrosine kinase c-src gene contains a small alternative exon (called Nl) that is o
included in neurons (Pyper and Bolen, 1989). A cis-acting element promoting the

neuron-specific inclusion of this exon has been identified in the downstream intro
Intronic Splicing Enhancer, ISE) and has been shown to activate inclusion of a

heterologous exon in the human (3-globin gene (Min et al., 1995; Modafferi and Bla

1997). UV-cross-linking experiments identified a complex of proteins that bind to t
element only in neuronal cell nuclear extracts (Min et al., 1995).
This complex included the hnRNP F and H proteins and a novel KH-containing
RBP named KSRP (for KH-type Splicing Regulatory Protein) that is homologous to the

Drosophila PSI protein and the human transcription factor Fuse-Binding Protein (FB

Min et al., 1995; Min et al., 1997; Chou et al., 1999). Immunodepletion experiments
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followed by the addition of recombinant proteins established a role for these proteins in

the activation of the Nl exon in vitro. The fact that none of the identified trans

RBPs is neuron-specific has precluded any conclusions that their action on Nl spli

sufficient for its neuron-specific inclusion. Cross-linking of KSRP to the downstr
ISE (also called the downstream control sequence, DCS) was enhanced in nuclear
extracts from neuronal cells compared to non-neuronal cells and the expression of

protein (but not mRNA) was slightly increased in neuronal cell lines (Min et al., 1
Additional sequences were found to regulate exon Nl inclusion including a
splicing enhancer sequence in exon Nl (an ESE) that cooperates with the ISE and a

splicing silencer sequence in the upstream intron (an ISS) that represses the acti
downstream ISE (Chan and Black, 1995; Modafferi and Black, 1999). Mutagenesis

analysis and in vitro splicing assays with nuclear extracts have identified a cons
CUCUCU element in the upstream intron to be required for splicing repression (Chan

and Black, 1995). RNA competition experiments have suggested that this repression i
mediated by RBPs and UV-cross-linking identified PTB as one of the proteins bound

the upstream ISS (Chan and Black, 1995; Chan and Black, 1997). Addition of purified

PTB to RNA competition experiments with this upstream ISS restores repression of t
Nl exon (Chan and Black, 1997), while immunodepletion experiments in HeLa nuclear
extracts suggest that PTB is necessary for Nl exon skipping (Chou et al., 2000).
PTB can be cross-linked to CUCUCU sequence elements in both the upstream
and downstream ISS and mutations in the downstream binding sequence can cause the

dissociation of PTB from the upstream ISS (Chou et al., 2000). In neuronal cells, w
Nl is included, PTB dissociates from the upstream ISS in the presence of ATP These
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results suggest that an ATP-dependent event in neuronal cells is responsible for the

removal of PTB from the upstream ISS, which in turn destabilizes PTB binding to the

downstream ISS and allows splicing of the Nl exon. A neuronally-enriched homologue

of PTB (called nPTB) was isolated from neuronal cell lines with affinity chromatog
using DCS RNA and was found to bind the CUCUCU sequence more stably than PTB

but to be a weaker splicing repressor in vitro (Markovtsov et al., 2000). This resu

to the hypothesis that nPTB mediates Nl exon inclusion through a permissive mechan
by binding the repressor element and preventing binding by PTB. However, it is not

certain that PTB functions in the repression of Nl splicing in vivo or that nPTB is

splicing activator (or, more accurately, a de-repressor). No in vivo splicing assa

been done on c-src and the presumed protein-protein interactions in the recruitmen

regulatory splicing complex have not been verified. Furthermore, there is no in vi

on the correlation of PTB levels and splicing patterns of c-src or, for that matte
other presumed PTB splicing target.
Another transcript that contains a neuron-specific cassette exon is the GABAA
receptor y2 subunit (GABAARy2) mRNA. Since the initial discovery that transcripts

GABAARy2 in brain tissues can contain a cassette exon of 24 nucleotides (Whiting e

1990), mutagenesis analysis on minigene constructs and transfection/RT-PCR splicing

assays in neuronal cell lines have identified an intronic repressor element near t

splice site upstream of the alternatively spliced exon 9 (Zhang et al., 1996). UV-c
linking and RNA competition assays with HeLa cell nuclear extracts suggested that
element is bound by PTB (Ashiya and Grabowski, 1997). Furthermore, the addition of

recombinant PTB protein in the RNA-competed in vitro splicing assays results in ex
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repression. A sequence alignment from intronic splicing repressor elements from this
and other transcripts with a demonstrated affinity for PTB in vitro, identified a

consensus (Patton et al., 1991; Mulligan et al., 1992; Chan and Black, 1995; Singh
1995; Ashiya and Grabowski, 1997).
When UV-cross-linking/RNA competition assays were repeated in rat brain

nuclear extracts, the levels of PTB protein were reduced and a protein (tentativel

p59) with different electrophoretic mobility from PTB (59 kDa vs. a 60 kDa doublet

nevertheless, immunoreactive to an hnRNP I-specific monoclonal antibody was observ

(Ashiya and Grabowski, 1997). Together with the results on the differential regulat
c-src splicing in neuronal cells (Chan and Black. 1997; see above), this suggested

model whereby exon repression by PTB is alleviated in the brain through the differ
expression of PTB protein and its p59 homologue (Grabowski, 1998).
In addition to GABAARy2, the repression of the neuron-specific exon in two

additional transcripts, clathrin light chain B and /V-methyl-D-aspartate (NMDA) re

NR1 subunit, was shown, in splicing switch assays with RNA competitors, to depend o

PTB-binding sites (Zhang et al., 1999). Again, the existence of a neural form of PT

correlated with exon inclusion in neuronal extracts, and the addition of recombina

protein switched splicing to the non-neuronal pathway. Besides being mostly correl
these studies do not present concrete evidence on the factors responsible for the

regulation of neuron-specific splicing in these pre-mRNAs. The significance of the

acting sequence elements identified has not been substantiated in vivo, and the tra
acting factors involved in splicing regulation are only hinted at. The cloning of
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presumably neuron-specific P T B homologue would be a step in the right direction, as
would the characterization of its function in splicing regulation in vivo.
A well-studied example of the coupling between alternative splicing and other

events in mRNA processing (e.g. polyadenylation), concerns the calcitonin/calciton

gene-related peptide (CGRP) transcript. Downstream of alternative exon 4 exists an

that resembles a pseudo exon, mutations on which reduce in vitro binding by PTB (L

al., 1996; Lou et al. 1998). Exon 4 contains a polyadenylation site and is included

thyroid C cells, thereby generating the shorter calcitonin mRNA. In neurons, exon 4

repressed and a second polyadenylation site at the end of exon 6 generates CGRP mR
In vivo transfection/RT-PCR splicing assays in non-neuronal cell lines using a

CGRP minigene resulted in the unexpected finding that PTB binding of the ISE enhan

exon 4 inclusion (Lou et al., 1999). Mutations in the ISE that favored binding by U

resulted in exon repression in vivo and inhibited polyadenylation in vitro. Howeve

apparent enhancement of exon inclusion by PTB can be explained if one considers th

the PTB-mediated repression of the 3' splice site of the pseudo exon results in in

usage of the upstream 3' splice site of exon 4. Moreover, an additional binding si

PTB (a pyrimidine tract) was identified close to the poly(A) signal sequence in ex

(Lou et al., 1999) similar to the PTB biding site identified near the poly(A) sign

mouse C2 complement gene (Moreira et al., 1992). These results, while preliminary a
unconfirmed in vivo, suggest that an added function of PTB is in the regulation of
polyadenylation and possibly in its functional coupling to splicing.
The Nova family of RBPs have been isolated through their involvement in
paraneoplastic opsoclonus myoclonus ataxia (POMA) and consist of two identified
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members, Noval and Nova2 (Buckanovich et al., 1993; Yang et al., 1998). They have

been shown to bind RNA through ribohomopolymer and filter-binding assays and their

vitro sequence preferences for RNA targets have been studied through RNA selection

strategies (Buckanovich and Darnell, 1997; Yang et al., 1998). Finally, crystal str
have demonstrated the mode of RNA binding (Lewis et al., 2000). A Noval knock-out
mouse was recently described that established Nova as the first mammalian neuronspecific splicing regulator (Jensen et al., 2000a).
A combination of RT-PCR, RNAse protection and co-transfection assays

identified two transcripts whose alternative exons were positively regulated by No

glycine receptor oc2 subunit and the GABAA receptor y2 subunit (Jensen et al., 2000

Noval-null mice the inclusion of alternatively spliced exons in these transcripts,

others tested, was reduced compared to their wild type litter mates. This effect w

similar to the one seen in co-transfection/splicing assays with minigene construct
same mRNAs (Jensen et al., 2000a; K. Dredge and R. Darnell, unpublished
observations). Furthermore, recent evidence suggests that the action of Nova in

regulating alternative splicing is part of an interplay with other tissue-restrict

(Polydorides et al., 2000; see Chapter 4). Even though the difference, if any, in t

physiological function of these splicing isoforms is not known, the fact that they

receptors for inhibitory neurotransmitters is in agreement with a lack of inhibito
phenotype, observed in patients with POMA (Darnell, 1996).
Recently, the Hu proteins have also been implicated in the control of alternative

splicing in the nervous system. The Drosophila HuB homologue Elav (Embryonic letha

abnormal vision) is a neuron-specific RBP that has been shown to regulate the alte
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splicing of neuroglian, armadillo and erect wing transcripts (Koushika et al., 1996;

Koushika et al., 2000; Lisbin et al., 2001). The authors used quantitative RT-PCR i

Elav-null eye imaginal disc clones and ectopic Elav-expressing wing imaginal discs

equivalent of knock-out and transgenic mice) to show that the neuron-specific spli

forms of armadillo and erect wing transcripts, but not of several ubiquitously-exp
genes, depend on and correspond to Elav levels (Koushika et al., 2000). Transgenic

carrying reporter minigene constructs of neuroglian were also used to identify the

sequences responsible for Elav-mediated alternative splicing (Lisbin et al., 2001).

Furthermore, as mentioned above, the Elav-like ETR proteins play a role in the reg

of cTNT splicing (Ladd et al., 2001). With the exception of HuA/R, the expression o

proteins and their Drosophila homologue Elav is restricted to the nervous system m

them important factors in tissue-specific splicing regulation (Okano and Darnell, 1

Postsynaptic localization of mRNA
The first example of an mRNA being selectively localized in the neuronal dendrite

reported by in situ hybridization assays for the transcript of the dendritic-speci
microtobule-associated protein MAP2 (Gamer et al., 1988). Since then, a number of

messages have been found to be localized in dendritic processes including the alph

subunit of type II calcium calmodulin-dependent protein kinase (CAMKIIa), the mRNA

encoding for the vasopressin precursor protein (VP) and the immediate-early gene A

(Benson et al., 1992; Miyashiro et al., 1994; Lyford et al., 1995; Crino and Eberw

1996; Mayford et al., 1996b; Mohr et al., 2001). As well, the localization of (3-act
mRNA has been observed in neurites and growth cones (Bassell et al., 1998).
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This localization has been proposed to provide a w a y for neurons to achieve
localized protein synthesis with all the advantages this might confer, i.e. polarity,
synaptic plasticity, memory, etc. Consistent with this hypothesis, the existence of
selectively localized polyribosomes in postsynaptic dendritic sites in CNS neurons has
been long known (Steward and Levy, 1982). Significantly, the localization of some of
those mRNAs in dendrites is stimulated by synaptic activity, a regulatory mechanism
which is present exclusively in neurons, suggesting that selective localization of
messages post-synaptically can indeed constitute a mechanism mediating plasticity. For
example, the localization of Arc mRNA in post-synaptic hippocampal dendrites and the
resulting selective protein synthesis was enhanced by high frequency activation and also
resulted in the selective accumulation of newly synthesized Arc protein in the same area
(Steward et al., 1998). Furthermore, this activity-dependent mRNA localization requires
the activation of NMDA receptors (Steward and Worley, 2001). The expression of an
activated CaMKII transgene that is independent of calcium regulation resulted in a loss of
hippocampal long-term potentiation and a deficit in spatial memory formation, implying

that the selective localization of transcripts in post-synaptic dendrites, is crucial for t
physiology of neurons (Mayford et al., 1996a).
While the cellular mechanisms responsible for the localization of these mRNAs
are not yet understood, some of the cis-acting elements on the 3' UTR that are necessary
for dendritic targeting have been identified and seem to share common features (Mori et
al., 2000). Therefore, it is reasonable to assume that trans-acting RBPs are responsible
for the dendritic localization of mRNA. Recently, the in vitro interaction of PABP with
the 3' UTR sequence responsible for the dendritic localization of the VP mRNA has been
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reported (Mohr et al., 2001), but these results are preliminary and their in vivo

significance unclear since binding of the 3' UTR by PABP is required for stabiliza
and translation initiation.
Another example of an RBP controlling cytoplasmic localization in the central
nervous system (CNS), involves MBP mRNA in oligodendrocyte peripheral processes

(Ainger et al., 1997). While the signals in the 3' UTR of the transcript responsibl

this effect have been characterized, the actual trans-acting protein regulating th
remains elusive. Contradictory reports have implicated one of the quaking KH-type

proteins and the hnRNP protein A2 in the localization of MBP mRNA (Hoek et al., 19
Munro et al., 1999; Li et al., 2000). However, in both cases the evidence is

circumstantial and indirect as no co-localization or direct binding in vivo was sh

The possibility that quaking is the RBP responsible for the localization of MBP mR

oligodendrocytes is intriguing since mutations in the quaking gene have been corre
with demyelination phenotypes (Ebersole, 1996).

RNA-binding proteins and neurologic disease

The importance of the role played by RBPs in normal cell function is underscored w

such processes are perturbed by genetic defects or other diseases targeting specif

products (e.g. autoimmune disorders). Furthermore, the study of various diseases ha

allowed for the identification of many RBPs and has hinted at their function in vi
example, defects in spermatogenesis have been attributed to specific deletions of
encoding for a protein with an RNA-binding domain (Reijo et al, 1995; Eberhart et

1996) but specific in vivo RNA targets for this protein and its homologues have no
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been identified. Autoantibodies from patients with systemic lupus erythematosus (SLE)
have been used to clone many of the proteins that participate in the formation of
the essential splicing factors (Hinterberger et al., 1983; Wieben et al., 1985).
Many RBPs have been implicated in the pathogenesis of neurologic disease.

Quaking is a KH-type RBP that also contains signal transduction motifs and has bee
implicated in the localization of target mRNAs in oligodendrocytes (see above).
Mutations in the quaking gene-product result in severe defects in myelination and

embryogenesis (Ebersole et al., 1996). Another function of quaking has been describ

in the induction of apoptosis (Chen and Richard, 1998). Curiously, other KH-type RB

have been implicated in the induction of apoptosis as well, including the Drosophi
homologues of Sam68, KEPI and Sam50 (Di Fruscio et al., 1998), the paraneoplastic
antigen Nova (Jensen et al., 2000a), the cellular p53 target MCG10 (Zhu and Chen,

2000), and the Drosophila homologue of FMRP (Wan et al., 2000). In the case of Nova

and FMRP proteins, apoptosis has been observed in neuronal cells suggesting that t
particular function of these proteins in mRNA metabolism is related to programmed

death, and providing clues about the mechanism of dysfunction in neurologic diseas
Other neurologic disorders have been identified where the protein involved is

thought to play a role in splicing regulation either as a regulator of the general
machinery, such as the survival of motor neurons (SMN) protein in spinal muscular

atrophy (SMA; Pellizzoni et al., 1998; see below) or by controlling the neuron-spe
splicing of an alternatively regulated exon, such as the Nova protein in POMA (see

above). SMA is a relatively common motor neuron degenerative disease that results f

mutations in the SMN gene (Lefebvre et al., 1995). SMN was found to interact and co
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localize with SIP1 (SMN-Interacting Protein 1), and this interaction is essential for the
biogenesis of snRNPs (Fischer et al., 1997; Liu et al., 1997). Dominant negative SMN
mutants cause the redistribution of snRNP complexes and inhibit pre-mRNA splicing in
vitro (Pellizzoni et al., 1998). However, apart from a role as a protein whose function is
critical in mRNA biogenesis, these studies do not specifically explain the pathogenesis of
SMA, or the actual cause of the commonly associated fatality in this disorder.
Neurologic disorders where the biochemical cause for the erratic mRNA
processing is not completely understood include inherited frontotemporal dementia and
Parkinsonism linked to chromosome 17 (FTDP-17) and amyotrophic lateral sclerosis
(ALS). In both cases, however, the involvement of RBPs and alternative splicing
mechanisms is highly suspected. In FTDP-17, some mutations identified in patients with
the disease map to a 5' splice site and result in the increased usage of an alternatively
spliced exon in the mRNA for tau, a microtubule-associated protein (Hutton et al., 1998).
The inclusion of this exon increases the number of microtubule-binding repeats in the tau
protein and this has been proposed to explain the increased tau deposits in the neurons
and glial cells of these patients (Spillantini et al., 1997). In the case of ALS, the mRNA
of the glutamate transporter EAAT2 (Excitatory Amino Acid Trasporter 2) was found to

be abnormally spliced, but only in neuro-pathologically affected areas in patients with the
disease (Lin et al., 1998). In vitro expression of these aberrant transcripts resulted in
proteins that were either rapidly degraded or predicted to function as dominant negatives
(Lin et al., 1998), thus providing a link to the glutamate-mediated excitotoxicity that has
been postulated to cause ALS (Rothstein, 1996). However, the cellular event responsible
for this abnormal splicing pattern has not been identified yet.
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The paraneoplastic neurologic disorders (PNDs) are a rare group of syndromes

that involve autoimmune responses to antigens ectopically expressed by systemic tu

(reviewed in Darnell, 1996; Musunuru and Darnell, 2001). These antigens are normall

expressed in the nervous system where they are suspected to have important functio

the physiology and development of neurons. A successful anti-tumor immune response
results in high-titer antibodies that, by crossing into the central nervous system

can cause specific neurological symptoms. The clinical presentation of PND patient

allows for insight into the various functions of these onconeural antigens that ha

cloned using patient sera (Buckanovich et al., 1993; Yang et al., 1998). Importantl

among the categories of onconeural antigens so far identified is a group of RNA-bi

proteins that include the Nova and Hu proteins (see above). Furthermore, since thes
proteins are present exclusively in neurons (except for HuA/R; Okano and Darnell,
1997), the study of their interactions with RNA targets or other proteins provides
to examine neuron-specific cellular functions.
The abundance of genetic or immunologically-mediated defects in neuronal

physiology attributable to improper function of RBPs together with specific exampl

RBP functions in the nervous system as described above, attests to the magnitude o

role played by RBPs in the regulation of RNA metabolism in neurons. Furthermore, it

underscores the fact that this role is likely to be important in the development a
maintenance of the nervous system, including information processing in the brain.

case, neurodegenerative disorders have been associated with abnormal mRNA processi

either as a primary defect (SMA) or as a specific dysfunction in a particular tran
pathway (FTDP-17, ALS, and POMA). A better knowledge of the interactions between
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the proteins involved and their R N A targets (and not only in neurons) will clearly open
the way for the understanding of physiological processes as well as the reasons why these
processes go wrong in disease and the consequences thereof. Insight from molecular,
genetic, biochemical and structural studies will be crucial in elucidating the mechanism
of RNA binding, the important cis- and trans-acting elements involved, the relative
sequence requirements and the functional significance of protein-RNA and proteinprotein interactions.

Summary

The study of RNA-binding proteins has been an area of tremendous growth in recent
years and it is highlighted by the existence of many human disorders where the function
of a specific RBP is affected. These disorders, as well as data on the structure and
localization of these proteins, provide the framework for examining their role in the
cellular metabolism of mRNA. A central theme in this introduction has been that
sequential biochemical steps in the metabolic evolution of mRNA within the cell are
tightly linked spatially and functionally and that this coupling can be mediated by RBPs.
Since they are unlikely to act completely independently of other factors, investigating
interacting partners of RBPs is useful in elucidating the mechanism of this coupling and
ultimately providing clues for their biological role. This thesis concerns the study of the
RBP Nova, the search for its interacting protein partners and the ways these interactions
may affect its function in alternative splicing and nuclear localization.
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C h a p t e r 2 - Materials a n d

Methods

Yeast two-hybrid library screens
Full-length Noval, full-length Nova2 and Nova2 spacer (amino acids 230-407) bait
constructs were cloned into the LexA vector p B T M 1 1 6 (trp+; kindly provided by Drs.
Susan Smith and Titia de Lange), and transformed with LiOAc into the L D 4 0 yeast strain
(also provided by Drs. Susan Smith and Titia de Lange). L D 4 0 yeast are leu-/trp- and
contain the lacZ and His+ genes under the control of LexA promoters. The resulting
transformants were control-tested to make sure that there was no induction of lacZ
expression independently of prey constructs (colony lift/X-gal assays without a cotransformed Gal4 activation domain construct). Screens of adult mouse brain or E 11.5
whole mouse Matchmaker c D N A libraries (in the p G A D I O vector, leu+; Clontech) were
performed following the Matchmaker System protocol (Clontech). The total number of
successful transformants in each screen (colonies that were trp+/leu+) was divided by the
number of independent clones in each library to give the percentage screened (% ser. in
Table 1). Large scale LiOAc transformations of each amplified library into L D 4 0 yeast
already carrying a bait construct were plated onto triple dropout media (tip-, leu-, his-).
The resulting colonies that were able to grow in these plates were his+ and were also
assayed for (3-galactosidase production (blue staining) in a colony lift/X-gal assay
(following a modified protocol from the Matchmaker System, Clontech; Yang, 1997,
P h D Thesis, Rockefeller University). These colonies were deemed true positives when
their (3-galactosidase staining turned white upon removal of the bait plasmid (by growing
in trp+/leu- single dropout media). The prey plasmid was then extracted from the white
colonies and sequencing of the clones was performed with vector-specific primers
(Operon). Sequences were analyzed with MacVector Software and compared to the
N C B I database for homology. Screens with full length Nova2 baits were performed by
Yolanda Yang and have been previously described (Yang, 1997). All D N A sequencing
throughout this work was performed by the Rockefeller University Protein/DNA
Technology Center.
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Yeast two-hybrid protein interaction assays
Deletion constructs of Nova2 (in p B T M 1 1 6 ) and brPTB (in p G A D 4 2 4 ; Clontech) were
made by P C R with specifically designed primers (Operon, see list below), gel-extracted
(Qiaex II, Qiagen), subcloned into p G E M T vectors (Promega), verified by sequencing,
digested with Sacl and Sail restriction endonucleases and cloned into the Sacl/Sall site of
p G A D 4 2 4 vectors. For the experiments mapping yeast-two-hybrid interactions between
deletion constructs (Table 2, Figure 8), plasmids were sequentially transformed (first
p B T M 1 1 6 bait constructs, then p G A D 4 2 4 prey constructs) into L D 4 0 yeast with LiOAc
and plated in the appropriate media (first trp-, then trp-/leu-). Colony lift/X-gal assays
were used to determine the strength of the interaction, judged by the intensity of blue
staining. Interactions between Nova full length and partial deletion constructs were also
tested as a control for the intensity of the blue staining.

Cloning of mouse brPTB cDNA
A gel-extracted (Qiaex II, Qiagen) 1.3 kb EcoRI fragment of coding sequence from the
brPTB clone isolated in the yeast-two-hybrid screen was used to make a radioactive D N A
probe (32P-dATP, Amersham; Prime-it II Kit, Stratagene) and to screen an adult mouse
brain c D N A phage library (Uni-ZAP X R , Stratagene). A total of 5.4xl05 phage clones
were screened (following the protocol in Molecular Cloning, by Sambrook, Fritch and
Maniatis, Cold Spring Harbor Laboratory Press, 1989), and after three rounds of initial
screening and two rounds of secondary isolation and hybridization, four single clones
were identified, three of which were identical by restriction digest analysis. Sequencing
revealed that the two unique clones were overlapping and contained the 1.6 kb predicted
open reading frame and a 1.4 kb 3'UTR as shown in Figure 1.

DNA preparation and restriction digest analysis
Unless otherwise stated, all plasmid D N A was prepared using Spin mini-prep kits
(Qiagen) and analyzed by restriction digestion using enzymes, buffers and protocols
supplied by N e w England Biolabs. D N A was separated by electrophoresis in standard lx
TBE/1-1.5 %

agarose gels and photographed under U V light. Plasmid D N A for
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transfections into cell lines was prepared by a modified cesium chloride method
(Molecular Cloning, by Sambrook, Fritch and Maniatis, Cold Spring Harbor Laboratory
Press, 1989).

RNA preparation and Northern blot analysis
Total R N A was extracted from wild type mice using a modified guanidine-acid phenol
protocol as previously described (Yang et al., 1998), separated on a 1 % agarose/2.2 M
formaldehyde gel and transferred to a nylon membrane ( N E N ) by capillary transfer in
10X S S C (Molecular Cloning, by Sambrook, Fritch and Maniatis, Cold Spring Harbor
Laboratory Press, 1989). The integrity and size of the R N A samples was determined by
ethidium bromide staining of a duplicate gel. The membranes were U V cross-linked, and
hybridized using the QuikHyb system and following the manufacturer's protocol
(Stratagene). The radioactively labeled probes used to screen the membrane included the
one used to clone brPTB c D N A (see above) and a 1.2 kb EcoRI fragment from the
coding sequence of mouse P T B , also isolated in the yeast two-hybrid screen, gel
extracted (Qiaex II, Qiagen) and labeled in the same way (32P-dATP, Amersham; Prime-it
II Kit, Stratagene). Exposure of the washed, wrapped membranes was carried out
overnight (-80°C) on Kodak X - O M A T A R film.

Protein preparation and Western blot analysis
Fresh tissue specimens were obtained from adult wild type mice, homogenized in IX
RIPA buffer (150 m M NaCl, 50 m M Tris-Cl p H 7.5, 1 % NP-40, 0.5 % D O C , 0.1 %
S D S ) and left on ice for 20 minutes. Alternatively, the medium from cultured cells was
aspirated and the cells were resuspended in IX lysis buffer ( 1 % Triton X-100, 10 m M
Tris-Cl p H 7.6, 50 m M NaCl, 30 m M sodium pyrophosphate, 50 m M NaF, 1 m M E D T A ,
1 m M E G T A , complete protease inhibitors-Boehringer Mannheim) and vortexed. Cell
debris were precipitated by centrifuging at 14,000 rpm for 15 minutes and the supernatant
was passed through a 20G needle to shear chromosomal D N A . Proteins were separated
by 10 % S D S - P A G E (following the protocol in Current Protocols in Protein Science,
John Wiley & Sons, Ine, 1995) and transferred to P V D F membranes (Millipore). Equal
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loading of total protein from each tissue (50 ng/lane) was determined by Bradford assay
and verified by Coomassie blue staining of a duplicate gel. Membranes were blocked for
one hour at room temperature in 5 % non-fat milk in R buffer (0.15 M NaCl, 10 m M
Tris-Cl, 1 m M E D T A , 0.1 % Triton X-100), incubated with primary antibodies in 5 %
milk in R buffer at 4°C overnight and washed five times with alternating high salt (1 M
NaCl, 20 m M Tris-Cl, 0.1 % Triton X-100) and high detergent (0.15 M NaCl, 5 m M
E D T A , 50 m M Tris-Cl, 1 % Triton X-100, 0.05 % S D S ) buffers. After incubation for an
hour at room temperature with secondary, HRP-conjugated antibodies (Jackson
Immunoresearch) in 5 % milk in R buffer, the membranes were again washed five times
with alternating high salt/high detergent buffers and the signal was detected by
chemiluminescence (NEN). The membranes were wrapped (SaranWrap) and exposed on
Biomax M R film (Kodak).

Generation of polyclonal anti-brPTB antibody
After an unsuccessful attempt to generate an antibody against a peptide unique to brPTB,
a polyclonal anti-brPTB antibody was produced by injection of two rabbits with fulllength recombinant brPTB fusion protein (see Fusion protein synthesis below) and
Freund's adjuvant (Pocono Rabbit Farm & Laboratory). Pre- and post-immune test sera
were assayed by Western Blot against purified recombinant P T B and brPTB fusion
proteins (50 ng/lane) to determine antibody reactivity, specificity and appropriate dilution
(see Figure 4). Of the two animals immunized with the full-length brPTB protein, one
developed immunity against brPTB and its serum was used in all subsequent experiments
at a 1:5000 dilution. The other animal exhibited background reactivity to brPTB protein
even in the pre-immune state.

Antibodies
The following primary antibodies were used throughout this work:
P O M A patients' Ri serum (Buckanovich et al, 1993)
Nova2-specific anti-peptide antibody (Yang, 1997)
polyclonal anti-HuA (generously provided by Dr. Joan Steitz)
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polyclonal anti-PTB (generously provided by Dr. Doug Black)
monoclonal anti-myc (9E10, generously provided by Dr. Jan Karlseder)
monoclonal anti-T7 (Novagen)
monoclonal M 5 anti-flag (Sigma)
polyclonal anti-GST (Sigma)
monoclonal anti-GFP (Clontech)
monoclonal anti-MAP2 (Sigma)
monoclonal anti-GFAP ( D A K O )
polyclonal anti-matrin3 (generously provided by Dr. Somanathan)
polyclonal anti-coilin p80 (R288, generously provided by Dr.Gall)
polyclonal anti-Noppl40 (RE10, generously provided by Dr. Meier)
monoclonal anti-SIP-1 (generously provided by Dr. Dreyfuss)
monoclonal anti-Sm (Y12, generously provided by Dr. Gall)
monoclonal anti-SC35 (generously provided by Dr. Gall)
monoclonal anti-SR (16H3, Covance)
monoclonal anti-SR (1H4, Covance)
monoclonal anti-CTD domain of R N A polll (Covance).
A variety of HRP-, Cy2-, Cy3- and Cy5-conjugated species-specific secondary antibodies
were used as appropriate, following dilutions suggested by the manufacturer (Jackson
Immunoresearch). D A P I stain (Sigma) was used at 1000 ug/mL to visualize cell nuclei.

Fusion protein synthesis
Full-length Noval and full-length Nova2 recombinant GST-fusion proteins were
produced and purified as previously described (Yang, 1997). Full-length T7/His tagged
brPTB and P T B proteins were produced by subcloning EcoRI fragments from the yeasttwo-hybrid prey vectors into pET21 (Novagen) and transforming BL21 competent cells,
followed

by

standard

IPTG-induction

chromatography.
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and

purification

by

nickel-chelation

G S T pull-down assays
In vitro G S T pull-down assays were performed as previously described (Yang, 1997).
Briefly, the indicated amounts of G S T and T7-tagged purified recombinant fusion
proteins were incubated in a low stringency buffer and G S T proteins were isolated using
Glutathione-Sepharose 4B beads (Pharmacia) following the manufacturer's protocol.
Any T7-tagged proteins pulled down with the G S T proteins were eluted in S D S loading
buffer, analyzed in S D S / P A G E and detected by Western blot. In vivo G S T pull-down
assays were performed by transfecting (Fugene6, Boehringer Mannheim) N 2 A cells with
Noval and Nova2 eukaryotic G S T fusion protein expression constructs (cloned in the
p E B G vector, kindly provided by Dr. T Shishido). Cells were harvested two days later,
lysed on ice for 45 minutes (1 % Triton X-100, 10 m M Tns-Cl p H 7.6, 50 m M NaCl, 30
m M sodium pyrophosphate, 50 m M NaF, 1 m M E D T A , 1 m M E G T A , complete protease
inhibitors-Boehringer Mannheim) and the D N A pellet was removed by centrifugation.
Nuclei were disrupted by sonication and G S T pull-downs were performed with
Glutathione-Sepharose 4B beads (Pharmacia) following the manufacturer's protocol.

Cell cultures
All cell lines were maintained in 1 0 % F B S / D M E M with penicillin/streptomycin, grown
to 6 0 % confluence in 6 well plates or chamber slides and transfected using Fugene6
according to the manufacturer's protocol (Boehringer-Mannheim). 293T cells ( A T C C )
are a primary human embryonal kidney cell line transformed with the S V 4 0 T antigen.
N 2 A cells ( A T C C ) are a mouse neuroblastoma cell line.

Immunofluorescence of cell cultures
For immunofluorescence of cell cultures, cells were plated onto chamber slides (Nalge
Nunc), transfected where appropriate, and two days laterrinsed,fixed (10 minutes in 2 %
paraformaldehyde in P B S at room temperature), washed, permeabilized (10 minutes in
0.5 % NP-40 in P B S at room temperature), washed again, blocked (1 hour at room
temperature in P B G : 0.2 % gelatin and 0.5 % bovine serum albumin in PBS) and stained
overnight with primary antibody in P B G at 4°C. After three washes in P B G , slides were
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incubated with fluorochrome-conjugated secondary antibodies in P B G for 1 hour at room
temperature. Slides were then washed three times in P B G , once with D A P I in PBS, and
once in P B S alone. Slides were left at room temperature to dry and then covered with
mounting medium (Biomeda) and a coverslip (Fisher) before being sealed with nail
polish (Revlon). The slides were observed under multiple wavelength fluorescence from
a mercury lamp (AttoArc), in an upright microscope (Zeiss Axiolpan). Pictures were
taken with a digital camera (Hamamatsu Orca), using Openlab software (Improvision)
and presented with Photoshop software (Adobe).

Immunofluorescence of tissue sections
For immunofluorescent staining of rat and mouse brains, tissue sections were fixed in
formalin/PBS and paraffin embedded as described above. After permeabilization in 0.5
% NP-40, the sections were blocked in 0.2 % gelatin and 0.5 % bovine serum albumin in
PBS.

Primary anti-brPTB polyclonal antiserum (1:5000 dilution) and anti-MAP2

monoclonal antibody ( S I G M A , 1:500), anti-GFAP monoclonal antibody ( D A K O
Corporation, 1:25) or P O M A patient sera (1:500) were incubated with tissue sections at
4°C overnight. Proteins were visualized using Cy2 anti-mouse IgG and Cy3 anti-rabbit
IgG or Cy5 anti-human IgG and Cy2 anti-rabbit IgG (all from Jackson ImmunoResearch)
by confocal microscopy (Zeiss). W e confirmed that sections stained with brPTB/Cy2
gave no signal when detected at the wavelength of Cy5 in the absence of P O M A / C y 5 .

Immunohistochemistry
Adult rats (male Sprague-Dawley), E 16 Rat embryo and P 5 mouse (male C D 1 ) were
used. Brains were perfused with formalin/PBS, paraffin embedded, and sectioned at 14
um. After deparaffinization, sections were boiled in 0.01 M citric acid (pH 6.0) in a
microwave for 10 minutes. All immune reactions were preceded by a blocking step
(PBS, 0.05 % triton X-100, 2 % normal horse serum), and were carried out at 4°C
overnight. All sections were washed (PBS, 0.05 % triton X-100), incubated with
biotinylated secondary antibodies (Vector Laboratories) and washed again. Signals were
enhanced by addition of HRP-conjugated avidin (Vector Laboratories), developed with
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diaminobenzidene ( D A B ) in the presence of H,0,, and visualized by light microscopy
using a Zeiss Axioplan microscope.

GFP-fusion constructs and live immunofluorescence
All GFP-Nova constructs were prepared by P C R of Nova fragments with specifically
designed primers (Operon, see list below), gel-extracted (Qiaex II, Qiagen), sub-cloned
into the p G E M T shuttle vector (Promega), verified by sequencing, digested with Sail and
Bglll restriction endonucleases and cloned into Sall/Bglll sites of the pEGFP-Cl vector
(Clontech). Plated N 2 A cells were transfected with Cesium Chloride preparations of the
plasmid D N A and observed two days later live, under a mercury lamp (AttoArc) with an
inverted microscope (Zeiss Axiovert S100). Pictures were taken as before. Specific
amino acid mutations on all G F P constructs were made with the QuikChange Sitedirected Mutagenesis Kit (Stratagene) and site specific primers (see list below) and
verified by sequencing. The constructs presented in Figure 29 were prepared as follows:
G F P vector: empty G F P vector (pEGFP-Cl, Clontech)
GFP-Noval: full length Noval sequence (amino acids 1-506) inserted into pEGFP-Cl
GFP-Nova2: full length Nova2 sequence (amino acids 1-489) inserted into pEGFP-Cl
GFP-NLS: amino acids 25-41 of Noval protein (putative N L S ) inserted into pEGFP-Cl
GFP-NLS K27E: as in GFP-NLS with a mutation substituting glutamate for lysine 27
G F P - N L S K40E: as in G F P - N L S with a mutation substituting glutamate for lysine 40
G F P - N L S K27,40E: as in GFP-NLS with glutamate substituting for lysines 27 and 40
GFP-Noval K27E: as in GFP-Noval with a mutation substituting glutamate for lysine 27
GFP-Noval K40E: as in GFP-Noval with a mutation substituting glutamate for lysine 40
GFP-Noval K27,40E: as in GFP-Noval with glutamate substituting for lysines 27 and 40
GFP-Noval A N L S : as in GFP-Noval with a mutation deleting amino acids 24-41
GFP-Noval KH1/2: amino acids 1-242 of Noval protein inserted into pEGFP-Cl
GFP-Noval sp/KH3: amino acids 242-503 of Noval protein inserted into pEGFP-Cl
GFP-Noval spacer: amino acids 242-423 of Noval protein inserted into pEGFP-Cl
GFP-Noval t.spacer: amino acids 242-360 of Noval protein inserted into pEGFP-Cl
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In vivo splicing assays
Cells ( 3 0 % confluent in 6-well plates, Corning) were transfected with 0.25 (xg of the
GlyRa2 minigene (described in Jensen et al., 2000a), 0.125 jug of p C M V P-galactosidase
(Gibco-BRL) and variable amounts of pcXHookNoval, pflagbrPTB and pcXHook empty
vector. The total amount of D N A transfected in each experiment was kept constant by
the addition of corresponding amounts of the appropiate empty vectors. Construction of
pcXHookNoval has been described (Jensen et al., 2000a); pflagbrPTB and pmycPTB
were made by sub-cloning EcoRI fragments of the yeast-two-hybrid prey isolates of
brPTB and P T B into pcDNAflag and p c D N A m y c respectively (both parent vectors were
kindly provided by Drs. Jan Karlseder and Titia de Lange). R N A was collected 40 hours
after transfection and R T - P C R was performed with primers (one radioactively labeled)
specific for exons 2 and 4 of GlyRa2 as previously described (Jensen et al., 2000a).
Exons 3 A and 3B were distinguished by Sspl digest of Exon 3A-containing P C R product
and their ratio was determined by non-denaturing S D S - P A G E , followed by quantitation
with a Molecular Dynamics Storm Phosphorimager and ImageQuant software. The
G A B A A R y 2 minigene construct was made by Kate Dredge. Mutations on both minigene
constructs were made with the QuikChange Site-directed Mutagenesis Kit (Stratagene)
and specifically designed primers (Operon) and verified by sequencing.

Filter binding assays
Radioactively labeled 90 nt fragments of wild type or mutant GlyRa2 intron2 and an
unrelated r R N A fragment were synthesized as described (Jensen et al., 2000b).
G A B A A R y 2 85 nt fragments of intronic R N A were made by P C R with specific primers,
the 5' of which contained the T 7 R N A polymerase sequence (Operon, see list below).
Filter binding assays using Noval and brPTB fusion proteins were performed as
described (Buckanovich and Darnell, 1997; Yang, et al., 1998) and the K d was
determined by graph analysis on KaleidaGraph software.
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Electrophoretic mobility shift assays
Electrophoretic mobility shift assays were performed by combining Noval and brPTB
fusion proteins, at the concentrations indicated, in gel shift buffer (250 m M K O A c , 50
mM

Tris-OAc p H 7.7. 10 m M

D T T , 5 m M Mg(OAC)2, 1 m g / m L tRNA), adding

radioactively labeled wild type or mutant GlyRa2 R N A fragments (final concentration
0.6 n M ) and Ficoll loading buffer (final concentration 2.5% Ficoll) and incubating for 30
minutes at 4°C. The samples were separated by non-denaturing 8 % PAGE/0.5 X T B E at
200V, 4°C, and exposed on Kodak Biomax M R film overnight (-80 °C).

Primers
For intronic GlyRcc2 and G A B A A R y 2 R N A fragments:
#GlyRFr905'T7:
AGTAATACGACTCACTATAGGGATCATGCAGTTCTGGTTTAAT
#GlyRfr903': A G C T C C A T C A A C A T C T G T G G
#T7GABA100:
GAAATTAATACGACTCACTATAGGGAGTAATTTGTCTTATTTTGTTTC
For mutations in P T B sites in GlyRcc2 and G A B A A R y 2 minigenes and R N A fragments:
#Gly90PTBC/T5': G C A G T T C T G G T T T A A T T T T T T T T T T T T G C A G T C T C A T C A T C
#Gly90PTBCAT3': G A T G A T G A G A C T G C A A A A A A A A A A A A T T A A A C C A G A A C T C
#GABA-GA2.5':GTCTTATTTTGTTTCGATTTCTCGATTTTTTTTCCTTTTCC
#GABA-GA2.3':
GGAAAAGGAAAAAAAATCGAGAAATCGAAACAAAATAAGAC
#GABA-GA1.5':GCAATTCGATTTTCTGTCTACAAATCCAAAGCTTCTTCGG
#GABA-GA1.3': C C G A A G A A G C T T T G G A T T T G T A G A C A G A A A A T C G A A T T G C
For mutations in amino acids of the Noval N L S in p E G F P constructs:
# N 1K27E5': C C G G A C T C G C G G G A A A G G C C G C T T G A A G C
#N1K27E3': G C T T C A A G C G G C C T T T C C C G C G A G T C C G G
# N 1K40E5': G C C G G C A G C A C C G A G A G G A C C A A C A C G
# N 1K40E3': C G T G T T G G T C C T C T C G G T G C T G C C G G C
For brPTB deletion mutants in yeast-two-hybrid prey constructs:
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#brPTB30:CTCGAGTGGACGGAATTGTCACTGAGG
#brPTB31: C T C G A G A A G A T A A A A T G G A T G G G G C
#brPTB32:CTCGAGACAAAGAACTAAAGACAGATAATAC
#brPTB33:CTCGAGAGAGTGCGGTGACTCCAGC
#brPTB34:CTCGAGTTGTGAATTTGAATGTAAAATAC
#brPTB35: C T C G A G T G C C T G G A G T C T C A G C
#brPTB36rc:CGGCCGGATTGGAGTACTGGATGTAAA
#brPTB37rc:CGGCCGGTTTGGAAAAATCAATCC
#brPTB38rc: C G G C C G C C A C T C G G C C A G C G G
#brPTB39rc:CGGCCGCGATTGTTGACTTGGAGAAAGAC
#brPTB40:GTCGACTGGACGGAATTGTCACTGAGG
#brPTB41: G T C G A C A A A T G G A T G G G G C T C C C T
#brPTB42:GTCGACACAAAGAACTAAAGACAGATAA
#brPTB43: G T C G A C A G A G T G C G G T G A C T C C A G C
#brPTB44:GTCGACTTGTGAATTTGAATGTAAAATAC
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PTB interacts with Nova

Introduction

The Nova proteins constitute a family of neuron-specific, RNA-binding proteins tha

have been implicated as the antigens in paraneoplastic opsoclonus-myoclonus ataxia
(POMA). They have high homology with the hnRNP K protein with which they share
their organization of three RNA-binding domains (RBD) of the KH (hnRNP K

Homology) type. Noval was one of the very first human, neuron-specific, RNA-binding

proteins (RBP) to be identified, but its role remained unclear at first. It was cl
screening a human cerebellar cDNA expression library with a high-titer serum from
POMA patient (Buckanovich et al., 1993).
Using the same serum to screen a small cell lung cancer expression library,
yielded a second family member named Nova2 (Yang et al., 1998). Interestingly, the

expression patterns of the two proteins in neurons are almost complementary with N

restricted to the hypothalamus and ventral midbrain, hindbrain and spinal cord and

present at highest levels in the cortex, thalamus, inferior colliculus, inferior olive and t
external granule cell layers of the cerebellum (Buckanovich et al., 1993; Buckanovich et
al., 1996; Yang et al., 1998).
The fact that Noval expression in the developing nervous system is restricted to
neurons of the ventral brain stem, ventral spinal cord and cerebellum suggested initially
that it might be important in the development and patterning of these structures
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(Buckanovich et al., 1993). Indeed, later work showed that Noval is essential for

neuronal viability since null mice exhibit apoptotic cell death in hindbrain and v
spinal cord neurons (Jensen et al., 2000a).
Nova proteins are similar in their amino acid sequence and structural features to

two other KH-type RBPs, hnRNP K and the fragile X mental retardation protein (FMRP)
They all harbor two adjacent KH domains, a spacer and a third RNA-binding domain
(KH domain in Nova and hnRNP K, RGG box in FMRP). Both FMRP and hnRNP K

contain nuclear export sequences and have been shown to shuttle between the nucleu

and the cytoplasm (Michael et al., 1997; Feng et al., 1997). Many nuclear KH-type R

have been shown to regulate pre-mRNA splicing in different organisms, such as MER-

in yeast (Nandabalan and Roeder, 1995), PSI in Drosophila (Siebel et al., 1995), and
and KSRP in mammals (Arning et al., 1996; Min et al., 1997). However, the best

characterized role for hnRNP K and FMRP involves translation control in the cytopl
(DeBoulle et al., 1993; Ostareck et al, 1997).
Because of the sequence homology of Nova with hnRNP K and the presence of
consensus KH-type RNA-binding motifs, it was hypothesized that it too is an RNA-

binding protein. A variety of in vitro and in vivo experiments demonstrated that N

an RNA-binding protein with a consensus sequence for binding and identified putati

target RNA transcripts in the metabolism of which Noval could play a role (Buckano

et al., 1996; Buckanovich et al., 1997). Similarly, Nova2 was found to bind RNA tar

in vitro but with a sequence specificity that differed from Noval (Yang, 1997; Yan

al., 1998). However, the disparity in the RNA sequences is subtle and Nova proteins
able to bind each other's targets, albeit with slightly smaller affinity.
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Besides clues obtained from sequence and structure similarities to h n R N P K and

FMRP, insight into the function of Noval came from studies of its binding to speci

physiologic RNA targets, such as the glycine receptor a2 subunit (GlyRa2) pre-mRNA

(Buckanovich et al., 1997). Structural and biochemical studies of the Noval protein

RNA interaction demonstrated it is of high affinity, specificity and functional im
and determined the particular RNA sequence characteristics and peptide domain

requirements (Buckanovich and Darnell, 1997; Lewis et al., 2000; Jensen et al., 2000
As well as making contacts with RNA, many RNA-binding proteins have been
known to engage in protein-protein interactions that are likely to be important in
mediating their biological function. For example, in the eukaryotic nucleus, many
ribonudeoprotein (RNP) complexes are known to exist (e.g. the spliceosome) whose

function is both dependent on and a consequence of specific protein contacts withi

complexes. Thus, the search for specific protein interactions of RBPs is expected t

important information on their function within the cell. Various domains of RBPs h

been hypothesized to be responsible for such protein-protein interactions includin

RNA-binding motifs themselves (RRM- or KH-type; Chen et al., 1997; Kielkopf et al.
2001), the RS domains of SR proteins (Valcarcel and Green, 1996; Xiao and Manley,

1997), and the glycine-rich domain of hnRNP Al and Sxl (Cartegni et al., 1996; Wang
al., 1997).
Several findings support the idea that Nova proteins may undergo protein-protein

interactions in addition to RNA binding. First, the co-crystal structure of a Nova
complex reveals that most of the KH domain is accessible for protein-protein

interactions, even when bound to RNA (Lewis et al., 2000). Dynamic light scattering
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experiments showed that the K H 3 of Noval is capable of forming dimers in solution and
tetramers in the presence of RNA. Second, 32% of Noval (164/510 aa) and 39% of

Nova2 (190/492 aa) peptide sequences consist of an unstructured spacer domain link

the second and third KH domains (Buckanovich et al., 1993; Yang et al., 1998). This

spacer domain is the region of greatest sequence divergence between Noval and Nova
family members (56% identity and 66% homology at the amino acid level; the KH
domains are 89% identical, 96% homologous) and between Nova and several closely
related KH-domain containing proteins (hnRNP El/2, hnRNP K; Lewis et al., 1999).

The spacer region contains several proline-rich and alanine/glycine-rich stretches
may represent protein interaction motifs. Third, there are several reports on the
of homotypic and heterotypic interactions between KH-containing RBPs such as the

Fragile X Mental Retardation Protein (FMRP) family (Siomi et al., 1996), the quakin

protein (Zorn and Krieg, 1997), and the Sam68 protein (Chen et al., 1997). Furthermo

preliminary experiments from our lab have shown that Nova proteins are able to for

homodimers and heterodimers in vitro and interact in the yeast-two-hybrid system (
1997; Yang etal., 1998).
To examine whether Noval and Nova2 interact specifically with other proteins

and to identify what those may be, yeast two-hybrid screens were performed using N
proteins as bait. The results shed new light to our understanding of Nova biology

made possible the exploration of the effect of specific protein interactions on th
function of Nova.
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Results

Identification of proteins that interact with Noval and Noval

Yeast two-hybrid screens were performed in order to identify proteins that might i
with Noval and Nova2. Adult mouse brain and embryonic day 11.5 (E 11.5) whole

mouse cDNA libraries were screened with various Nova bait constructs including ful
length Noval, full length Nova2, and the Nova2 spacer (amino acids 230-407). The
latter domain of Nova2 does not contain any RNA binding motifs and has been

previously shown to mediate at least part of the homotypic and heterotypic interac
between Nova proteins (Yang, 1997).
As summarized in Table 1, a number of different RNA-binding proteins were

isolated in the yeast-two-hybrid screens as possible Nova interactors, including t
sequences. One of these novel sequences (novel RRM) contained RRM-type RNA-

binding motifs and exhibited a brain-specific mRNA expression pattern (data not sho
The other, was named brain-enriched polypyrimidine tract-binding protein (brPTB)

because it displayed a strong sequence similarity to PTB (also known as hnRNP I) a
was characterized further (see below).

Strikingly, several of the proteins pulled out of the libraries belong to distinct

well-defined families such as the paraneoplastic antigen Hu protein family (HuA, H
and HuD) and the PTB protein family (matrin3, hnRNP I/PTB, hnRNP L, and brPTB).

Additionally, other proteins that play a role in RNA metabolism were found to inte
with Nova2. SRp20 is a member of the SR family of splicing factors with a role in

mRNA processing and alternative splicing regulation (Zahler et al., 1992; Heinrich

Baker, 1997; Neugebauer and Roth, 1997). YL2/p32, a protein known to co-purify with
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ASF/SF2 and interact with the H T V protein Rev, is thought to mediate nuclear export of
unspliced messages (Luo et al. 1994, Tange et al. 1996).

Cloning of brain-enriched Polypyrimidine Tract-Binding Protein (brPTB)

Since the sequence of brPTB identified in the yeast-two-hybrid screen lacked a por
the 5' end (as determined by the absence of alignment with PTB in that region), an
fragment was used to make a radioactively-labeled probe and screen an adult mouse

cDNA phage library. A 3.0 kb brPTB cDNA containing the predicted full length codin
sequence was isolated after three rounds of screening (see Materials and Methods).
The 1.6 kb open reading frame encodes for a predicted 532 amino acids and is
followed by a 1.4 kb 3' UTR (Figure 1). Sequence analysis shows that brPTB protein

shares 73% identity and 84% similarity with PTB at the amino acid level. These num
jump to 80% and 91%, respectively, over the four RRM domains (Figure 2). The brPTB
cDNA also contains a putative nuclear localization signal (NLS) and a consensus
polyadenylation signal.

A sub-family of RRM-type RNA-binding proteins interact with Nova

Interestingly, some of the proteins that were identified in the yeast two-hybrid s
with Nova baits (hnRNP I/PTB, hnRNP L, brPTB and matrin 3) form a distinct sub-

group of the RRM-type family of RNA-binding proteins based on amino acid homologie
over their RRM domains (Figure 2; Burd and Dreyfuss, 1994). While the sequence of

these proteins matches the RRM domain consensus overall, they differ significantly

their ribonudeoprotein motifs (RNPs), which are thought to mediate the actual bindi
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R N A targets (Nagai et al., 1990).

Specifically, the PTB/brPTB family lacks the

glycine/phenylalanine doublets (GF) that are prominent in the RNP1 motif of most R
and instead contain hydrophobic and polar amino acids. In the case of RNP2, the
consensus among RRM-containing proteins calls for the presence of glycine and
hydrophobic residues whereas the PTB/brPTB family in addition to the hydrophobic
residues, contains a histidine and polar amino acids.
The interaction of these proteins with the Nova family members was equally

robust (Table 2). In assays measuring the interaction between the PTB/brPTB family
members with Noval and Nova2 in the yeast-two-hybrid system, their behavior was

indistinguishable. All four proteins were capable, when fused to the Gal4 activati
domain (GAD), to interact with Noval or Nova2 fused to the LexA binding domain and

activate the LexA promoter thus conferring the ability to grow in his- media. In c

lift/X-gal assays, the same interactions resulted in strong blue staining confirmi
strong interaction with Noval and Nova2.

brPTB expression in the nervous system

To examine the expression pattern of brPTB, Northern blot analysis was performed o

several mouse tissues (Figure 3). brPTB mRNA was detected preferentially in the br

including the cortex, cerebellum and brainstem, with very reduced levels evident i

organs outside the nervous system, most notably the heart. brPTB is expressed at s

levels across different developmental stages, ranging from El8 to adult. In contras

PTB probe detected mRNA in all tissues, although the possibility that this probe m
cross-react with brPTB cannot be ruled out.
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In order to evaluate the tissue expression of brPTB protein, w e generated a

specific antibody by immunizing rabbits with a purified, recombinant full-length b
fusion protein. While the pre-immune serum was non-reactive, the anti-brPTB

polyclonal serum (a-brPTB) recognizes a protein of approximately 57-59 kDa (Figure
4A). Furthermore, this antibody is brPTB-specific at this dilution (1:5000) since
with brPTB fusion protein but not with the same amount of PTB (Figure 4B).
Western blot analysis using this brPTB antibody revealed that brPTB protein, like

its mRNA, is enriched in neural tissues, including the cortex, cerebellum, brainst

spinal cord (Figure 5). brPTB is also expressed at high levels in the testis and at

considerably lower levels in the liver, heart, lung, skeletal muscle and thymus wi

expression evident at all in the spleen and kidneys. This pattern contrasts with t
brain-specific expression of Nova proteins.
Immunohistochemical studies were performed in order to further define the

expression pattern of brPTB protein in rat and mouse tissues (Figure 6). Strong re

to the brPTB -specific antibody was present in most brain tissues including cerebe
brainstem, spinal cord and hypothalamus (Figure 6A, B, C and D). brPTB was also

expressed in the peripheral nervous system and neural crest derivatives, including

dorsal root and trigeminal ganglia (Figure 6C and D), the cochlear spiral and inte

ganglion cells (Figure 6E and F) and the adrenal medulla (Figure 6C). Non-neural t
that expressed brPTB included the heart and, at low levels, the liver and adrenal
(Figure 6C and data not shown).
To examine the subcellular distribution of brPTB, we used immunofluorescence

microscopy on rat sections. brPTB protein is predominantly nuclear and stains both
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neurons and astrocytes in confocal microscopy images of cells doubly stained for brPTB

and the neuronal marker MAP2 (Figure 6G) or the astrocytic marker GFAP (Figure 6H).
While not strictly a neuronal protein like Nova, brPTB is preferentially enriched

nervous system where it stains neurons as well as other cell types such as astrocy

brPTB and Nova proteins interact in vitro and in vivo
To confirm the results of the yeast two-hybrid assay, and to demonstrate that the

brPTB interaction is not dependent on additional yeast proteins or RNA, we assayed

interaction between brPTB and the Nova proteins in vitro and in vivo, using a GST p

down assay. In vitro, purified brPTB specifically interacts with Noval and Nova2 f

proteins, and this interaction is not affected by pre-treating each protein sample
RNAse A (Figure 7A).
In N2A cells, a neuroblastoma cell line that expresses endogenous brPTB (see
below), transfected Noval and Nova2 GST-fusion expression vectors result in the
precipitation of the endogenous brPTB protein (Figure 7B). In contrast, a control
transfection with a vector expressing GST protein alone does not pull down brPTB.
Taken together, these data demonstrate that brPTB and Nova proteins are capable of

interacting directly and independently of an RNA intermediate in both the test tub
cultured cell lines.
We further dissected the interaction between brPTB and the Nova proteins by

using truncation constructs in the yeast-two hybrid assay (Figure 8). The spacer d

of Nova2 (aa 230-407) lacks a KH-type RNA-binding motif but is sufficient in produ

as robust an interaction with brPTB as were full length Noval or Nova2, confirming
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result of the G S T pull-down assay that no R N A intermediate is required for the NovabrPTB interaction.
In contrast, no single brPTB deletion construct was adequate in mediating a
strong interaction with Nova. Multiple peptide domains in the brPTB protein seem to be
required for the contact with Nova as witnessed by the fact that non-overlapping
truncation mutants of brPTB were incapable of interacting with Nova as strongly as the
full length protein. From these experiments, at least two important regions in brPTB can
be identified that are necessary for the interaction with Nova, one in the N terminus and
another in the C terminus. However, these conclusions are preliminary since the question
of functionality and proper structural folding of the truncation mutants in the yeast
system needs to be addressed. The truncation constructs were indeed capable of
expressing proteins of the appropriate size as judged by Western blot assays of yeast cell
lysates (data not shown).
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Discussion

A novel, brain-enriched, PTB-like protein has been identified that specifically in

with the neurologic disease antigen Nova. Several earlier studies predicted the ex
of a neuronal isoform of PTB. Three distinct isoforms of PTB are known, each with

different sizes of a spacer region between the second and third RNA binding domain

(Gil et al., 1991; Patton et al., 1991; reviewed in Wagner and Garcia-Blanco, 2001).
existence of a neuronal PTB homologue was predicted from studies of cell extracts

were able to replicate aspects of neuron-specific alternative splicing in vitro (r
Grabowski, 1998). These studies documented a PTB-like protein species enriched in

nuclear extracts of brain tissue (Ashiya and Grabowski, 1997) and retinoblastoma c
lines (Chan and Black, 1997) that migrated more slowly on SDS-PAGE than PTB

(around 59 kDa; named p59 or nPTB). The brPTB cDNA clone identified here predicts a

protein that is slightly larger than PTB (57.6 vs. 57.2 kDa; Gil et al., 1991), and
likely the previously identified p59/nPTB brain-enriched species.
Yeast two-hybrid screens using Nova proteins as bait identified several PTB-

related RNA-binding proteins. Four of the most robustly interacting proteins in th

screens were PTB, hnRNP L, matrin3 and brPTB. These proteins constitute a subfamil
of RRM-type RNA binding proteins, as first suggested by comparisons of PTB and

hnRNP L (Ghetti et al., 1992), because their RRM motifs are strongly homologous wit

each other but only weakly homologous to the canonical RRM consensus sequence. The

interactions between Nova and the various members of this subfamily suggest that t
may be mediated by a domain shared among these proteins, which seems likely to

include the atypical RRM motif itself. However, mapping of the interaction between

71

Nova and brPTB failed to reveal a single deletion mutant that interacted strongly with

Nova, suggesting either that the full-length protein is necessary for the interact

several different domains are important for a robust interaction. It is also possi
improper structural folding of the deletion constructs precluded any interaction.
While matrin3 was the only protein that was isolated with both Noval and Nova2

baits, it can be further supported from the results of the yeast-two-hybrid screen
two Nova proteins participate in comparable types of protein-protein interactions
quite possibly, through the same peptide domains. First, Noval and Nova2 have very

high amino acid sequence identity and prominent structural similarities (Buckanovi

al, 1996; Yang et al, 1998; Lewis et al, 1999; Lewis et al, 2000). Second, they int
homotypically and heterotypically with each other (Yang, 1997; Yang et al., 1998;

8). Third, they are able to function as baits in yeast-two-hybrid screens and iden

proteins belonging to the same family of RNA-binding proteins: Noval interacts wit
HuB, HuD and matrin3 and Nova2 interacts with HuA, hnRNP L, matrin3, PTB and

brPTB (Table 1). These interactions of Nova proteins are highly likely to be media

similar structural motifs and point to their possible interchangeability within th

system. Preliminary evidence from our lab has hinted at a compensatory mechanism f
the expression of Nova2 in Noval-null mice (M. Ruggiu and R. Darnell, unpublished
observations).
The region of highest sequence divergence between Noval and Nova2 is the
spacer region between RNA-binding domains KH2 and KH3. It has not been possible to
use the Noval spacer as bait in a yeast-two-hybrid screen as it activates the LexA

promoter on its own without the need for a GAD-fusion prey. However, given the prey
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isolated with the N o v a 2 spacer and their resemblance to the ones isolated by N o v a l and

Nova2 full-length constructs, it is unlikely that drastically different proteins would have
been identified by a screen with the Noval spacer domain as bait. Furthermore, fulllength Noval and Nova2 constructs exhibit the same behavior in their interactions with
some of the prey isolated in the screens performed here (see Table 2 and Figures 7 and 8).
For a complete list of prey isolated with the Nova2 spacer and their interactions with
Nova constructs in yeast-two-hybrid see the Appendix.
The experiments presented have identified proteins that interact with Noval and
Nova2. In the yeast-two-hybrid screens, some proteins were isolated independently in
different screens or had sequence and domain similarities with other prey, even belonging
to the same sub-family of proteins. Because of this and by virtue of their expression

pattern and their functional attributes it seems likely that these interactions are real an
biologically significant. In one example, that of the newly-identified, brain-enriched
homologue of PTB, the interaction with Nova has been verified in vitro and in vivo.
Thus, attractive hypotheses can be formed about the effect that these interactions may
have on the function of Nova proteins and about the roles that Nova proteins may play in
RNA metabolism within the cellular environment.
The expression of brPTB is significantly enriched in the brain at the mRNA and

protein level (this work; Lillevali et al., 2001). It is also robustly expressed in the test
and at much lower levels in the heart and skeletal muscle. The expression of PTB mRNA
is thought to be mostly ubiquitous (Markovtsov et al. 2000; Polydorides et al., 2000;

Figure 3) although this is controversial as some reports claim significantly reduced levels

in adult brain (Patton et al., 1991; Lillevali et al., 2001) and skeletal muscle (Lillevali
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al., 2001). Reports on the protein expression of P T B are also contradicting in that it is
found in several neural cell lines (Markovtsov et al. 2000) but not in nuclear extracts
from rat brain (Ashiya and Grabowski, 1997).
Several lines of evidence suggest that the interaction between brPTB and Nova is
real and of biological significance. Both proteins are expressed in the same cells, i.e.
neurons, and while brPTB is also expressed in other cells of the nervous system, such as
glial cells, as well as in other tissues altogether, its brain-enriched expression pattern
suggests that it is of functional importance in the nervous system. Nova and brPTB are
predominantly nuclear proteins and share homology with hnRNP K and I, respectively,
both of which are mostly nuclear proteins that are known to participate in various aspects
of RNA metabolism. The two proteins are able to interact in vitro without any RNA
intermediates and in vivo as GST-Nova fusion constructs overexpressed in N2A cells pull
down endogenous brPTB protein. An attempt to co-immunoprecipitate endogenous
proteins from brain tissues using either the anti-brPTB polyclonal antibody or anti-Nova
patient serum was unsuccessful. In the latter case, it is possible that the anti-Nova serum

disrupted protein-protein interactions, since it is thought to recognize parts of the space
and third KH domains of the Nova proteins which have been shown here to mediate, at
least partially, the interaction with brPTB (Buckanovich et al., 1996; Dredge and Darnell,
personal communication; Figure 8). To verify that brPTB and Nova proteins interact
functionally, immunofluorecence studies were performed on their nuclear localization
(Chapter 5). The effect of this interaction was tested with in vivo splicing assays that
have recently been developed for Nova (Chapter 4).
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The interactions with known splicing factors and regulators (such as SRp20 and

hnRNP I/PTB) would suggest that Nova contributes to the splicing regulation of som

its RNA targets (see Chapter 4). Another function for Nova proteins could be in the

nuclear export of mRNA messages due to its interaction with proteins that particip
such transport (e.g. hnRNP L and hnRNP I/PTB). The cellular protein p32/YL2 was
originally identified due to its co-purification with the SR protein ASF/SF2 from

cells (Krainer et al., 1991). It has been shown to interact with many viral protein

including the HTV Rev and Tat proteins (Luo et al., 1994; Yu et al., 1995). The mur

homologue of p32, called YL2, increases the nuclear export of unspliced viral mess

mediated by Rev (Luo et al., 1994). Furthermore, Rev acts a bridge between its resp

element (RRE) on the RNA and p32 (Tange et al., 1996). Together with the interactio

between p32 and ASF/SF2, this suggests that p32 acts to mediate an interaction bet

Rev and the splicing machinery, perhaps allowing Rev-bound viral RNAs to bypass th
splicing apparatus and other checkpoints and to be exported unspliced. In concert

this theory, p32 has been found to specifically inhibit ASF/SF2 phosphorylation an

inactivate it as a splicing enhancer or repressor (Petersen-Mahrt et al., 1999). Si
contains a Rev-like NES sequence its interaction with p32/YL2, if proven, can have
significant functional implications in its action in splicing and nuclear export.
The interaction of Nova with the Hu family of proteins is interesting because

these proteins are paraneoplastic antigens as well and may suggest an interplay am
proteins whose ectopic expression appears to be beneficial for some tumors. The Hu

proteins participate in the control of mRNA stability and translation and a role c

envisioned in these processes for the small but significant portion of Nova that i
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cytoplasmic. Finally, many of these proteins (such as SRp20, P T B , matrin3, h n R N P L)

form distinct structures in the eukaryotic nucleus and the participation of Nova i
formation of such bodies will be examined (see Chapter 5).
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Table 1. Yeast two-hybrid screens with N o v a protein constructs.

LD40 yeast host strains were transformed with the indicated bait constructs (Bait,

fusions) and mouse libraries (Library, GAD fusions). Positive prey were isolated b

growth on His" media and selected by positive (blue) LacZ staining in a colony li

assay (see Materials and Methods). The identities of the interacting proteins were
determined by examining prey sequences against the NCBI database (Prey isolated).

11.5: embryonic day 11.5 whole mouse library. # Clones: total number of independen

clones in the library. % ser: percentage of clones in the library that were scree

multiple transformations, aa: amino acid sequence. The first two full-length Nova2
screens presented here were the result of previous work (Yang, 1997).
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Bait

Library

Nova2

adult brain

# Clones

1.5x106

%

ser.

407

full length

P r e v isolated

matrin3
HuB
brPTB

Nova2

E 11.5

1.2 x 1 0 6

758

full length

matrin3
PTB
SRp20
hnRNP L

Nova2

E11.5

1.2 x 1 0 6

167

(aa 2 3 0 - 4 0 7 )

p32/YL2
HuA
novel

Noval

adult brain

1.5 x 1 0 6

107

RRM

matrin3
HuB

full length

HuD

Noval
full length

E 11.5

1.2 x 1 0 6

142

matrin3

Figure 1. Nucleotide a n d a m i n o acid sequence of m o u s e b r P T B .

The cDNA sequence of mouse brPTB contains a 1.6 kb open reading frame encoding for
a predicted 532 amino acids. The four RRM-type RNA-binding domains are boxed. A

putative nuclear localization sequence (NLS) is marked with a double underline. Th
polyadenylation signal located approximately 300 bp upstream of the poly(A) tail

underlined. A bold box indicates an amino acid not present in the cDNA clone from

yeast two-hybrid library. Nucleotide number from the start of the clone is indica
the right. ***: stop codon.
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CTGGCTCCGTGGCTCGGTTCTTC^GAGCGAAGCTTTGTCCGGTTCGGCA
CTA
Leu
GAA
Glu
CCT
Pro
AAT
Asn
AAC
Asn

ACT
Thr
GGT
Gly

CTC
Leu
GAT
Asp
TTT
Phe
TAC
Tyr
CAA
Gin

CCA
Pro
GCT
Ala

TCA
Ser
AAA
Lys
GGT
Gly
TAT
Tyr
CGT
Arg

GCC
Ala
GTA
Va]

GGC
Gly
ATG
Met
AAG
Lys
TCT
Ser
GCG
Ala

AGT
Ser
GAT
Asp
GTG
Val
GCT
Ala
CAA
Gin

CAG AGT
Gin Ser
TTG AAG
Leu Lys

GTT
Val
GGG
Gly
ACT
Thr
GTG
Val
GTA
Val

CTC
Leu
GCT
Ala
AAC
Asn
ACA
Thr
GTT
Val

AGC
Ser
CCC
Pro
ATC
He
CCT
Pro
CTT
Leu

CCA GTA CTT
Pro Val Leu
ATA ATC ACA
He He Thr

AGC
Ser
TCT
Ser
CTT
Leu
CAT
His
CAA
Gin

AGA
Arg
TTT
Phe

CCC
Pro
CGT
Arg
ATG
Met
CTT
Leu
GCT
Ala

AAC
Asn
GTA
val
CTG
Leu
CGT
Arg
GTG
Val

TCT
Ser
CTT
Leu
AAA
Lys
AAC
Asn
ACA
Thr

ATA ATT ATT
He He He
ACA AAA AAC
Thr Lys Asn

AAT
Asn
CAC
His
GGA
Gly
CAA
Gin
GCG
Ala

GAC
Asp
AAC
Asn

ATG
Met
ATG
Met
ATT
He
AAA
Lys
CCA
Pro
GTC
Val

GAC
Asp
AGT
Ser
CGA
Arg
AAC
Asn
ATT
He
CAG
Gin

GGA
Gly
GGC
Gly
AAG
Lys
CAG
Gin
TAC
Tyr
ACA
Thr

ATT
He
ATG
Met
TTA
Leu
GCA
Ala
ATC
He
GCA
Ala

AAT ATG TAC TAC
Asn Met Tyr Tyr
CAG TTT CAG GCT
Gin Phe Gin Ala

GTC
Val
GTA
val
CCT
Pro
TTT
Phe
CAG
Gin
AAT
Asn

CCT
Pro
TTG
Leu

ACT
Thr
GTT
Val
GGT
Gly
TTG
Leu
TAC
Tyr
ACA
Thr

GAG
Glu
ACA
Thr
GAA
Glu
GAA
Glu
TCC
Ser
CCT
Pro

GTT
Val
GCC
Ala
GTG
Val
CTG
Leu
AAT
Asn
CTT
Leu

GTA ACA CTT
Val Thr Leu
CTC CAG TAT
Leu Glr. Tyr

GCT
Ala
AAC
Asn
ACT
Thr
GCA
Ala
CAC
His
AGT
Ser

GAT
Asp
GGT
Gly

GTT
Val
GGT
Gly
GAA
Glu
ACA
Thr
AAA
Lys
GGC
Gly

GTC
Val
GAT
Asp

GGT
Gly
AAC
Asn
ACA
Thr
GAG
Glu
GAA
Glu
ACC
Thr

CTT
Leu
CCG
Pro

GTG
Val
GAT
Asp
GAA
Glu
GAA
Glu
CTA
Leu
ACA
Thr

AAG
Lys
AGT
Ser
GTT
Val
GCA
Ala
AAG
Lys
GTC
Val

AGA
Arg
AAG
Lys
ATT
He
GCT
Ala
ACA
Thr
AGT
Ser

GGA
Gly
AAA
Lys
GCT
Ala
ATT
He
GAT
Asp
GAG
Glu

TCT
Ser
TTT
Phe
TTA
Leu
ACT
Thr
AAT
Asn
AGT
Ser

GAC
Asp
AAA
Lys
GGT
Gly
ATG
Met
ACA
Thr
GCG
Ala

CAC CAA ATA TTT TCT AAG
HisGin He Phe Ser Lys
GTA AAC GCT CAA CAA GCC
Val Asn Ala Gin Gin Ala

GAG
Glu
GGA
Gly
TTA
Leu
GTT
Val
TTA
Leu
GTG
Val

TTT
Phe
AAG
Lys

CTA
Leu
GAT
Asp
ACA
Thr

GCC CTA GAT GGT CAA AAT ATT TAT AAT GCT TGC TGT ACC CTA AGG ATT GAT TTT TCC AAA CTT GTG AAT TTG AAT GTA AAA TAC AAC AAT
Ala Leu Asp Gly Gin Asn H e Tyr Asn Ala Cys Cys Thr Leu Arg H e Asp Phe Ser Lys Leu Val Asn Leu Asn Val Lys Tyr Asn Asn
AAA AGT AGG GAT TAT ACT CGA CCT GAT CTG CCA TCT GGA GAC GGC CAG CCT GCG TTA GAC CCA GCC ATT GCT GCA GCA TTT GCC AAG GAG
Lys Ser Arg Asp Tyr Thr Arg Pro Asp Leu Pro Ser Gly Asp Gly Gin Pro Ala Leu Asp Pro Ala H e Ala Ala Ala Phe Ala Lys Glu
TCC CTA CTA GCT GTT CCA GGG GCT CTC AGT CCT TTG GCT ATT CCA AAT GCT GCT GCA GCA GCT GCT GCC GCT GCC GCT GGC CGA GTG GGC
Ser Leu Leu Ala Val Pro Gly Ala Leu Ser Pro Leu Ala H e Pro Asn Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Gly Arg Val Gly
ATG CCT GGA GTC TCA GCT GGT GGC AAT ACA GTC CTG TTG GTT AGC AAT TTA AAT GAA GAG ATG GTT ACG CCC CAA AGT CTG TTT ACC CTC TTC
Met Pro Gly Val Ser Ala Gly Gly Asn Thr Val Leu Leu Val Ser Asn Leu Asn Glu Glu Met Val Thr Pro Gin Ser Leu Phe Thr Leu Phe
GGT GTT TAT GGA GAT GTG CAG CGC GTG AAG ATT CTG TAC AAT AAG AAA GAC AGT GCT CTG ATA CAG ATG GCT GAT GGG AAC CAG TCC CAG CTC
Gly Val Tyr Gly Asp Val Gin Arg Val Lys H e Leu Tyr Asn Lys Lys Asp Ser Ala Leu H e Gin Met Ala Asp Gly Asn Gin Ser Gin Leu
GCC ATG AAT CAT CTT AAT GGG CAG AAG ATG TAT GGA AAA ATT ATT CGT GTT ACT CTC TCT AAA CAT CAG ACT GTG CAA CTA CCT CGA GAG GGA
Ala Met Asn His Leu Asn Gly Glr. Lys Met Tyr Gly Lys H e H e Arg Val Thr Leu Ser Lys His Gin Thr Val Gin Leu Pro Arg Glu Gly
CTT GAT GAT CAA GGG CTA ACA AAA GAT TTT GGG AAT TCA CCA CTG CAC CGT TTT AAA AAA CCG GGA TCC AAA AAC TTT CAG AAC ATT TTC CCT
Leu Asp Asp Gin Gly Leu Thr Lys Asp Phe Gly Asn Ser Pro Leu His Arg Phe Lys Lys Pro Gly Ser Lys Asn Phe Gin Asn H e Phe Pre
CCT TCT GCT ACC CTT CAC CTG TCT AAC ATC CCC CCT TCT GTA GCA GAA GAG GAT CTG CGA ACT CTG TTT GCC AAC ACC GGG GGC ACT GTG AAA
Pro Ser Ala Thr Leu His Leu Ser Asn H e Pro Pro Ser Val Ala Glu Glu Asp Leu Arg Thr Leu Phe Ala Asn Thr Gly Gly Thr Val Lys
GCA TTT AAG TTT TTT CAA AGA GAT CAC AAA ATG GCT CTT CTT CAG ATG GCA ACA GTG GAG GAA GCT ATT CAG GCT TTG ATT GAT CTT CAT AAT
Ala Phe Lys Phe Phe Gin Arg Asp His Lys Met Ala Leu Leu Gin Met Ala Thr Val Glu Glu Ala H e Gin Ala Leu H e Asp Leu His Asn
TAT AAC CTT GGA GAA AAC CAT CAT CTG AGA GTG TCT TTC TCC AAG TCA ACA ATC TAA GCACGGGAGATGAAGATGGCGGGCAGATCCCATTGTTGGTGTCATCA
Tyr Asn Leu Gly Glu Asn His His Leu Arg Val Ser Phe Ser Lys Ser Thr H e ***
CCTATTGACTGTTCAGAAAAGTGGGGGACCAGAGTTTGATTTTTTTCATGCTGTTATCATTCCTTGGTTATAAAA 1816
GTTCAATAGGGAAGCCATTTTTGTCTGTTTAAATTTTTAGTTTAATTTTC
TACTAGG AAAAAGG AATTGGTTGTTTAGGGCAC ATCGTTATGTGGG AATTAAAATATGTTTGGGC AGGGGTGTC
TTGGCTTATCACATTTCTTTCTATTTAATCTAATAAGATACTTGATACTGAGAGTATAAAACAGC^
CTCACAAATCTGGTCTAGATTCAGTTATGAATGTAGGCATTAGTTAAAATTAACAAGATGCA^
TGGAACCTT-^CCTTTTTCTACACACTCTTGTGGGACGTCTCATATAAATGTCAGCA
CATTTAAATATATATTGCCATCCTTAGTTTGTAATTAAGATTTGGAAAATGGTTGTGGA
AAGAAAGTCTACTGCGAAAACTTGCAGGAAGATTAATTTTGTGGCAGTTT^
AGTTT-^ET^^rTTCAAAATATTTTGTATTTAGGAATAGATCTG
TGTTAAATGACCAATACTTTTTGAAATTGATGTACTTAGTTTCAAGATTCATAGATTCTC
ATGTAAAATTGTATAGTTTGAAAGCGGCACA.^TTAAAJ^TTAATTTTCTAACAAAAAAAAAAAAAAAAAAAA
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1941
2064
2187
2310
24 33
2556
267 9
2B02
292 5
2999

Figure 2. A sub-family of R R M - t y p e R B P s interacts with N o v a .
Alignment of the RRM motifs from mouse brPTB (Figure 1), mouse PTB (Bothwell et

al, 1991), human hnRNPL (Pinol-Roma et al., 1989), and rat matrin3 Q3elgrader et al.

1991) shows that these proteins comprise a distinct subset of RRM-containing prot

based on the presence of RNP motifs that do not conform to those present in the RR

consensus (Burd and Dreyfuss, 1994). Similar amino acids are color coded and dashe
are inserted in the sequence for alignment purposes.
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Table 2. Interactions of N o v a l a n d N o v a 2 with R R M - t y p e proteins.

LD40 yeast host strains were transformed with the indicated bait (LexA fusion) an

(GAD fusion) constructs and their interaction was scored by staining for LacZ exp

and growth on His-media. Negative controls included unrelated proteins fused to G
(TD1) and LexA (TRFI). +++, robust staining and growth; -, no staining or growth;
GAD: Gal4 Activation Domain; ND: not determined.
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Bait ( L e x A )
LacZ
TRF1

His"

Noval

Nova2

Noval

Nova2

+++

+++

+++

+++

h n R N P I/PTB

ND

+++

ND

+++

hnRNP L

ND

+++

ND

+++

+++

+++

+++

+++

Prey ( G A D )
TD1
brPTB

matrin 3

Figure 3. b r P T B m R N A levels are enriched in the brain.

Northern blot of total RNA from the indicated mouse tissues and developmental sta

(20 (ig/lane), probed with a 1.3 kb DNA probe from the coding sequence of brPTB (t

panel). The blot was stripped and reprobed with a 1.2 kb probe from the coding seq

of PTB (bottom panel). The two messages were of approximately the same size (3.6 k
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Figure 4. Production of a brPTB-specific polyclonal antibody.

(A) Western blot of total rat cerebellum and brainstem tissue proteins (20 u.g/lan

probed with rabbit polyclonal anti-brPTB serum (left panel) or pre-immune serum (

panel, P.I.) from the same animal (see Materials and Methods). A band of approxima

57 kDa is recognized only after the immunization with full length brPTB fusion pr

(B) Western blot of purified recombinant PTB and brPTB fusion proteins as indicat

(50 ng/lane), probed with anti-brPTB serum (left panel, 1:5000 dilution). Polyclon
anti-brPTB serum specifically recognizes the brPTB fusion protein but not PTB. A

duplicate blot was probed with PTB polyclonal antibody (right panel, 1:500 diluti
served as a loading control. Molecular weight markers are indicated in the middle
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Figure 5. b r P T B protein levels are enriched in the brain.

Western blot of the indicated mouse tissues (50 fig total protein/lane), probed wi

various primary antibodies. Molecular weight markers are indicated on the left (kD
Polyclonal anti-brPTB antibody recognizes a 57 kDa band most prominent in brain

tissues and the testis (top panel). POMA patient serum shows that Nova proteins ar
restricted in the brain (middle panel). A polyclonal anti-HuA antibody recognizes
ubiquitously expressed Hu isoform (Fan and Steitz, 1998a) and served as a loading
control (bottom panel).
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Figure 6. Immunoreactivity of b r P T B in rat a n d m o u s e tissues.
(A) Sagittal section from E16 rat, stained with brPTB polyclonal antibody shows

reactivity in most cells of the brain, including cerebellum (cb) and brain stem (b
(B) brPTB immunoreactivity in rat spinal cord and dorsal root ganglia (arrows).

(C, D) brPTB expression in the developing peripheral nervous system. Immunostainin

of E16 rat sagittal sections indicate that brPTB expression is strong in embryonic
root ganglia (C, arrow), trigeminal ganglia (D, arrow), developing adrenal medulla
arrowhead) and hypothalamus (D, ht) however very low in liver (C, lv) and adrenal
primordium (C, ap).

(E) brPTB staining in P5 mouse cochlea. Note the intensive staining in cochlear sp
ganglion cells (arrow).

(F) brPTB expression in the ganglion cells of the small intestine (E16 rat embryo)
(G) Confocal image of immunofluorescent double exposure for MAP2 (green) and
brPTB (red) in a sagittal section of E16 rat cortex.
(H) Confocal image of immunofluorescence double exposure for GFAP (green) and
brPTB (red) in a sagittal section of adult rat cerebellum.
Scale bars: 80 um in A-E; 160 u.m in F; 3.4 ium in G; 2.3 fim in H.

Control sections stained with pre-immune serum or with brPTB antibody pre-adsorbed
with brPTB fusion protein were negative (data not shown).
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B

Figure 7. N o v a a n d b r P T B proteins interact in vitro a n d in vivo.

(A) In vitro GST pul-down assay. Five jug of purified recombinant GST, GST-Noval o
GST-Nova2 fusion proteins as indicated, were incubated with 2 (xg of purified
recombinant T7-tagged brPTB fusion protein. The T7-brPTB protein that was

precipitated by Glutathione Sepharose beads was assayed by Western Blot using an a
T7 monoclonal antibody (top panel, a-T7). The presence of equal amounts of GST

fusion proteins in each precipitation reaction was confirmed by probing the same b

with an anti-GST polyclonal antibody (middle panel, cc-GST). T7-brPTB runs at 59 kD
GST at 27 kDa, GST-Noval at 82 kDa and GST-Nova2 at 80 kDa. To examine whether

RNA was needed for the Nova-brPTB interaction, pull down assays were repeated in t
presence (left column, +RNAse) or absence (right column, -RNAse) of 1 mg/ml RNAse

A. To confirm the activity of the RNAse, reactions were spiked with 32P-labelled R
and aliquots were run on denaturing urea/polyacrylamide gels and exposed by
autoradiography (bottom panel).
(B) In vivo GST pull-down assay. Equal amounts of GST, GST-Noval and GST-Nova2

eukaryotic expression vectors were transfected into N2A cells as indicated. Cell l

were incubated with glutathione sepharose beads and the amount of endogenous brPTB

precipitated was assayed by Western Blot using the brPTB -specific polyclonal anti

(top panel, cc-brPTB). Lysate from untransfected N2A cells (cell lysate) identifie
endogenous brPTB band. The same blot was also probed with a polyclonal GST

antibody (bottom panel, a-GST) to confirm expression of the transfected GST protei
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Figure 8. Yeast two-hybrid interactions between N o v a a n d b r P T B .

A number of bait constructs (LexA fusions) encoding for the indicated Noval or No
amino acids (rows) were co-transformed with different Noval, Nova2 or brPTB

activation constructs (GAD fusions) as indicated (columns). Interaction was measur
P-galactosidase activity in a colony lift/X-gal assay (++, very strong staining;

staining; +/-, weak staining or not all colonies positive; , no staining). Control
(pVA3) and prey (pTDl) transformations exhibited no (3-galactosidase activity, as
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Introduction

Alternative splicing is an important mechanism by which cells regulate gene expres

and generate diversity (reviewed in Smith and Valcarcel, 2000). Neurons specificall

make great use of alternative splicing in order to regulate functional differences
proteins (reviewed in Dredge et al., 2001; Grabowski and Black, 2001). For example,
wide variety of neurotransmitter receptor activities are regulated by alternative
including regulation of the NR1 NMDA receptor subcellular localization (Ehlers et

1995) and its interaction with the neurofilament subunit NF-L (Ehlers et al., 1998)
physiology of the glutamate (Sommer et al., 1990) and NMDA (Hollmann et al., 1993)
receptors, and the ability of agrin to induce clustering of acetylcholine receptors (Ferns
al., 1992; Tsim et al., 1992). Moreover, several neurologic diseases such as spinal
muscular atrophy, amyotrophic lateral sclerosis and paraneoplastic opsoclonusmyoclonus ataxia (POMA) have been associated with defects in proteins involved in
generating the splicing machinery or in the accurate splicing of target RNAs (Fischer et
al., 1997; Liu et al., 1997; Jensen et al., 2000a; for review see Dredge et al., 2001).
Since the discovery of tissue-specific splicing of the calcitonin/CGRP transcript in
neurons, there has been an extensive search for cis-acting RNA elements and trans-acting
factors (RNA-binding proteins) that mediate neuron-specific splicing. The first example
of cis-acting regulatory elements in neuronal pre-mRNAs was identified in the

87

calcitonin/CGRP p r e - m R N A (Amara et al., 1982; E m e s o n et al., 1989) and a number of
specific sequences have been identified that are responsible for calcitonin/CGRP tissuespecific processing (Emeson, et al., 1989; Hedjran et al., 1997; Lou et al., 1999).
Subsequent work identified regulatory sequences near other neuron-specific exons such
as the Nl exon of src (Black, 1992) and a 24 nucleotide exon of the GABAA receptor y2
subunit (Zhang et al., 1996).
The identification of trans-acting factors that regulate neuronal splicing has been a
greater challenge. Two general mechanisms might account for the way such factors

could mediate regulation of neuronal splicing. Brain-specific variants in splicing patterns
could be achieved by differing levels or modifications of ubiquitously expressed splicing
factors. For example, antagonism between the hnRNP Al and ASF/SF2 proteins
determines the selection of 5' splice site (Krainer et al., 1990; Ge et al., 1991; Mayeda
and Krainer, 1992; Caceres et al., 1994; Horowitz and Krainer, 1994), and varying ratios
of these proteins have been shown to affect neuron-specific splicing of clathrin exon EN
in cell transfection studies (Caceres, et al., 1994). Additionally, post-translational
modifications such as phosphorylation influence the activity of general splicing factors
including ASF/SF2 (Colwill et al., 1996; Duncan et al., 1997; Misteli et al., 1997; Xiao
and Manley, 1998; Petersen-Mahrt et al., 1999). Such variations might be difficult to
detect if they are transient or localized to specific cell types and not reflected in the
overall tissue distribution of the proteins. This may be particularly true in the brain
where there is great complexity in cell type and number.
A second and perhaps more direct way to regulate pre-mRNA splicing in neurons
would be to utilize tissue-restricted regulatory proteins. But evidence for such trans-
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acting factors has been limited. Some examples of tissue-restricted splicing events

concern the polypyrimidine tract binding protein (PTB; reviewed in Wagner and Garc

Blanco, 2001). PTB is thought to represses the neuron-specific splicing of calcitoni
CGRP pre-mRNA in non-neuronal cells (Lou et al., 1996; Lou, et al., 1999).

Furthermore, PTB has been implicated in tissue-specific alternative splicing event

a-tropomyocin and a-actinin transcripts, where it is thought to repress exons in a

specific manner (Gooding et al., 1998; Southby et al., 1999). Finally, data have em

that support a model whereby PTB acts as a universal repressor of alternatively sp
exons. For example, in the fibroblast growth factor receptor 2 (FGFR2) transcript,
splicing of exon Illb is actively repressed by PTB, and this inhibition has to be
for successful splicing in certain cell types (Carstens et al., 2000).
Some reports have identified a brain-enriched protein recognized by PTB

antibodies (Ashiya and Grabowski, 1997; Zhang et al., 1999). Neuron-specific splici

of c-src involves several generally expressed RNA binding proteins (Chan and Black

1997; Min et al., 1997; Chou et al., 1999), including KSRP which is enriched in bra

(Min, et al., 1997). Also, there is data that the neuron-specific RNA binding prote

may regulate splice site selection in Drosophila neurons (Koushika et al., 1996; K
et al., 2000; Lisbin et al., 2001).
Recently, there has been evidence that the neuron-specific RNA-binding protein

Noval regulates alternative splicing in neurons (Jensen et al., 2000a). In vitro RN

selection experiments identified stem-loop RNAs harboring UCAU elements in the loo

sequence to which Noval and Nova2 proteins bound with sequence-specificity and hig

affinity (Buckanovich and Darnell, 1997; Yang et al., 1998). The co-crystal structu
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Nova bound to an in vitro selected U C A Y element has been solved (Lewis et al., 2000),
which confirms the specific nature of the Nova-RNA interaction. The Noval RNA

selection consensus sequence matched an intronic UCAU repeat element in the glycin

receptor a2 subunit (GlyRa2) pre-mRNA and identified it as a candidate Nova target

Co-precipitation and cross-linking experiments demonstrated that Nova in brain ext

specifically interacted with the GlyRa2 UCAU repeat element, and co-transfection a
demonstrated that Noval enhanced utilization of an adjacent 3' splice site of an

alternatively spliced exon, E3A (Buckanovich and Darnell, 1997; Jensen et al., 2000

Conversely, Noval-null mice have a specific defect in the utilization of GlyRa2 ex

E3A demonstrating that Noval is necessary for accurate GlyRa2 exon selection in vi

(Jensen et al., 2000a). Furthermore, a second target of Noval splicing control, the

GABAA receptor y2 subunit (GABAARy2) mRNA, exhibits specific splicing defects of a

alternative exon in the absence of Noval in vivo. In light of these results, exper
were performed to address the effect of the brPTB-Nova interaction in the control

alternative exon selection in the GlyRa2 and GABAARy2 transcripts, and are present
below.
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Results

brPTB downregulates Nova-dependent splicing activation ofGlyRal

It has been previously demonstrated that the Nova protein regulates the alternativ

splicing of glycine receptor a2 subunit (GlyRa2) pre-mRNA by specifically increasi

the inclusion of exon 3A at the expense of exon 3B (Jensen et al., 2000a). Furtherm
this activation of splicing by Noval was shown to be dependent on binding of the

GlyRoc2 RNA at Noval sites. To determine whether brPTB is able to affect the abili

Nova to activate GlyRa2 exon 3A inclusion, we co-transfected 293T cells with a Gly

minigene construct (Figure 9A) together with various concentrations of brPTB and N
The amount of protein expressed from the varying doses of transfected DNA was

verified by Western blot analysis (Figure 10A). The ratio of exon 3A over 3B in th
mRNA transcribed from the minigene was analyzed by an RT-PCR assay taking

advantage of a unique Sspl restriction site in exon 3A (Jensen et al., 2000a; Figu

The PCR product specifically depended on the presence of reverse transcriptase and
transfection with the minigene construct (Figure 10B; data not shown).
Noval transfection alone stimulated exon 3A inclusion by approximately two-

fold, as previously reported (Jensen et al., 2000a; Figure 11). When co-transfecte
brPTB suppressed the effect of Noval in a dose-dependent manner. When the maximum
amount of brPTB is co-transfected (6ug), the ratio of exon 3A/3B returns to levels
to those seen with no Noval activation at all. In control experiments, increasing

of transfected brPTB DNA in the absence of Noval did not alter the splicing patter
GlyRa2 pre-mRNA (Figure 11). These results suggest that the interaction between
brPTB and Noval is specific and functional in vivo.
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Inhibition ofGlyRa.2 splicing by b r P T B requires R N A binding
Earlier work has shown that Noval specifically binds to a GlyRa2 UCAU-repeat RNA
element located just upstream of exon 3A, the first of the two mutually exclusive
(Figure 9B). Interestingly, a consensus sequence binding site for PTB, consisting
UCUU element within a polypyrimidine tract, exists proximal to the Nova-binding
element. Given the high degree of sequence identity between brPTB and PTB, it was

proposed that brPTB binds to this PTB consensus site on the GlyRct2 intronic eleme
Filter binding assays were performed with brPTB and a radiolabeled 90
nucleotide RNA that included the Noval and PTB binding sites (Figures 9B and 12).

brPTB bound to this RNA, but with approximately a 12-fold reduced affinity (Kd = 5
nM) relative to Noval (Kd = 46 nM). Nonetheless, this binding is specific since no
detectable binding was observed to an unrelated piece of ribosomal RNA of similar

length. Furthermore, when the putative brPTB binding site on this 90 nt RNA fragme
was mutated (cytidine to thymidine; Figure 9B) its binding was reduced to the rRNA
background levels (C->T mutant in Figure 12).
When the co-transfection/splicing assays were repeated using a mutant GlyRa2
minigene harboring the C->T mutation that abrogated brPTB binding to isolated RNA

described above), brPTB was no longer able to block the ability of Nova to stimulat
exon 3A inclusion (Figure 13). The ratios of exon 3A/3B stayed at the high, Noval-

induced levels and increasing amounts of co-transfected brPTB did not bring them d
to baseline. Again, the presence of synthesized brPTB and Noval proteins in levels
related to the amount of transfected DNA in these experiments was confirmed by
Western blot analysis (data not shown). Taken together, these results suggest that
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inhibits the Noval-dependent activation of exon 3 A inclusion and that this action is

mediated, at least in part, by brPTB binding to the GlyRa2 pre-mRNA upstream of the

Noval binding site, since when binding of the brPTB protein is abolished, so is the
inhibitory effect on splicing.

brPTB and Noval form a complex on GlyRa2 intronic RNA
In order to study the interaction between brPTB and Noval in relation to this RNA

we performed electrophoretic mobility shift assays with the same radiolabeled GlyR
intronic RNA fragment and purified recombinant Noval and brPTB fusion proteins.
When each protein was independently added to the GlyRcc2 RNA fragment to a final
concentration of 100 nM the mobility of the RNA was shifted by Noval but not by
brPTB (arrow in top panel of Figure 14, compare lanes 3 and 5).
This was consistent with the results of the filter binding assays that showed

Noval affinity for this RNA piece to be at least ten-fold higher than brPTB and was
relatively equivalent in terms of binding constants. Noval protein had a Kd of 46

filter binding assays and was able to band shift the RNA complex at concentrations

100 nM (and to a lesser degree at 50 nM). Conversely, brPTB protein with a Kd of 55

nM in the filter binding assays did not result in a band shift at 50 or 100 nM, as
However, when concentrations of brPTB that did not bind RNA individually (50100 nM) were added to 100 nM of Noval, a supershifted complex was seen (arrowhead
in top panel of Figure 14, compare lanes 8 and 9 with 4 and 5) suggesting that if
already present on the RNA, brPTB can bind resulting in a brPTB-Nova-RNA complex.
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As a control, the same concentration of an unrelated protein (TRF2) did not affect the
mobility of the Nova-RNA complex (data not shown).
To examine whether the ability of brPTB to mediate this change in mobility was
dependent on Nova-RNA binding, we repeated these assays using a GlyRoc2 90 nt RNA
fragment in which the Noval-binding UCAU repeat elements were mutated to UAAU

(Figure 14 bottom panel). Using this mutant RNA, Noval binding was abolished and no

supershifted complex was observed, consistent with previous data showing that Nova

does not bind to this RNA (Buckanovich and Darnell. 1997; Jensen et al., 2000a). Ta

together, these results suggest that Noval and brPTB form a complex on GlyRcc2 tar

RNA upstream of the alternatively spliced exon 3A and that this complex is crucial
dependent on Noval binding the UCAU intronic RNA element.

brPTB inhibits splicing activation of GABAARy2

Similarly with the results obtained for the glycine receptor a2 subunit mRNA, Nova

been shown to regulate the alternative splicing of GABAA receptor y2 subunit (Jens

al., 2000a). In this case, exon 9 is alternatively spliced and its inclusion depend

presence of Noval as shown by splicing assays comparing RNA obtained from wild typ
and Noval knock-out mice. Furthermore, in splicing assays, the inclusion of exon 9
a GABAARy2 minigene (Figure 15A) is directly proportional to the amount of Noval
synthesized from a co-transfected construct (Dredge et al., work in progress; this
In 293T cells co-transfected with the GABAARy2 minigene construct, Noval

increased the inclusion of exon 9 by approximately four-fold (Figure 16). These as

were analogous to the ones performed with the GlyRa2 minigene and were based on RT-
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P C R analysis of R N A obtained from various transfected cell lines. The amount of

protein synthesized from the transfected constructs was verified by Western blot (
shown), and the relative ratios of long form (including exon 9) over short form
(excluding exon 9) of the GABAARy2 mRNA were determined by Phosphorimager

analysis. As can be seen in Figure 16, the increase in exon 9 inclusion obtained b
transfection of Noval is eliminated by simultaneous co-transfection of increasing

amounts of br-PTB. When there is no Noval present, brPTB still has an inhibitory e
on the inclusion of exon 9, however much less than in the presence of Noval. This

suggests that in this case, as opposed to GlyRoc2, brPTB plays a general repressiv
the inclusion of exon 9 that is not strictly dependent on the action of Noval.
In contrast to GlyRa2, Noval binding sites in the GABAARy2 pre-mRNA have
not been defined in detail (K. Dredge and R. Darnell, unpublished observations).

However, given the results with GlyRa2, we examined the intronic sequence upstream

alternatively spliced exon 9 in the GABAARy2 transcript. An 85 nucleotide fragment

immediately upstream of exon 9 contains three sites that seemed promising in terms
binding brPTB (Figure 15B). These included a total of three UCUU sequences in the
context of polypyrimidine tracts. Two of them were closer to each other and were
mutated together (RNA mutant GA2, Figure 15B). The other was mutated alone (RNA
mutant GA1, Figure 15B). However, whether one (GA1) or two (GA2) of these putative
brPTB sites were mutated, the net effect observed in binding assays was negligible

(Figure 17). These experiments failed to identify binding sites for brPTB immediat
upstream of the alternatively spliced exon in the GABAARy2 pre-mRNA.
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Consistent with this data, when 293T cells were transfected with G A B A A R y 2

minigene constructs containing these mutations, the inhibitory effect of brPTB rem
substantial (shown in Figure 18 for RNA mutant GA2; similar results obtained with
mutant GA1 are not shown). Therefore, brPTB inhibits Noval in the inclusion of
GABAARy2 exon 9, but this effect is not mediated by intronic UCUU RNA sequences
present immediately upstream of the alternative spliced exon.

brPTB has no effect on Nova-dependent alternative splicing in N2A cells

To examine the interaction of Nova and brPTB in the control of alternative splicin
environment that more closely resembles neurons in vivo, we performed the co-

transfection/splicing assays in cultured N2A cells, a neuroblastoma cell line. Sinc

cells contain endogenous Nova and brPTB (see below), the ratio of exon inclusion in

untransfected cells was expected to be different than 293T cells which do not cont

Noval. Indeed, the background level of the ratio of exon 3A over 3B with the GlyRa2
minigene was higher in N2A cells than in 293T cells (Figure 19; compare to Figure
Expression of additional, transfected Noval increased the inclusion of exon 3A

approximately two-fold. The 3A/3B exon ratios obtained in this experiment are slig

lower than the ones previously observed (Jensen et al., 2000a) and could be due to

optimal splicing from this minigene. However, the two-fold increase in the ratio u

addition of Noval is consistent with previous results. Co-transfection of increasi
amounts of brPTB, has no effect on the ratio of exon 3A over 3B that stays in the
induced levels (Figure 19).
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Similarly, in assays with the G A B A A R y 2 minigene, there is a ten-fold increase in
the inclusion of exon 9 compared to the ratio obtained with 293T cells (Figure 20;
compare to Figure 16) and it was closer to the ratios obtained from wild type tissue RNA
samples (Jensen et al., 2000a). The effect of Noval co-transfection is again striking,
increasing the inclusion of exon 9 by four-fold. However, the transfection of brPTB
expression vectors does not significantly inhibit the effect of Noval (Figure 20).

PTB inhibits Nova-dependent splicing activation ofGlyRcd
To test whether the original PTB homologue has a similar effect on the increase of exon
inclusion mediated by Noval, co-transfection/splicing assays were performed in 293T
cells with the wild type GlyRoc2 minigene. As shown in Figure 21, PTB has the same, if
not a stronger effect than brPTB in inhibiting Noval-dependent exon 3 A inclusion. The
transfection constructs for the two PTB homologues were based on the same vector with
the same promoters and polyadenyation sites but containing different epitope tags. Thus,
while Western blot analysis showed that both proteins were synthesized in increasing
levels with more DNA transfected, as before, it was impossible to compare the relative
levels of the two protein homologues as they were recognized by different primary
antibodies.
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Discussion

The action of brPTB to inhibit Nova-dependent activation of exon inclusion is cons
with the general role described for PTB in suppressing exon inclusion in pre-mRNA
splicing. This is believed to be mediated by PTB binding to polypyrimidine rich
elements in intronic sequences and blocking the assembly of a splicing competent

complex in a manner analogous to the action of Sxl in blocking U2AF65 binding of t

polypyrimidine tract (Valcarcel et al., 1993). For example, PTB acts to repress smo
muscle-specific inclusion of alternatively spliced exons in the a-tropomyosin and

actinin pre-mRNAs, by binding to regulatory elements upstream of the 3' splice sit
and Patton, 1995; Perez et al., 1997; Southby et al, 1999).
In neuronal cells, PTB inhibits inclusion of the c-src exon, in part by an action
3' splice-site selection that can be competed by U2AF65 (Chan and Black, 1997).

Similarly, previous studies with p59/nPTB as well as current studies on brPTB, all

to an inhibitory action on splice site selection. Even in the single instance wher

enhances exon inclusion in the alternative splicing of the calcitonin-CGRP pre-mRN

is believed to act by disrupting U2AF recognition of an enhancer pseudo-exon. ther
indirectly promoting correct exon utilization (Lou et al., 1999).
Given several instances in which PTB acts on alternatively spliced pre-mRNAs

to inhibit the inclusion of neuronal exons, it has been suggested that a general a

PTB might be to inhibit neuron-specific exon utilization (Valcarcel and Gebauer, 1

Grabowski, 1998). In previous reports, the presence of the brain enriched form of PT

was correlated with the presence of neuron-specific splicing in vitro, while the a
the general form of PTB inhibited neuron-specific exon utilization (Ashiya and
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Grabowski, 1997; Zhang et al., 1999). These results had suggested the possibility that the

inhibitory action of PTB is replaced in the brain by a permissive or stimulatory a
the brain-PTB isoform (Grabowski, 1998; Wagner and Garcia-Blanco, 2001). However,
the proposal that brPTB promotes neuron-specific splicing is not supported by the
experiments presented here, where brPTB antagonizes Noval action in promoting
neuron-specific exon inclusion.
There are several possible mechanisms by which brPTB could regulate Nova

activity in splicing. One model is that brPTB competes with the ability of Nova to

the GlyRa2 UCAU element, in a manner reminiscent of the action of PTB to compete ou
U2AF binding. However, we find that brPTB binds to the isolated GlyR 90nt RNA with

a 12-fold weaker affinity than Noval. Moreover, brPTB appears to supershift a Nova

RNA complex, suggesting that it does not interfere with the ability of Nova to bin

RNA. Therefore, it is unlikely that brPTB and Nova compete for the same site on the

RNA and that this competition inhibits the ability of Nova to enhance exon inclusi
Notably, immediately upstream of the GlyRa2 UCAU repeat element exists a

potential PTB consensus binding element, as defined by Patton and colleagues (Pere

al., 1997): a UCUU motif in the context of a pyrimidine rich element. Although this
sequence does not clearly define a PTB binding site (for example see Singh et al.,
and brPTB and PTB binding specificities may differ, our results suggest that Nova

brPTB may bind adjacent intronic sequence elements. However, based on this data, w

cannot rule out the possibility that brPTB binds exclusively to the RNA target. We
that brPTB and Nova proteins interact and that brPTB binds the GlyRa2 RNA weakly

but with sequence specificity. Furthermore, binding of the RNA is necessary for th
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inhibitory action of brPTB on Noval function. The simplest model consistent with this

data is that brPTB binds the GlyRa2 pre-mRNA at a site adjacent to Nova and mediate
an inhibitory effect on Nova-dependent exon inclusion through protein-protein

interactions, perhaps by preventing assembly of a multiprotein complex necessary t
activate splicing.
A core sequence termed the Downstream Control Sequence (DCS) is necessary

for enhancement of c-src splicing in vitro (Modafferi and Black, 1997; Modafferi a
Black, 1999). Repression of c-src splicing in non-neuronal cells requires both the
upstream element and sequences within and adjacent to the DCS. The DCS RNA

element has been used to clone trans-acting factors that may bind to brPTB in a ma

analogous to the proposed Nova-brPTB interaction to regulate neuronal splicing. Fo

example, a complex of at least six proteins cross links to DCS RNA, including a po

acting factor related to Nova by the presence of multiple KH type RNA binding doma

termed KSRP (Min et al., 1997). In addition, the same brPTB protein identified here
recently shown to bind DCS RNA as part of a larger complex including KSRP and

hnRNP H, and to exhibit weak repression of c-src splicing (Markovtsov et al., 2000)

These observations and our observations on Nova and brPTB suggest that protein-RNA

complexes acting to regulate splice site selection may include brPTB, and that brP
as an antagonist of neuron-specific splicing mediated by positive acting factors.
In the case of the GABAARy2 mRNA, the situation appears to be slightly more
complicated. Noval increases the inclusion of alternative exon 9 by a margin that
larger than the effect on GlyRa2 (Jensen et al, 2000a; this work). However, the
contribution of brPTB in inhibiting this effect seems less specific. First, there

100

inhibition of exon 9 inclusion even in cells that express no N o v a (i.e. 293Ts; Figure 16).
While this result is consistent with the role of PTB as a splicing inhibitor, it also
contradicts previous work that has suggested that the neural isoform of PTB (i.e. brPTB)
plays a permissive role in the splicing of neuronal transcripts (Ashiya and Grabowski,
1997; Zhang et al., 1999). Significantly, the inhibition of brPTB on GABAARy2 splicing
in the absence of Nova in neuronal N2A cells is less pronounced, indicating that the
behavior of brPTB in neuronal cells can be different, perhaps depending on the presence
of other factors.
Mutations in what ostensibly appeared to be brPTB sites upstream of alternative
exon 9 in GABAARy2 mRNA, had no effect on binding or on the inhibition of splicing.
Preliminary data suggests that the Noval binding site controlling the splicing increase in
this exon is located within a downstream intron and work is currently being done to
establish whether brPTB also affects GABAARy2 splicing through other sites nearby
(Dredge et al., work in progress). So, while the location for the Nova and brPTB sites
might be different than GlyRa2, the mechanism of exon selection regulation could be
similar (i.e. competition for the recruitment of splicing factors) only occurring at the
downstream intron as has been proposed for the c-src transcript (see below).
Splicing inhibition by brPTB in cell lines that more closely resemble neurons
(N2A cells) is significantly reduced, suggesting that other cell type-specific factors
required for this effect might be interacting with and negatively regulating Nova and/or
brPTB proteins. brPTB is not a strictly neuron-specific protein, as its presence has been
detected in tissues other than the brain, such as the heart and testis (Polydorides et al.,
2000; Markovtsov et al., 2000; Lillevali et al., 2001). Thus, it is hard to imagine that
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b r P T B independently acts to derepress neuron-specific splicing patterns, as it has been
suggested (Ashiya and Grabowski, 1997; Zhang et al., 1999). Instead, it is more likely
that brPTB participates in the control of splicing in a complex with other factors some of
which can be cell-specific, such as Nova, and might explain the variation in the results
obtained here in the splicing assay with different cell types.
In light of these results, the model proposed for the tissue-specific regulation of
splicing in Drosophila should probably be replaced in the case of mammalian cells with a
more dynamic model where proteins with antagonistic effects in splicing are in a constant
battle. The final outcome of this battle is one that depends on the relative levels of the
factors involved as well the specific circumstances that could be influenced by a
multitude of other factors that are temporally and spatially regulated.
In support of this model, recent data has furthered the idea that different isoforms
of PTB can have distinct activities in splicing inhibition (Markovtsov et al., 2000;
Wollerton et al., 2001). Alternatively spliced isoforms of the PTB transcript itself result
from the insertion of short amino acid stretches between RRM2 and RRM3 (Gil et al.
1991; Patton et al., 1991). The various PTB isoforms have different effects in the
splicing repression of the alternative exon in the oc-tropomyosin mRNA in vitro and in
vivo (Wollerton et al., 2001). However this effect was not observed in the repression of
the a-actinin transcript where all PTB isoforms were equally effective in splicing
repression. Together with the result that the nPTB homologue is less repressive than

PTB in c-src splicing (Markovtsov et al., 2000) this suggests that tissue-specific splicing
regulation can be achieved by variations in the levels of homologues or otherwise
processed isoforms of splicing factors.
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In conclusion, the w o r k presented here extends our understanding of the
mechanism by which neurons differentially regulate alternative splicing. It is suggested
that the function of the neuron-specific protein Nova to promote exon inclusion can be
modulated by interaction with additional proteins. The brPTB protein is not strictly
neuron-specific as is the Nova protein: brPTB is also expressed in glial cells, and to a

lesser but significant extent, in cells outside of the nervous system, particularly the hea
and testis. Nonetheless, the existence of a brain-enriched protein interacting with a
strictly neuron-specific protein suggests a layer of neuronal regulation different from a
model in which tissue-specific alternative splicing is regulated by varying levels or
modifications of general splicing factors (such ASF/SF2).
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Figure 9. Schematic of the glycine receptor oc2 subunit minigene.

(A) The glycine receptor oc2 subunit (GlyRa2) minigene construct used in the in v
splicing assays. It contains alternative exons 3A and 3B flanked by exons 2 and 4

most of the intronic sequence in between, under the control of an SV40 promoter (S
Pro) and with the addition of an SV40 polyadenylation sequence (SV40 polyA).
(B) DNA sequence of a 90 nt fragment of intronic GlyRa2 RNA upstream of exon 3A

that contains Nova binding sites (UCAU; solid underline) and a candidate binding s
brPTB (UCUU in pyrimidine context; dashed overline). The C->T mutation in the

brPTB binding site is indicated. RNA contains U instead of T. Numbering of base p
in intron 2 starts at the junction with exon 3A, upstream is negative.
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Figure 10. Altered splicing patterns in G l y R a 2 minigene assays.

(A) Western Blot analysis of cell extracts. One twentieth the amount of protein in
transfection was separated on SDS-PAGE, followed by immunoblotting with anti-flag
monoclonal antibody (brPTB) or POMA patient serum (Noval) to confirm that

increasing amounts of transfected DNA correlated with proportionally increasing a
of protein synthesized by the cells.
(B) Sample autoradiogram of RT-PCR assay in brPTB/Noval co-transfections in 293T

cells. Digestion with Sspl only cuts the 2->3A->4 splice product, leaving the 2->

band intact within the same lane. The relative intensity of the bands (ratio 3A/3B
quantified using a Phosphorimager (Molecular Dynamics) and calculated with

ImageQuant software (as described in Jensen et al., 2000a; see Materials and Metho
This data represents a single experiment with the C->T mutant GlyRa2 minigene as
presented in Figure 13.
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Figure 11. b r P T B antagonizes N o v a l in GlyRcc2 splicing.

Bar graph of the ratio of exon 3A to exon 3B in 293T cells transfected with the i

amounts of Noval and brPTB expression vectors plus the GlyRa2 minigene containing
exons 2 to 4 (Jensen et al 2000a; see Figure 10). Ratios of included exon 3A over

were determined by RT-PCR, followed by Sspl digestion (which only cuts within exo

3A; see Figure 10) and quantified using a Phosphorimager (see Materials and Method
Each point represents the average of four transfections, and error bars indicate
standard deviation. For a representative data set, see the Appendix.
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D N A transfected (fig)

Figure 12. C - > T mutation in GlyRot2 R N A diminishes b r P T B binding.

Filter binding assays of purified recombinant fusion proteins Noval and brPTB, as
indicated, with wild type (WT) and C->T mutant (C->T) GlyRa2 RNA and an unrelated

fragment of ribosomal RNA (rRNA) of equal length. Mutating the brPTB binding site

(as shown in Figure 9) reduced its binding to background levels (compare with rRN
curve) while it had no effect on Noval binding (data not shown).
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Figure 13. G l y R a 2 binding is necessary for b r P T B splicing inhibition.

Bar graph of the ratio of exon 3A to exon 3B in 293T cells transfected with the i

amounts of Noval and brPTB expression vectors plus the GlyRa2 minigene carrying t

C->T mutation (C->T) that prevented brPTB binding in vitro (Figure 12). Each poin

represents the average of four different transfections and error bars indicate th

deviation (purple bars). The results obtained with the original minigene construct

are included here for comparison (blue bars; Figure 11). For a representative data
the Appendix.
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Figure 14. b r P T B a n d N o v a l f o r m a c o m p l e x o n G l y R a 2 intronic R N A .
Electrophoretic mobility shift assays of brPTB and Noval proteins on GlyRa2 RNA.
Purified, recombinant fusion proteins in the concentrations indicated (nM) were
incubated with a radioactively labeled wild type or mutant GlyRoc2 RNA that does
bind Noval in filter binding assays (data not shown). Noval is able to band-shift
wild type GlyRoc2 RNA (top panel, arrow) while brPTB does not. When both proteins

are present, the RNA is super-shifted (top panel, arrowhead). Noval does not mediat
gel-shift with the mutant GlyRa2 RNA (bottom panel), and neither does brPTB. The

presence of an unrelated protein (TRF2) at the same concentration (100 nM) did no
affect the binding of either Noval or brPTB (data not shown).
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Figure 15. Schematic of the G A B A A receptor yl subunit minigene.
(A) The GABAA receptor y2 subunit (GABAAy2) minigene construct used in cotransfection/splicing assays. It contains alternatively spliced exon 9 flanked by
and 10 and most of the intronic sequence in between, under the control of a CMV

promoter (CMV Pro) and with the addition of a polyadenylation sequence from Bovine
Growth Hormone (BGH polyA).

(B) In the 85 nucleotide intronic sequence upstream of alternative exon 9, there a

candidate binding sites for brPTB (UCUU in a pyrimidine context; dashed underline)
The UC->GA mutations in the putative binding sites (two in Mutant RNA GA2 and one
in Mutant RNA GA1) of brPTB on GABAAy2 are shown. Numbering of base pairs in
intron 8 starts at junction with exon 9, upstream is negative.
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Figure 16. b r P T B antagonizes N o v a l in G A B A A R y 2 splicing.

Bar graph of the ratio of exon 3A to exon 3B in 293T cells transfected with the i

amounts of Noval and brPTB expression vectors plus the GABAAy2 minigene containin

exons 8 to 10 (Figure 15). Ratios (L/S) of RNAs including alternative exon 9 (long

L) over those excluding exon 9 (short form, S) were determined by RT-PCR, quantifi

with a Phosphorimager (Molecular Dynamics) and calculated using ImageQuant softwa

(see Materials and Methods). Each point represents the average of eight transfecti

error bars indicate the standard deviation. The amount of protein expressed in eac

transfection was verified by Western Blot (data not shown). For a representative d
see the Appendix.
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Figure 17. Mutations in G A B A A y 2 R N A d o not affect b r P T B binding.

Filter binding assays of purified recombinant brPTB fusion protein with wild type
GABA) and two mutant (GABA GA2 and GA1; Figure 15) GABAAy2 RNAs and an
unrelated fragment of ribosomal RNA (rRNA). As shown, mutating the putative brPTB
binding sites did not substantially reduce its binding.
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Figure 18. Mutations in G A B A A R y 2 R N A d o not affect b r P T B splicing.

Bar graph of the ratio of exon 3A to exon 3B in 293T cells transfected with the i
amounts of Noval and brPTB expression vectors plus the Mutant GA2 GABAAy2
minigene (as shown in Figure 15). Ratios (L/S) were calculated as before (Figure

Each point represents the average of four transfections and error bars indicate t

standard deviation. The amount of protein expressed in each transfection was verif
Western blot (data not shown). For a representative data set, see the Appendix.
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Figure 19. b r P T B has n o effect o n the splicing of GlyRcc2 in N 2 A s .

Bar graph of the ratio of exon 3A to exon 3B in N2A cells transfected with the in
amounts of Noval and brPTB expression vectors plus the wild type GlyRa2 minigene.

Ratios of included exon 3A over exon 3B were calculated as before (Figure 10). Ea

point represents the average of four transfections and error bars indicate the st

deviation. The amount of protein expressed in each transfection was verified by We
blot (data not shown). For a representative data set, see the Appendix.
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Figure 20. b r P T B has n o effect o n the splicing of G A B A A R y 2 in N 2 A s .

Bar graph of the ratio of exon 3A to exon 3B in N2A cells transfected with the in
amounts of Noval and brPTB expression vectors plus the wild type GABAARy2

minigene. Ratios of included exon 9 were calculated as before (Figure 16). Each po
represents the average of four transfections and error bars indicate the standard

The amount of protein expressed in each transfection was verified by Western blot
not shown). For a representative data set, see the Appendix.
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Figure 21. P T B a n d b r P T B have similar effects o n N o v a inhibition.

Bar graph of the ratio of exon 3A to exon 3B in 293T cells transfected with the i
amounts of Noval, PTB and brPTB expression vectors and the wild type GlyRa2

minigene. Ratios of included exon 3A over 3B were determined as before (Figure 10)

Each point represents the average of four transfections and error bars indicate t

standard deviation. The amount of protein expressed in each transfection was verif
Western blot (data not shown). For a representative data set, see the Appendix.
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Introduction

The coupling of biochemical steps in RNA metabolism is a common and useful method
to achieve multi-step control and regulation of various processes in tandem. RNA-

binding proteins are uniquely positioned to play an important role in this couplin

virtue of their specific association with target RNAs and their localization in pa

sub-compartments of the cell where such events are taking place. Thus, examining th

localization of RBPs is necessary in order to understand their function and to stu
possible causes of dysfunction in human disease.

Initially, it was hypothesized that the spatial organization of the nucleus occurr

in static, morphologically distinct areas that functioned to compartmentalize nucl

processes in a manner analogous to cytoplasmic organelles (reviewed in Misteli and
Spector, 1998; Sleeman and Lamond, 1999; Lewis and Tollervey, 2000). However,

while most cytoplasmic organelles are membrane-bound, sub-nuclear structures invol

in RNA metabolism are lacking a membrane suggesting that the nucleus is a more flu

structure allowing for greater movement and communication between its compartments
In fact, recent studies have shown that, when visualized in living cells, these
compartments are highly dynamic and subject to reorganization upon changes in

transcriptional activity (Huang and Spector, 1996; Misteli et al., 1997; Sleeman e

1998). Thus, it is more likely that the spatial organization of the nucleus in vivo
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w h e n fixed for observation) reflects an intricate pattern of interactions with functional
significance and consequences.
It may seem obvious that the cellular location of each protein is dependent on its
functional activity and vice versa. However, information is still lacking on many fronts
in deciphering the dynamics and regulation of this connection between localization and
function. In the nucleus, there is still debate whether some structures represent inactive
storage sites or the settings of active RNA processing. For example, alteration in staining
techniques results in the redistribution of splicing factors from previously considered
storage sites to sites of active RNA transcription suggesting that functional requirements
guide localization rather than the need for compartmentalization (Neugebauer and Roth,
1997; Mintz and Spector, 2000). The situation is further complicated by the existence of
the nuclear matrix whose composition and function are not completely understood and it
is not known whether its role in the localization and movement of nuclear proteins is one
of hindrance or assistance. The advantages of concentrating protein factors to specific
areas of functional significance are many and include conservation of energy, increased
efficiency and ease of regulation. Finally, the question remains whether the existence of
distinct sub-nuclear domains and the distribution of nuclear factors is the cause or the
consequence of specific biological processes and changes in the cellular steady state.
The eukaryotic nucleus contains an array of morphologically distinct
substructures (reviewed in Lamond and Earnshaw, 1998; Misteli and Spector, 1998).
While the function of many of these nuclear bodies remains unclear, their organization
and constitution is thought to be in a dynamic state and to even depend on a range of
pathological cellular conditions including viral infection, oncogene expression and
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disease phenotype. Rather than providing purely structural roles, m a n y of these domains
contain factors that are required in the cellular processes that take place in the nucleus,
namely chromosomal organization, DNA replication, transcription, RNA processing and
transport. Therefore, as morphological observations on the appearance and biochemical
evidence on the composition of these bodies grow more prevalent, it becomes evident
that the localization and function of cellular macromolecules are inexorably linked.
Perhaps the most prominent of nuclear structures, chromosomal DNA assumes
varied function-dependent states during the cell cycle. For example, the interplay
between heterochromatin and euchromatin has profound effects on gene expression and
is possibly regulated by proteins localized in either structure (e.g. the polycomb-group
proteins). The remainder of the nucleus, loosely defined as interchromatin space,
contains various nuclear bodies that are better studied during interphase, the relatively
steady state of the cell cycle (Table 3). The largest structure among those is the
nucleolus, where ribosomal RNA (rRNA) is synthesized, processed and assembled into
ribosomes. The nucleolus is a dynamic structure that is transcription- and cell cycledependent and also interacts with other sub-nuclear structures that it is in close contact
with, such as coiled bodies and the perinucleolar compartment (PNC; see below).
One of the very first nuclear organelles to be described, coiled bodies (also called
Cajal bodies) are thought to be involved in the assembly of the nuclear transcription
machinery and are best characterized by the marker protein p80-coilin (Gall et al., 1999;
reviewed in Gall, 2000; Gall, 2001). The capacity of p80-coilin for self-association,
phosphorylation and shuttling are believed to be key factors in the formation and function
of coiled bodies, including the proposition that they play a role in a nucleo-cytoplasmic
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transport system (Alliegro and Alliegro, 1998; Bellini and Gall, 1999; Hebert and Matera,

2000). Among the proteins that localize to coiled bodies besides p80-coilin are Nop

(a nucleolar shuttling protein) and snRNPs (key components of the splicing apparatu
Related to but not coinciding with coiled bodies are structures called Gemini of

coiled bodies (or gems) that contain the SMN protein and its interacting partner S
and Dreyfuss, 1996; Liu et al., 1997). Gems are thought to participate in snRNP

biogenesis, maturation and trafficking, perhaps through their association with coi

bodies (Fischer et al., 1997). Importantly, the disease spinal muscular atrophy (SM

which is caused by mutations in the SMN gene, is manifested on a cellular level by

disruption of a critical protein interaction of SMN and its lack of localization t
(Gangwani et al., 2001; Matera and Hebert, 2001). Specifically, the localization of

to nuclear bodies depends on its interaction with the zinc-finger protein ZRP1 and

interaction is disrupted by mutations of SMN in SMA patients. This data is in conc
with the hypothesis that the localization of SMN in gems is one of functional

significance. Furthermore, and possibly because of improper SMN localization, snRN
biogenesis is disrupted and pre-mRNA splicing is affected when SMN is mutated
(Pellizzoni et al., 1998).
While the biochemical steps of RNA processing from DNA to protein have been

extensively characterized, the localization of these processes lacks critical evid

plagued by the problem of identifying and separating active sites from inactive st

areas (reviewed in Lewis and Tollervey, 2000). Active transcription and perhaps spl

as well are thought to take place in perichromatin fibrils (Zhang et al., 1994). Co

with the idea of coupling between pre-mRNA processing and transcription, the stain
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of spliceosomal components (general splicing factors) matches the distribution of nascent

transcripts. In addition, PML bodies are nuclear domains where the protein involve

pro-myelocytic leukaemia is localized and may play a role in transcription regulat

since they are targets of viral transformation, in oncogenesis (Zhong et al., 2000)
One of the first splicing factors found to localize in discrete regions within the

nucleus was SC35, whose staining pattern was found to be distinct from that of snR

(Fu and Maniatis, 1990). It was hypothesized that SC35 plays an active role in spli

and is thus localized in perichromatin fibrils, whereas snRNPs and SR proteins are

localized in so-called nuclear speckles. Speckles are concentrations of proteins t

produce a punctate pattern when analyzed by immunofluorescence and are also called

interchromatin granule clusters when visualized by electron microscopy (reviewed i

Huang and Spector, 1992; Sleeman and Lamond, 1999). Speckles do not co-localize wit

sites of active transcription (nascent transcripts) or splicing (snRNAs, SC35 prot

were thus thought to be areas of assembly and storage of inactive components of the
splicing machinery (Pombo and Cook, 1996; Mintz and Spector, 2000). However, the

localization of spicing factors in nuclear speckles is thought to be a highly dyna
process and depends on gene activation, RNA transcription and pre-mRNA splicing
(Spector, 1996; Misteli et al., 1997; Phair and Misteli, 2000).

Another nuclear structure that has been recently characterized is the perinucleola
compartment (PNC). As the name suggests, it is localized in the periphery of the

nucleolus, and contains small RNAs transcribed by RNA polymerase III (e.g. Y RNAs),
and PTB/hnRNP I (Ghetti et al., 1992; Matera et al., 1995; Huang et al., 1997). The
does not coincide with any of the known nuclear sub-domains and a functional role
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has not been suggested. A protein n a m e d PTB-Associated Splicing Factor (PSF) has
been found to interact with PTB and to be an essential splicing factor participating early
in spliceosome formation (Patton et el., 1993; Gozani et al., 1994). PSF localization in
the nucleus occurs in a punctate pattern that coincides with PTB staining only when the
salt-soluble PTB fraction is removed, suggesting that the remaining, more stable fraction
interacts with PSF, possibly as part of a larger spliceosomal complex (Meissner et al.,
2000). Interestingly, PSF localizes to the PNC in a manner that is dependent on its
second RRM and redistributes from speckles to the PNC upon inhibition of transcription
(Dye and Patton, 2001). This is in contrast to other splicing factors, which upon
transcription inhibition generally accumulate in speckles that presumably function as
storage depots. This provides evidence for the functional link between splicing and
transcription and suggests that the role of PSF in the PNC is not one of active splicing.
The localization of matrin3, which is also a member of the PTB sub-family of RRM-type
RNA-binding proteins, has not been extensively studied other than the observation that it
co-fractionates with the nuclear matrix (Nakayasu and Berezney, 1991).
Earlier experiments have identified the Nova proteins as mostly nuclear. In order
to examine the sub-nuclear localization of Nova in more detail and get insight into the
specific protein interactions that might be guiding this pattern, immunofluorescence
studies were undertaken in cell lines and tissue sections. Additionally, the localization
pattern of brPTB was studied since it has been shown to interact with Nova in vitro and
in vivo, and in light of the discrete nuclear structures occupied by PTB in the PNC. The
functional aspect of the brPTB-Nova interaction in the regulation of alternative splicing
prompted the examination of the nuclear staining pattern of the two proteins.
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Results

Nova proteins localize in distinct sub-nuclear structures

In order to examine the sub-cellular distribution pattern of Nova proteins, N2A ce

stained with POMA patient serum. This serum has been previously shown to recognize

both Noval and Nova2 (Buckanovich et al., 1993; Yang et al., 1998). N2A cells are a

mouse neuroblastoma cell line that expresses endogenous Nova (Jensen et el., 2000a

data not shown). Approximately 4 to 5 distinct structures can be seen in the cell n

that are specific to the anti-Nova serum (Figure 22A). These foci do not appear wi

secondary antibody alone, or in other cells that do not express Nova (data not show

When N2A cells were stained with an affinity-purified Nova2-specific antibody (Yan

1997), a similar staining pattern emerged (Figure 22B). Since the anti-Nova patient

serum recognizes both Nova proteins, the possibility that Nova2 is responsible for

signal in both of these experiments cannot be excluded. However, the slight differ

the staining pattern obtained with the two antibodies and the larger size of the s

visualized with the anti-Nova serum suggest that both Noval and Nova2 proteins loc

in distinct nuclear foci. When mouse brain sections were stained with anti-Nova se

neuronal cells in the cerebellum (most likely Purkinje cells) exhibited a similar,

as sharp, staining pattern (Figure 22C). The localization of endogenous Nova prote

neurons consists of concentrations in approximately four to five discrete foci per

Nova proteins do not co-localize with any known sub-nuclear domains

Nova proteins play a role in pre-mRNA splicing and quite possibly in other aspects

RNA metabolism (Jensen et al., 2000). Since these functions of Nova could be mediat
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by interactions with other proteins and could occur in these nuclear foci, it w a s important
to test whether the localization of Nova coincided with any of the known nuclear
structural domains many of which are defined by RNA-binding proteins (see Table 3).
To that end, a series of monoclonal and polyclonal antibodies that identified most of
these sub-nuclear structures were used to examine possible co-localization with Nova.
As seen in Figure 23, N2A cells were doubly stained with anti-Nova serum
(green, second column) and the indicated antibodies (red, first column; see Materials and
Methods). Panels demonstrating the staining pattern of each antibody are shown and
correlate with the staining previously observed for these proteins (see this Introduction
for references). In the third column, the merged panels clearly show that Nova does not
co-localize with any of these proteins as the green and red foci remain distinct. From
these results it can be concluded that the concentrations of Nova in neuronal nuclei do not
coincide with coiled bodies (p80-coilin and Noppl40 protein), gems (SIP-1 protein),
speckles (Sm and SR proteins), or perichromatin fibrils (SC35, RNA polymerase II).

Nova proteins co-localize with brPTB in N2A nuclei
Since a functional interaction of Nova with brPTB has been suggested by the work
presented this far, it was of importance to examine whether the two proteins co-localize,
especially since both proteins stain mostly neuronal nuclei (Buckanovich et al., 1996;
Polydorides et al., 2000; this work). N2A cells contain both proteins endogenously and
were doubly stained with anti-Nova patient serum and the brPTB-specific polyclonal
antibody (see above). Figure 24A shows that the two proteins display a similar pattern of
punctate staining in the nucleus, consisting of approximately five distinct foci (brPTB in
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red, Nova in green). Importantly, when the panels are merged, the foci co-localize, as
manifested by the yellow color.
To verify that this co-localization is real and not the result of bleed-through

between the two filters used to detect the Cy2- and Cy3-conjugated secondary antib
single staining with Nova or brPTB was performed in N2A cells. As shown in Figure

24B, there is no signal when the red filter is used to excite cells that have been
with anti-Nova serum and a Cy2-conjugated anti-human secondary antibody (which is

normally excited by the green filter). Correspondingly, there is no signal when the
filter is used to excite cells stained with anti-brPTB polyclonal serum and a Cy3-

conjugated anti-rabbit secondary antibody. Furthermore, there is no cross-reactivi

between the two antibodies in Western blot assays (data not shown). Thus, the stain

observed and the co-localization between Nova and brPTB is not the result of aberr

excitation but rather the coincidence of two antibodies staining for two different

To clarify the issue of whether the staining pattern observed so far with the anti-

Nova patient serum is the result of Noval localization, Nova2 or both, N2A cells w
transfected with eukaryotic GFP-fusion expression constructs of full length Noval

Nova2 proteins and in addition stained the cells with anti-brPTB (Figure 25A). Bot
GFP-Noval and GFP-Nova2 exhibit the same localization pattern observed with
endogenous Nova, namely four to five foci per nucleus. Furthermore, these foci colocalize with endogenous brPTB when the panels are merged (third row, Figure 25A).
Thus, both endogenous and transfected Nova proteins, and both Noval and Nova2 colocalize with endogenous brPTB in N2A nuclei.
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In order to confirm that brPTB is indeed the protein that co-localizes with Nova

and to control for background immunoreactivity with the anti-brPTB antibody, N2A c

were transfected with a flag-tagged brPTB expression construct. These cells were t

stained with a monoclonal anti-flag antibody as well as anti-Nova patient serum an

appropriate secondary antibodies in order to visualize the proteins. As can be see
left column of Figure 25B, transfected brPTB co-localizes with endogenous Nova,

witnessed by the yellow color when the panels are merged. Again, the pattern of br

expression seems to be broader than that of Nova but there still exist foci of inc
protein concentration and those co-localize with Nova. Appropriately, in the case

some multi-nucleated cells in the left column of Figure 25B, more foci are present.

Nova proteins co-localize with PTB in N2A nuclei
N2A cells were transfected with a myc-tagged PTB expression construct and stained

a monoclonal anti-myc antibody and anti-Nova serum. In cells that expressed PTB, i

localized with endogenous Nova in a pattern similar to that of transfected brPTB (
column in Figure 25B). Thus, while the endogenous PTB family member that is

recognized by the anti-brPTB antibody in N2A cells is most likely brPTB (in Figure

24A and 25A), transfected PTB in N2A cells behaves in the same way by co-localizing
with Nova proteins in a specific nuclear punctate pattern.
However, when N2A cells were stained with a polyclonal anti-matrin3 antibody,
the result was unexpected. Even though matrin3 is one of the proteins isolated in

yeast-two-hybrid screen with both Noval and Nova2 (Tablel), and its interaction wit

the Nova proteins is as robust as the other members of the PTB sub-family (Table 2
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did not co-localize with endogenous Nova in N 2 A cells (Figure 25B,rightcolumn). This

observation could be due to the pattern obtained with this matrin3 antibody that d
result in a clear, punctate staining in the nucleus and was instead more diffuse.

Nova proteins do not co-localize with brPTB in non-neuronal cell lines

Since the functional interaction between Noval and brPTB varied among different ce

lines in the splicing assay presented in Chapter 4, it was important to examine th

localization pattern in cell lines other than neuronal N2As. For that purpose, 293
(derived from human kidney epithelium), that do not express brPTB or Nova proteins

endogenously (data not shown), were transfected with a GFP-brPTB expression constru

and either a Noval or a Nova2 expression construct (Figure 26A). In either case, w

the panels were merged, it became obvious that Nova proteins do not co-localize wi
brPTB in this cell line. The same result was obtained when GFP-Noval or GFP-Nova2

were co-transfected with a flag-tagged brPTB construct and then stained with an an
monoclonal antibody (Figure 26B).

Nova proteins do not co-localize with PTB in non-neuronal cell lines
When GFP-Noval and GFP-Nova2 expression constructs were transfected into 293T

cells that were stained with anti-brPTB antibody, there was no co-localization (Fi
27A). Since PTB is most likely recognized by this antibody (now used at a higher

concentration it cross-reacts with PTB), and because there is no brPTB protein pre

293T cells data not shown), the slightly lower level of staining of PTB can be expl
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T o verify this result, and to m a k e sure that P T B did not co-localize with N o v a
proteins in 293T cells, a myc-tagged PTB construct was co-transfected with either GFPNoval or GFP-Nova2 (Figure 27B). Again, no co-localization is observed. Finally, the
same result was obtained in HeLa cells transfected with either GFP-Noval or GFPNova2 and stained with anti-brPTB antibody (again presumably staining the endogenous
PTB protein): no co-localization was evident (Figure 28). Given that the localization of
brPTB and PTB proteins in cell nuclei is diffusely nucleoplasmic, the co-localization
with Nova proteins could be the result of this widespread nuclear staining. However, as
seen in Figure 24A, brPTB is concentrated in distinct foci and these coincide with the
Nova concentrations.

N o v a proteins co-localize with b r P T B in tissue sections
To examine the localization pattern of Nova and brPTB in tissues, immunohistochemistry
was performed in rat and mouse spinal cords (Figure 29A). Sagital sections of formalinperfused tissues were stained with Nova and brPTB sera and the appropriate secondary
antibodies and were observed under confocal microscopy. The results demonstrate that
the co-localization observed in cell cultures corresponds to a biologically significant
process observable in the context of the whole brain. Both mouse and rat tissues stained
for Nova and brPTB and the localization pattern was similar to that obtained in cell
culture, but with higher background staining. Even though this background staining
made it more difficult to pinpoint the nuclear inclusions of Nova and brPTB, the merged
planes demonstrated the existence of co-localization in neuronal nuclei.
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To examine the co-localization pattern of Nova2 with brPTB, Noval knock out

mice were used (described in Jensen et al., 2000a). When stained with anti-Nova hum
serum (now only recognizing the Nova2 protein) and brPTB polyclonal antibody,

cerebellar sections of null mice and their wild type litter mates both showed simi

staining patterns. While the staining was slightly reduced in the case of the knoc
mice (in wild type animals both Nova proteins are present and the staining should
stronger), co-localization of Nova2 with brPTB was nevertheless still observed in
mouse cerebellum (Figure 29B).

Identifying localization domains in Noval

The multiple peptide domains present in Nova proteins have been studied in terms o

their contribution to overall function as examined for protein interactions, RNA b

structural considerations and splicing activity (Lewis et al., 2000; Jensen et al.,

this work; Dredge and Darnell, personal communication). To test whether different N

elements are responsible for its nuclear localization and to identify what those m

fusion constructs of Noval deletions with the green fluorescent protein (GFP) were

transfected into N2A cells and their localization was examined under live conditio

complete amino acid listings of these constructs see Chapter 2, Materials and Meth

Full-length Noval and Nova2 proteins, when fused to GFP, exhibit an expression pat

similar to that observed for endogenous proteins or otherwise tagged and transfect

constructs in various cell lines (N2A, 293T and HeLa cells; see above). In live N2A

too, this pattern consists of four to five concentrated domains per nucleus, clear
even when GFP-fusion proteins are overexpressed (Figure 30).
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Nova proteins contain near their amino terminus a sequence that matches the
consensus bipartite NLS element (amino acids 25-41), similar to that identified in
Nucleoplasm^ and hnRNP K proteins (Pinol-Roma and Dreyfuss, 1992; Siomi et al.,
1993; Michael et al., 1997). This element consists of approximately 16 amino acids

basic residues (arginines and lysines) on both ends. Moreover, it is highly conser

between Noval and Nova2, suggesting that it is a functional domain. To test the ca

of this domain in mediating the nuclear localization of Nova, a GFP fusion constru

the putative Noval NLS sequence was transfected into N2A cells. The localization o

this construct was decidedly nuclear, but not punctate (GFP-NLS, Figure 30) as opp
to GFP alone which was diffusely observed throughout the cell (GFP vector).
When two of the basic residues in this NLS (lysines in positions 27 and 40) were

mutated, first individually and then in concert, to negatively charged glutamates,

effectively destroying the basic nature of the signal, the GFP-NLS fusion construc
failed to localize to N2A nuclei (GFP-NLS K27E, K40E, and K27,40E). This result
implies that amino acids 25-41 of the Noval protein are sufficient for nuclear
localization, functioning as an NLS, and that, furthermore, substituting lysine in
27 or 40 of this sequence with glutamate successfully eliminates this signal.
However, when GFP construct of full-length Noval protein containing these

mutations were transfected into N2A cells, they were able to partly localize to th
and, furthermore, exhibited the punctate staining pattern seen with the wild type
(GFP-Noval K27E, K40E, and K27,40E in Figure 30). This suggests that the NLS of

Noval, while sufficient, is not necessary for nuclear localization and, more impor

does not mediate the distinct, punctate nuclear staining pattern of Nova. Consiste
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this data, a G F P construct completely lacking the entire N L S sequence of N o v a l (GFPNoval ANLS, Figure 30) was still able to partly localize in nuclear foci. Thus, it can be
concluded from these results that other domains in the Nova protein are responsible for
its punctate staining pattern.
In order to identify these domains, more Noval deletion constructs were made

and tested for their contribution to its localization pattern. A GFP fusion construct of th
first and second KH domains (GFP-Noval KH1/2, Figure 30) was completely nuclear as
expected, since it contains the NLS sequence. Nevertheless, it did not exhibit a punctate
pattern within the nucleus, suggesting that the domain responsible for this may be located
in the carboxy terminal half of the protein.
Indeed, when a construct containing the spacer and KH3 domains of Noval was
tested (GFP-Noval sp/KH3, Figure 30), the staining observed was mostly nuclear and
appeared to be forming discrete concentrations suggestive of the foci described thus far.
Therefore, a domain guiding the localization of Nova to the nucleus is present in the
second half of the protein and it could be responsible for its concentration in the subnuclear structures observed. An attempt to pinpoint this domain by examining the
localization of a full-length and a truncated form of the spacer (GFP-Noval spacer and
GFP-Noval t.spacer, respectively, Figure 30) was not successful as these constructs did
not differ appreciably from the diffuse cellular staining obtained with the empty vector.

131

Discussion

The study of a protein's cellular localization can provide valuable clues as to ot

proteins it may interact and co-localize with ultimately leading to an understandi

function. The paraneoplastic disease antigen Nova is an RNA-binding protein that h

been shown to be essential for the development and survival of neurons, possibly t
its role in regulating alternative splicing (Jensen et al., 2000a). Many RBPs and
specifically splicing factors have been shown to localize to distinct sub-nuclear

(reviewed in Sleeman and Lamond, 1999; Lewis and Tollervey, 2000). In this study, t
nuclear localization of Nova was examined, both in cell lines and tissue sections

purpose of gathering more information about its function in neuronal RNA processin
The results presented identify discrete foci where both Noval and Nova2
concentrate in neuronal nuclei and where none of the other RBPs whose nuclear

localization has been described in some detail can be found. These Nova foci amoun
between four and five structures per nucleus which would place them in a similar
category with coiled bodies and gems, based on size and number (see Table 3).

Importantly, brPTB, a protein identified by virtue of its interaction with Nova, co
localizes with it in these foci (Polydorides et al., 2000; this work).
The absence of co-localization of Nova with proteins that occupy speckles (Sm
and SR proteins) or perichromatin fibrils (SC35, RNA polymerase II) is perhaps

surprising, given its role as a splicing activator. However, not all splicing fact

in speckles. Furthermore, speckles have been described as storage sites for splici

factors, while the functional role of the nuclear concentrations of Nova has not b
elucidated yet and might not be one of inactive storage. Many of the active sites
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transcription that have been loosely described as perichromatin fibrils, are hard to detect,
only appear after special treatment, and do not necessarily conform to a given pattern
(Huang and Spector, 1992; Misteli and Spector, 1998). Thus, if Nova played a role in

splicing regulation, and this was coupled to active transcription, it could still be possib
that the Nova nuclear foci are sites of active splicing and do no co-localize with the
proteins tested here. In that respect, the Nova sites could be the setting of splicing for
specific target RNAs (hence their small number in the nucleus) and not sites where the
general splicing machinery (e.g. RNA polymerase II, SC35, etc.) is localized.
The co-localization of Nova with brPTB was observed with endogenous and
transfected proteins in N2A cells but not in other cell lines, suggesting that this
interaction is neuron-specific. The simple in vitro protein-protein interaction between
Nova and brPTB did not require the presence of other protein or RNA co-factors (see
Chapter 3). When transfected in 293T or HeLa cells, both brPTB and Nova proteins can
individually localize in a pattern similar to the endogenous pattern seen in N2A cells, but
they do not co-localize (Figures 26, 27, and 28). This result insinuates that another
neuronal-specific co-factor is required for this co-localization while no such factor is
necessary for their in vitro GST pull-down interaction. Importantly, the in vivo GST pulldown was performed with N2A cell extracts and was not attempted in 293T or HeLa

cells. Alternatively, factors that restrict this interaction could exist in 293T or HeLa ce
only and not in N2As, thereby forbidding co-localization in these cells.
It is important to note the apparent contradiction between the results presented
here (i.e. the absence of co-localization between brPTB and Nova proteins in 293T cells)
and the effect of brPTB on Noval-dependent exon selection discussed in Chapter 4. The
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gross pattern observed in these co-localization studies depends on antibody recognition of
large amounts of proteins in fixed, permeabilized cells. In contrast, the splicing assays
presented in Chapter 4 concern individual proteins on a molecular level and their
functional interaction over a single RNA molecule. While a significant amount of
splicing events would be required to explain the differences observed in exon selection,
the RT-PCR assay is much more sensitive than immunofluorescent techniques.
Similarly, while Nova and brPTB co-localize in N2A cells, there seem to be no brPTBmediated inhibition of Noval splicing activation. The implications of these results for
the proposed functional significance of the interaction between brPTB and Nova proteins
will be discussed in more detail in Chapter 6.
It is not clear from these results whether the localization of one of the two

proteins is required first, in order to serve as an anchor for the localization of the seco
brPTB contains a putative NLS as well, and it has not been possible to map the
interaction between Nova and brPTB to specific domains. While an RNA factor is not

required for the in vitro interaction, it is entirely possible that the co-localization, wh
would probably require larger amounts of proteins in order to be detectable by
immunoreactive methods, occurs over an RNA target that both proteins bind to. For
example, in the case of the GlyRa2 mRNA, the binding sites that have been identified for
Nova and brPTB are not overlapping and could serve as the anchor for bringing these
proteins together in the nucleus (see Chapter 4).
As previously discussed, the perinucleolar compartment is a newly recognized
structural entity in the nucleus that contains the PTB, PSF, RNA polymerase II and KSRP
proteins (Matera et al., 1995; Huang et al., 1997; Black et al., RNA 2001 meeting poster
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presentation). N o information is available on the differential composition of the P N C
between various tissues. In the results described here, PTB co-localized with Nova only

in N2A cells, yet when examined in other cells lines, it displayed a pattern that could very
well be described as perinucleolar (for example, see Figure 28). Nova also seemed to be
perinucleolar in those cases but it did not coincide with PTB. However, Nova did not colocalize with RNA pol II which has been detected in the PNC (Huang et al., 1997), while
its co-localization with KSRP and PSF was not tested. It remains to be seen whether the
co-localization of Nova with brPTB in neuronal nuclei occurs within the context of the
PNC and whether this structure contains different proteins among various cell types.
It is evident that the staining pattern of brPTB is not as punctate as the one for
Nova. Besides staining the cytoplasm, brPTB stains the nucleus more broadly than Nova

does, yet can still be seen in distinct concentrations of higher intensity that coincide wi
Nova staining. The broader staining of brPTB could be the result of background
reactivity due to the polyclonal antibody and not due to more widespread expression of
the protein. However, this is unlikely as transfection of GFP- or flag-tagged brPTB
constructs result in a similar staining pattern. Moreover, a general caveat of experiments
such as these, involves the problem of proteins being over-expressed from transfected
constructs. Nevertheless, since the localization pattern of Nova and brPTB was also
examined in the case of endogenous proteins with immunostaining techniques, this is
unlikely to account for the data presented.
Some of the domains of Noval that could mediate nuclear and sub-nuclear
localization involve regions of sequence homology with domains of known function from
other proteins. These include a classic NLS signal similar to the one present in the
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h n R N P K protein, and an N E S sequence, homologous to the one present in the H I V

protein Rev. As the experiments presented here show, the Noval NLS is sufficient b

not necessary for nuclear localization. Once deleted, Noval is still able to be im
into the nucleus and, once there, it can localize in a punctate pattern. Save the

of diffusion of this construct into the nucleus, this would suggest that another d

exists in Noval that is able to guide it into the nucleus where it can localize in
pattern observed (see below).
Similar results have been observed with the localization pattern of the closest,

evolutionary, protein to Nova, hnRNP K. Deletion of the classical NLS in hnRNP K s

allows it to localize to the nucleus (Michael et al., 1997). However, in that case,

import becomes transcription-dependent, supporting the evidence that shuttling and

nuclear localization of these RBPs is contingent on their function. This line of e

led to the discovery of KNS, a novel shuttling domain that can carry hnRNP K in an

of the nucleus even when the classical NLS is absent. While Nova has not been show

shuttle yet, insight from the results with hnRNP K can prove helpful in elucidatin
mechanism by which, even in the absence of a functional NLS, Nova can localize in
foci observed with full-length protein.
As implied by the above, the sub-nuclear localization of Nova proteins could be

the result of actual RNA binding, as is the case for other RBPs. This would entail

function of its three KH domains. However, when constructs containing the first tw

domains of Noval were tested, no discernible sub-nuclear localization pattern emer
(Figure 30). When the spacer/KH3 construct was tested some foci materialized, but

as pronounced as in the case of the full-length protein. The spacer domain has been
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hypothesized to play a role in homotypic or heterotypic dimer formation that could
facilitate RNA binding. Some preliminary evidence has hinted that the third KH domain
of Nova plays an important role in RNA binding and perhaps could be the main RNA
binding motif (Lewis et al., 2000; Jensen et al., 2000b; Dredge et al., work in progress).
This would suggest that the sub-nuclear structural formations of Nova are sites of
active RNA-binding and perhaps of functional activity (i.e. splicing regulation) as well.
In concert with this hypothesis, experiments with actinomycin D (a drug that inhibits
transcription) reduce the appearance of Nova foci suggesting that those are active sites
related to ongoing gene expression and not storage facilities of inactive proteins as has
been proposed for splicing factors and speckles which get bigger with such treatment
(Jensen, Dredge and Darnell, personal communication). However, Nova does not
localize in sites where presumably transcription and splicing are taking place (i.e.
perichromatin fibrils).
It would be interesting to repeat the actinomycin D experiment with the Nova
construct lacking the NLS sequence, which has been shown here to still be able to
localize to the nucleus and, furthermore, concentrate in sub-nuclear foci. If in fact the
Nova ANLS constructs are still responsive to actinomycin D treatment, as they are in the
case of hnRNP K, it would suggest that other domains in Nova are responsible for its
ability to enter the nucleus and that the classical NLS identified here is not part of a
possible shuttling domain in Nova, but rather exists in addition to it.
It will be instructive to ascertain whether Nova proteins shuttle between the
nucleus and the cytoplasm and delineate the requirements for this shuttling (e.g.
transcription dependence, domains, receptors, etc.). Along these lines, it will also be
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important to examine the function of the Rev-like N E S sequence present in Noval and
Nova2. Importantly, the NES present in Nova2 contains one less leucine residue and

preliminary evidence suggests that the localization of Nova2 is predominantly nucl
whereas Noval can also be found in the cytoplasm (Yang, 1997). Together with some
evidence suggesting that Noval and Nova2 form dimers (Yang, 1997; this work), the

hypothesis that Noval helps guide Nova2 out of the nucleus can be tested in heterokaryon assays and transgenic mice.
The actual functional implication of these Nova/brPTB bodies remains to be seen.

Important experiments that will help elucidate this, involve in situ hybridization
Nova RNA targets (genes whose splicing is regulated by Nova, such as GlyRoc2 and
GABAARy2) and concomitant visualization of the Nova and brPTB proteins. These
studies will determine whether Nova foci contain RNA and furthermore whether this

interaction (RNA binding in the sub-nuclear localizations) reflects the role of No
splicing activation.
The interaction between Nova and brPTB and its importance in their nuclear co-

localization can be further studied with the generation of dominant negative const
For example, Nova mutants that do not bind RNA but can mediate protein-protein

interactions or conversely, that still bind RNA targets but do not interact with b

vitro, can be used to determine whether the co-localization in the nucleus depends
RNA binding or protein interaction with brPTB. Finally, the generation of a brPTB

knock out mouse will also shed light on its requirement for the nuclear localizati
Nova as well as determine whether brPTB (and by extension hnRNP I/PTB) is an

essential splicing factor and/or necessary for the development of the nervous syst

138

Table 3. S u m m a r y of structural d o m a i n s in the interphase nucleus.

Summary table of the most prominent and best-characterized structural features in

nucleus during interphase. Included are the name of the structure, the number of b

per nucleus (No.), the proposed function, and some of the proteins known to localiz
within these bodies. For references, see text. NK: not known.
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Figure 22. N o v a localizes in distinct sub-nuclear structures.

(A) N2A cells were fixed and stained with anti-Nova human serum and visualized wi

Cy2-conjugated anti-human secondary antibody (green). Notice the four to five dist
bright-staining foci per cell nucleus.

(B) N2A cells were stained with Nova2-specific affinity-purified polyclonal antib

(Yang, 1997) and Cy3-conjugated anti-rabbit secondary antibody (red). Similar stain
to Noval was observed.
(C) Mouse brain sagital sections were stained with anti-Nova human serum and

visualized with Cy2-conjugated anti-human secondary antibody (green, see Materials
Methods).
DAPI stain was used in all slides to visualize cell nuclei.
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Figure 23. N o v a does not colocalize with k n o w n sub-nuclear structures.

N2A cells were fixed and stained with the indicated primary antibodies and human a

Nova serum. The appropriate Cy3-conjugated secondary antibody was used to visualiz

each protein (red, first column). Cy2-conjugated anti-human secondary antibody was
used to visualize Nova (green, second column). The two planes were then merged to

examine co-localization (third column). The cells were also stained for DAPI to vi

cell nuclei (blue, fourth column). For the antibodies used and the specific protei
recognized by each, see Materials and Methods.
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Figure 24. E n d o g e n o u s N o v a a n d b r P T B co-localize in N 2 A cell nuclei.

(A) N2A cells were fixed and stained with rabbit polyclonal anti-brPTB serum (top

panel) and human anti-Nova patient serum (top right panel). Cy2-conjugated anti-hu

(green) and Cy3-conjugated anti-rabbit (red) secondary antibodies were used to vi

the proteins, respectively. The panels were merged to examine co-localization, evi

by the yellow color (bottom left panel). Cells were also stained with DAPI to deli
the nuclei (blue, bottom right panel).
(B) Bleedthrough Controls. N2A cells were stained individually for Nova (top row)
brPTB (bottom row) as before, the indicated secondary antibodies, and DAPI. When

observed with the red filter, Cy-3 conjugated anti-human antibody did not cause an
bleed-through (top row, middle panel). Similarly, the Cy2-conjugated anti-rabbit

antibody used to visualize brPTB protein did not light up with the green filter (

row, left panel) demonstrating that the co-localization patterns observed were no
secondary antibodies emitting signal with the wrong filter.
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Figure 25. Transfected b r P T B a n d P T B co-localize with N o v a in N 2 A s .
(A) GFP-Noval (left) and GFP-Nova2 (right) eukaryotic expression constructs were

transfected into N2A cells. After fixation, cells were stained with anti-brPTB ser

Cy2-conjugated secondary antibody (red, first row panels). GFP-Noval (left column,

second row) and GFP-Nova2 (right column, second row) were visualized with the gree
filter. The merged images (third row) demonstrate co-localization, as seen by the
colored foci. DAPI stain was used to delineate cell nuclei (blue, fourth row).

(B) Eukaryotic expression constructs for flag-tagged brPTB (left column) and myc-

tagged PTB (middle column) were transfected into N2A cells that were subsequently

fixed and stained with anti-Nova serum and anti-flag or anti-myc monoclonal antibo

respectively. Alternatively, anti-matrin3 polyclonal chicken antibody was used tog
with anti-Nova serum (right column). Cy2-conjugated anti-human secondary antibody

was used to visualize Nova proteins (green, second row) and Cy3-conjugated anti-mo

or anti-chicken secondary antibodies were used to visualize brPTB, PTB and matrin3
(red, first row). Merged panels (third row) show that both transfected brPTB and
are able to co-localize with endogenous Nova proteins in N2A cells. In contrast,

endogenous matrin3 protein, perhaps because its staining is more diffuse, does not
localize with Nova. DAPI was used to stain cell nuclei (blue, fourth row).
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Figure 26. Transfected b r P T B does not co-localize with N o v a in 2 9 3 T s .

(A) 293T cells were transfected with T7-tagged Noval (left column) and GST-tagged

Nova2 (right column) as well as brPTB eukaryotic expression constructs. The cells
fixed and stained with the appropriate primary monoclonal antibodies. GFP-brPTB

protein was visualized with the green filter (first row) and Nova proteins were v

with Cy3-conjugated anti-mouse secondary antibodies (red, second row). Merged ima

(third row) show no co-localization. DAPI was used to delineate cell nuclei (blue,
row).
(B) 293T cells were transfected with GFP-Noval (left column) or GFP-Nova2 (right

column) and flag-tagged brPTB. brPTB was visualized with anti-flag primary antibod

and Cy3-conjugated anti-mouse secondary antibody (red, first row) while Nova prot

were visualized with the green filter (second row). No co-localization is observe

the panels are merged (third row). DAPI was used to stain cell nuclei (blue, fourt
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Figure 27. P T B does not co-localize with N o v a in 2 9 3 T cells.
(A) 293T cells were transfected with GFP-Noval (left column) or GFP-Nova2 (right

column), visualized with the green filter (second row). Anti-brPTB antibody was us

stain PTB proteins present in 293T cells and was visualized with Cy3-conjugated an
rabbit secondary antibody (red, first row). Merged images (third row) show no colocalization. DAPI was used to delineate cell nuclei (blue, fourth row).

(B) 293T cells were transfected with myc-tagged PTB constructs and again GFP-Nova

(left column) or GFP-Nova2 (right column). PTB was visualized with anti-myc primar

antibody and Cy3-conjugated anti-mouse secondary antibody (red, first row) and No

proteins were visualized with the green filter (second row). No co-localization i

observed when the panels are merged (third row). DAPI was used to stain cell nucl
(blue, fourth row).

145

A . 1

a-brPTB

N o v a 1/2

|

merge

DAPI
|

B .

myc-PTB
|

N o v a 1/2
|

|

merge

DAPI

•

Figure 28. P T B proteins d o not co-localize with N o v a in H e L a cells.
HeLa cells were transfected with GFP-Noval (left column) or GFP-Nova2 (right
column). After fixation, cells were incubated with anti-brPTB antibody. PTB was

visualized with Cy3-conjugated anti-rabbit secondary antibody (red, first row) an

proteins were visualized with the green filter (second row). Merged images (third
show no co-localization. DAPI was used to stain cell nuclei (blue, fourth row).
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Figure 29. N o v a a n d b r P T B proteins co-localize in tissue sections.

(A) Confocal laser images of Nova and brPTB expression patterns in P5 mouse spina
cord horizontal sections (top row) and adult rat spinal cord horizontal sections

row). Nova proteins (green, left column) were visualized with patient serum and Cy

conjugated anti-human secondary antibody. In the same optical section, brPTB prote

(red, middle column) was visualized with anti-brPTB antibody and Cy-2-conjugated a

rabbit secondary antibody. Merged panels (right column) show co-localization of b

and Nova proteins within nuclei of motor neurons. Some cells (presumably glia) sta
only with anti-brPTB antibody and not with anti-Nova serum.
(B) Immunohistochemical studies of cerebellar sections of P5 Noval knockout mice

(KO, bottom row) and their wild type litter mates (WT, top row). Sections were st

with anti-Nova serum (green, left column) and anti-brPTB antibody (red, middle col
as well as Cy2-conjugated anti-human and Cy3-conjugated anti-rabbit secondary
antibodies. Merged panels (right column) show co-localization.
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Figure 30. Localization of N o v a l deletion mutants in live N 2 A cells.
N2A cells were transfected with the indicated GFP fusion eukaryotic expression
constructs and were observed live in an inverted microscope under a mercury lamp.

deletion constructs (except for the indicated full-length Nova2) were of the Nova
(see Materials and Methods for an analytical description of the constructs).
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Discussion

R N A - b i n d i n g p r o t e i n s a n d neuron-specific alternative splicing

Approaches to examine the regulation of transcripts that are differentially splice

nervous system have made significant contributions to our basic understanding of t

mechanisms by which neuron- and, by extension, cell-specific splicing, is achieved

Collective data from the study of genes implicated in neuronal diseases suggest th

efficient regulation of such a tissue-specific cellular process requires several l

control (reviewed in Dredge et al., 2001). First, specific cis-acting regulatory se

are likely to be present near differentially spliced exons, as has been demonstrat

c-src and GABAARy2 transcripts. In general, splice sites in alternatively regulate
are weak compared to the consensus and are poorly recognized by the basal splicing
machinery. Second, trans-acting RNA-binding proteins, such as Nova, hnRNP Al and

hnRNP I/PTB need to recognize and interact with these sequences. In the case of we
splice sites in regulated exons, binding by hnRNPs and other factors could help

"strengthen" them by recruiting components of the splicing machinery. Finally, the

must be key protein-protein interactions whether positive or negative, direct or i

When these interactions occur between sequence- and gene-specific RBPs recognizing

individual binding sites in exons or introns, they set the stage for "exon definit

the other hand, when these RBPs interact with and recruit components of the genera

splicing machinery in the recognition of splice sites, they help form the spliceos
"commitment complex" and provide for an additional level of splicing regulation.
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The search for transcripts that undergo neuron-specific splicing has generated an
important set of pre-mRNAs and splice variants (reviewed in Dredge et al., 2001;
Grabowski and Black, 2001). Studies of the neuron-specific splicing of the c-src,
GABAARy2 subunit, NMDA receptor NR1 subunit and clathrin light chain B mRNAs

have identified cis-acting repressor elements that mediate the exclusion of the ne
specific exon in other tissues (Chan and Black, 1997; Ashiya and Grabowski, 1997;

Zhang et al., 1999). These repressor elements were mostly pyrimidine-rich and, when

present as competitors in vitro, were able to derepress splicing back to the neura
At the same time, a variety of biochemical approaches including UV cross-linking

and immunoprecipitation experiments identified the polypyrimidine tract-binding pr

(PTB) as an RBP that binds many of these repressor elements. (Chan and Black, 1997;
Ashiya and Grabowski, 1997; reviewed in Wagner and Garcia-Blanco, 2001). In vitro
splicing assays after immunodepletion and adding-back of recombinant protein have

established that PTB protein is able to repress neuron-specific exon inclusion. In

contrast, several splicing enhancers have been found to bind a regulatory sequence
downstream of the neuron-specific exon in c-src, including hnRNP H, hnRNP F, and a

protein named KSRP, a new splicing regulator that may be enriched in neuronal cell
(Min et al., 1997; Chou et al., 1999).

One interpretation of such results is to view neuron-specific splicing as a defaul

process, selectively repressed in non-neuronal tissues by trans-acting RNA-binding

proteins such as the ubiquitous factor PTB. In neural cells, this repression is pr

be relieved by the presence of positive regulators that would compete by simple ma
action for the same or overlapping binding sites on the mRNA (Zhang et al., 1999;
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reviewed in Grabowski, 1998). In support of a role for P T B in splicing repression, an

antagonism between PTB and the U2AF splicing factor has been implied (Lin and Patt

1995; Singh et al., 1995; Lou et al., 1999), that is mechanistically similar to the
antagonistic binding of Sxl protein and U2AF on the transformer mRNA in Drosophila

(Valcarcel et al., 1993). Due to the proximity of poly-pyrimidine tracts to the bra
point intronic sequence, an interference by PTB in spliceosome assembly at the U2
snRNP step has also been suggested, in a manner parallel to the antagonism between
ASF/SF2 and hnRNP Al at the 5' splice site (Caceres et al., 1994). However, the

ubiquitous expression of these factors (PTB, U2AF) has precluded any conclusions a
their role in tissue-specific splicing regulation.
As mentioned above, the study of neurologic disease has been particularly
powerful in terms of identifying key players in the regulation of neuron-specific
The regulation of splicing in GlyRa2 by Nova has emerged as a clear example of the

interplay between different RNA-binding proteins in the control of splicing. In th

study, a brain enriched form of PTB named brPTB was cloned by virtue of its intera

with Nova and was shown to specifically antagonize the neuron-specific increase in
GlyRrxZ and GABAaRy2 exon inclusion mediated by Nova.
The presence of a neuronal form of PTB had been hinted at by UV crosslinking

studies of both the GABAARy2 subunit and the c-src m-RNAs, and a possible permissi
role in splicing had been proposed to replace the repressive action of ubiquitous
(Chan and Black, 1997; Ashiya and Grabowski, 1997). However, brPTB does not de-

repress splicing in neurons as had been suggested, and also does not appear to ant
the positive effect of Nova in splicing by a simple displacement mechanism, since
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lower affinity for the target R N A than did Nova (Polydorides et al., 2000; this work).
Furthermore, in the experiments presented here, PTB had a similar, if not more
pronounced, effect in antagonizing the Noval-dependent splicing increase.
More recently, it was shown that in neurons, ATP, most likely via another

unidentified factor, removes PTB from repressor sequence elements present in the c

transcript and thus allows for neural splicing to occur (Chou et al., 2000). Moreov
was suggested that the behavior of brPTB was different than PTB in terms of RNA

binding and splicing repression. While this model would still require the presence
neuron-specific factor to mediate the effect of ATP, it provides insight as to the
regulatory mechanisms of such a process. PTB may prevent the assembly of U2 snRNP
on the RNA in non-neuronal cells and removal of PTB from the RNA in an ATP-

dependent fashion leads to derepression of splicing in neurons. In this model, brP
may add an additional level of splicing repression in neuronal cells.
Post-translational modifications of RNA-binding factors have also been described

as a means of regulating their function. Specifically, phosphorylation of SR prote

been shown to be required for their splicing enhancer or repressor function and ad
proteins that regulate this modification have been identified (Cao, et al., 1997;

1997; Kanopka et al., 1998; Petersen-Mahrt et al., 1999). However, there has been n

evidence that any of these modifications, or the proteins that mediate them, are t

cell-type specific. Therefore, until such data emerges, the effect of phosphorylat

other post-translational modifications in the regulation of neuron-specific splici

remain unclear. The interaction of Nova with p32/YL2 in the yeast-two-hybrid scree

presented here and the suggestion that p32 negatively regulates ASF/SF2 by inhibit
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phosphorylation (Petersen-Mahrt et al., 1999), suggest that the N o v a splicing factor m a y
also be regulated in such a manner. In support of this, Noval is phosphorylated in vitro
and in vivo (Stefani et al., work in progress).
Neuron-specific splicing is likely to have many layers of control that will
undoubtedly involve the regulated interplay between various tissue-specific and
ubiquitous factors. In addition, the unique physiology of neurons allows them to modify
these cellular processes even further. There have been reports that neuronal activity can

alter the splicing pattern of various transcripts. For example, depolarization of pituitary
neurons represses the inclusion of an exon in the BK potassium channel mRNA through
the action of CaMKIV on an RNA element that is sufficient to confer repression control
to a heterologous, constitutive exon (Xie and Black, 2001). Other transcripts that are
regulated by activity-dependent splicing in the brain include the human tra-2 gene
(Daoud et al., 1999) and the NMDA receptor NR1 subunit (Vezzani et al., 1995). To get
a better understanding of how splicing works in mammalian cells (and specifically in

neurons), and identify the role of the different cis- and trans-acting factors involved, the

will need to be a concerted effort to identify these factors, examine their relative levels

different cell types, and analyze their function. Then, it will be feasible to elucidate the
ways with which splicing is regulated, and how it is interconnected with other cellular
processes such as signal transduction, transcription regulation and cell cycle control.
In summary, many regulatory processes such as signal transduction, neuronal

synaptic activity and protein-protein interactions can control alternative splicing which i
turn can result in the differential RNA processing of other, downstream RNA targets.
This can be achieved if the alternative isoforms of the regulated gene product exhibit
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different patterns of association and co-localization with other R B P s (including splicing

factors) or other regulatory proteins (inclusing kinases). Examples include the rec

description of different functional activities for the alternative spliced isoform

cyclin Ania-6 (Berke et al., 2001) and PTB (Wollerton et al., 2001) and have spark

interest in the co-localization patterns of splicing factors as a means for identi

functional interactions. The splicing of Ania-6 depends on the stimulation by vari

neurotransmitters and exhibits functional consequences in vivo, as the longer isof
the transcript co-localizes, when translated, with nuclear speckles, the splicing

SC35 and RNA pol II and could, thus, affect RNA processing in turn (Berke et al., 2

Since alternative splicing occurs in the nucleus, the search for trans-acting fact

that might regulate it has focused on nuclear RNA-binding proteins. Reports that n

events have further consequences in the cytoplasmic regulation of the transcript h

expanded this model and have refocused attention on the localization of splicing f

as a means of identifying protein-protein interactions and regulatory associations

Nuclear localization patterns of RNA-binding proteins

As more RBPs are found to have multiple roles in the regulation of RNA metabolism
are believed to contribute to the coupling of sequential steps in the life of the

transcript, it becomes increasingly important to examine their specific localizati

the cell and its regulation thereof. Additionally, as the model of nuclear organiz

switches from a rigid compartmentalization to one of dynamic fluctuation, the proc

that regulate this architecture are likely to be of major significance to the func

these proteins (Phair and Misteli, 2000). The mechanisms controlling protein locali
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include specific interactions with other macromolecules, post-translational modification
and processing of the actual RNA-binding protein and, lastly, methods based on cellular
activity and protein function.
The nuclear localization of RBPs can be affected by their interactions with other
macromolecules, including themselves (dimerization), other proteins, and RNA targets.
Self-association has been described as a method for the regulation of nuclear localization
in the case of p80-coilin (Hebert and Matera, 2000), PML (Ishov et al., 1999), SMN
(Lorson et al., 1998), and Sam68 (Chen et al., 1999) proteins. Protein-protein
interactions that affect the nuclear localization of RBPs have been described for many
proteins that localize to specific sub-nuclear structures. For example, the interaction
between p80-coilin and Nopp 140 is crucial to the proper formation of coiled bodies
(Isaac et al., 1998). The CTD domain of RNA pol II interacts with and targets SR

proteins and snRNP splicing factors to sites of active transcription in the nucleus (Mistel
and Spector, 1999). While both RNA polymerase II and splicing factors have distinct
and not always overlapping localization patterns, their interaction suggests that splicing
dependent on transcription (perhaps occurring at the same location) and that a peptide
domain is responsible for that connection.
The RS domains of SR proteins, which are thought to mediate interactions with
other proteins (e.g. splicing factors), are sufficient for guiding proper sub-nuclear
localization (Li and Bingham, 1991; Gama-Carvalho, 1997) and their overexpression can
prove deleterious to it (Romac and Keene, 1995). Phosphorylation of the RS domain also
promotes protein shuttling and can regulate the proper transport of bound mRNAs
(Gilbert et al., 2001). Furthermore, interactions of SR proteins with other proteins
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lacking R S domains are capable of targeting them to nuclear speckles (Patton et al., 1993;

Hedley et al., 1995). Other domains implicated in targeting certain proteins to the
nucleus have been shown to mediate an interaction with U2snRNP (Eilbracht and
Schmidt-Zachmann, 2001).
Other functional domains of RBPs, including the RNA binding motifs, have been

shown to be required for their specific staining pattern, again linking functional
to nuclear localization. For example, the localization of poly(A)-binding protein

(PABP2) and PTB-associated splicing factor (PSF) to sub-nuclear speckles depends o

their capacity to bind RNA and is in contrast to other splicing factors whose loca

in speckles increases in the absence of transcription (Calado and Carmo-Fonseca, 20
Dye and Patton, 2001). In some human SR proteins, the RRM domains mediate nuclear

localization, at least partly (Caceres et al., 1997). Finally, multiple RRM domains

PTB protein are required for its localization to the PNC, suggesting that RNA-bind
necessary (Huang et al., 1997).
Post-translational modifications that influence protein localization mostly focus

on the regulation of the phosphorylation state of the protein by kinases and phosp

perhaps as a result of cell cycle regulation. The nuclear localization of snRNP sp

factors and SR proteins has been shown to be influenced by phosphorylation (Gui et

1994; Colwill, et al., 1996; Misteli and Spector, 1996; Sleeman et al., 1998). The s

nuclear localization of Sam68, a protein that mediates a connection between signal
transduction pathways and RNA metabolism, also depends on phosphorylation

(Hartmann et al., 1999). Coiled body formation has been suggested to be dependent o
the phosphorylation level of p80-coilin (Lyon et al., 1997; Sleeman et al., 1998;
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and Matera, 2000). Finally, the association of nuclear matrix components with active
splicing complexes may also be regulated by phosphorylation (Chabot et al., 1995). The
cytoplasmic accumulation of hnRNP K, depends on its phosphorylation and is necessary
for its function in silencing mRNA translation (Habelhah et al., 2001). Another
modification that has recently generated interest concerns the ubiquitin-like protein
Sumo-1, as sumoylation of the PML protein has been hypothesized to regulate its
localization in nuclear bodies (Muller et al, 1998, Zhong et al., 2000)
The effect of phosphorylation on the nuclear localization of RBPs suggests that
the cellular machinery that achieves and regulates the localization pattern of a given
protein is likely to have some universal features and can thus be highjacked by viral
proteins. Indeed, the HIV protein Rev contains NLS and NES domains that allow it to
shuttle, as well as a loop domain, located between two helices, that is required for proper
phosphorylation of the protein by a cellular kinase (D'Agostino et al., 2000). The loop
structure, together with the NES, is required for the proper sub-nuclear localization and
association with splicing factors and hence for the functional activity of Rev in binding
and trans-activating target viral RNAs.
The localization of RBPs can also be controlled by changes in cellular activity or
as required by alterations in their function. For example, as nuclear RNA export is
mostly mediated by RBPs, their localization in both the nucleus and the cytoplasm and
their capacity to shuttle between the two becomes a requirement for proper function. In
neurons, it has been reported that the dendritic targeting of certain messages (e.g. the
CaMKIIa mRNA) depends on cis-acting elements in their 3' UTRs and is regulated by
functional activity, namely neuronal depolarization (Mayford et al., 1996a; Mayford et

157

al., 1996b ; Mori et al, 2000). Furthermore, neurotrophin release induces the formation
of an mRNP complex between (3-actin mRNA and Zipcode-binding protein 1 (ZBP1).
Transport of this complex to neurites is dependent on the 3' UTR of the mRNA and

results in localized P-actin protein synthesis, which eventually affects growth co
motility (Zhang et al., 2001).

Localization-function coupling and RNA-binding proteins

By virtue of their diverse functions, varied localization patterns and ability to

assorted RNA targets, RNA-binding proteins have the capacity to be in the center o

machinery that controls gene expression. This capability is manifested by the role

RBPs in linking the different stages of RNA metabolism in a manner that is efficie
economical and advantageous to the cell.

Transcription has been linked to splicing which, in some cases, is thought to occur

concurrently (Misteli and Spector, 1999), and to the nucleocytoplasmic transport of
RNAs (Pinol-Roma and Dreyfuss, 1991; Pinol-Roma and Dreyfuss, 1992). Splicing has

also been shown to influence the nuclear export process (Kataoka et al, 2000; Le H
al, 2000a; Huang and Steitz, 2001) and the mRNA surveillance/non-sense mediated

decay pathways (Kim et al., 2001a; Lykke-Andersen et al., 2001). In turn, nuclear e
of RNA is linked, through the function of common RBPs, to mRNA processing, i.e.
capping, 3' end cleavage and polyadenylation (Brodsky and Silver, 2000; Daneholt,

2001). Finally, the nuclear export process influences subsequent cytoplasmic locali
and efficient translation (Choi et al., 2000; McKendrick et al., 2001).

158

A requirement for the ability of R B P s to efficiently serve as linkage factors

between different steps in RNA metabolism and thus become crucial regulators of ge

expression and cellular activity, is that they perform more than one function on t
RNA molecules. This is underscored by the presence of multiple domains within the

structure of RBPs and by the versatility of specific domains in mediating more tha

biochemical reaction. For example, different regions of the carboxy-terminal domai

RNA polymerase II can independently regulate capping, splicing, 3' end cleavage, a
polyadenylation (Fong and Bentley, 2001). The members of the Hu/Elav family have

been suggested to play a role in mRNA splicing (Koushika et al., 1996; Koushika et

2000; Lisbin et al., 2001), stability (Myer et al., 1997; reviewed in Brennan and St

2001), and translation control (Jain et al., 1997) and could possibly mediate all o
above on a single RNA target.
Reports show that commitment to a particular splicing pattern occurs very rapidly

after transcription and might even be functionally coupled to it (Roberts et al., 1
This is also supported by data that the perinucleolar compartment (PNC), where the

splicing repressor has been shown to localize, may be an active site of transcript

(Matera et al., 1995; Huang, et al., 1998). Besides its role in splicing repression

I/PTB has been implicated in the regulation of cap-independent translation (Gosert

2000), cytoplasmic mRNA localization (Cote et al, 1999), stability (Irwin et al., 19

and efficient polyadenylation (Lou et al., 1996; Moreira et al., 1998). In any case

specific multifunctional RBPs, such as PTB, are at the forefront of coupling event
lifecycle of RNA molecules in a way that allows for effective regulation and firm
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The R S domain of two Drosophila SR proteins is necessary for splicing function

and sufficient for nuclear localization, suggesting that these two processes are i

linked (Li and Bingham, 1991; Hedley et al., 1995). The situation in humans is thou
to be more complex however, as reports have demonstrated that domains of the SR

proteins (including the RS and RRM domains) can have additive and redundant functi

in guiding sub-nuclear localization and targeting to sites of active splicing (Cac
1997; Gama-Carvalho et al., 1997). Even components of the nuclear matrix that have
been hypothesized to belong to the SR family of RBPs can be associated with active
splicing complexes (Blencowe et al., 1994).
The importance of the proper cellular localization of RBPs for their function is

highlighted by the phenotype exhibited when this process is perturbed. For example

spinal muscular atrophy is a disease that is thought to disrupt the interaction of

gene affected by the disorder, with another protein, resulting in the absence of S
localization from nuclear bodies and, presumably, defective function in snRNP
biogenesis (Gangwani et al., 2001). The incorrect accumulation of the CUG-Binding

protein (perhaps due to altered phosphorylation patterns) and the resulting aberra
processing of target RNA transcripts in the nucleus has been hypothesized to be a

in the pathophysiology of myotonic dystrophy (Roberts et al., 1997; Philips et al.,

Nova-brPTB protein interactions in alternative splicing and

nuclear localization

The results presented in this thesis concern the functional interactions between t
neuronal RNA-binding proteins, Nova and brPTB. The brPTB protein, a member of the
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P T B sub-family of R B P s that includes P T B , matrin3 and h n R N P L, is specifically
enriched in the brain at the RNA and protein level. It was identified and cloned by virtue
of its interaction with the paraneoplastic onconeural antigen Nova, through a yeast-twohybrid screen. This interaction was confirmed both in vitro and in vivo and was shown to
play an important role in the regulation of alternative splicing of a couple of neuronal
transcripts. Furthermore, brPTB and Nova were shown to co-localize in distinct subnuclear structures in neuronal nuclei.
Placed in the context of the function of RBPs in the control of RNA metabolism,
as discussed in Chapter 1, the interaction between brPTB and Nova has numerous
implications. It is important to note that these two RBPs contain different types of RNAbinding motifs and yet can interact on the protein level. While the exact domains
responsible for this interaction were not identified, and the question of whether an RNA
molecule intermediates this interaction in vivo was not completely resolved, it is
nevertheless apparent from the assays measuring the effect on splicing regulation, that
this interaction has biological significance. The brPTB protein inhibits the Nova-specific

increase in alternative exon utilization in a manner that is contingent on its binding to t
RNA transcript. This would imply that the act of RNA-binding is necessary for the effect
of brPTB in splicing inhibition, as it has been shown for the effect of Nova in splicing
activation (Jensen et al., 2000a).
The possible means by which brPTB could inhibit the action of Nova, have
already been discussed (see Chapter 4, Discussion). However, in light of the localization
studies presented earlier, it is feasible that the effect of the brPTB-Nova protein
interaction in splicing regulation is related to the nuclear setting of the two proteins. A
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model that could tie these results together is presented in Figure 31. Three functional
states of the Nova protein have been described in this work. One concerns the splicing
activation of certain exons by Nova proteins in both neuronal and non-neuronal cell lines
as evident by previous work and experiments presented here (Jensen et al., 2000a; this
work). In some cases, when brPTB is also present, the result of its inhibitory action on
Nova is splicing inhibition (Polydorides et al., 2000; this work). Finally, brPTB and
Nova co-localize in distinct nuclear bodies (this work).
It is proposed in this model that the three functional states of Nova protein are in
an equilibrium relationship with each other, the relative balance of which depends on the
particular cell type and possible co-factors. In neuronal cells, specific co-factors may
exist that could enhance the co-localization of brPTB and Nova proteins in nuclear
bodies, thus shifting the equilibrium from the splicing inhibition state. This would
explain both the presence of nuclear bodies in N2As and the absence of inhibitory action
by brPTB in the splicing assays performed in these cells (see Chapters 4 and 5, Results).
In non-neuronal cells, the absence of co-localization between brPTB and Nova
(possibly due to the lack of the required co-factor) allows the equilibrium to be switched
to the splicing inhibition state and explains the observed effect of brPTB in bringing the
level of exon inclusion back to the pre-Nova baseline (see Chapter 4). Since Nova and,
most likely brPTB as well, do not exist in 293T cells these results concern transfected
proteins. This poses a problem, as the interaction between brPTB and Nova proteins in
these non-neuronal cells still occurs yet no co-localization is observed. One explanation
could be that the localization interaction would require many more molecules colocalizing to become evident by immunostaining methods, while perhaps the splicing

162

inhibition on an R N A target transcript, where single molecules of Nova and brPTB could
be interacting, is easily observable by the more sensitive RT-PCR assay.
Hence, the debate whether the nuclear bodies occupied by co-localizing brPTB
and Nova proteins in neurons are indeed active splicing sites or inactive storage
be somewhat resolved. The mechanism by which brPTB inhibits Nova in splicing could

involve blocking the recruitment of general splicing activators (such as SR protei

the exon. Alternatively, the nuclear bodies observed in neuronal cells could be th
manifestation of sequestration of Nova by brPTB away from the RNA, thus inhibiting
splicing. However, this would be contrary to the result presented here that brPTB

inhibition of splicing requires its RNA binding and the observation that transcrip
inhibition reduces the appearance of the Nova nuclear concentrations.

Summary

RNA-binding proteins play a significant part in the regulation of neuron-specific

alternatively splicing. This function is intricately linked to their sub-nuclear l

which can, in turn, influence their regulation. RBPs also couple splicing events t
steps in the metabolism of RNA molecules. A model where this hypothesis can be

applied, involves the interaction between Nova and brPTB in terms of their roles in

alternative splicing and nuclear localization in specific cell types. brPTB and No

localize in neuronal cell nuclei where splicing assays fail to detect a repressive
brPTB in Nova-dependent alternative splicing. It is proposed that the explanation

discrepancy lies in an intricate balance in the equilibrium between functional sta
brPTB and Nova in the nucleus.
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Figure 31. Schematic m o d e l of the N o v a - b r P T B functional interaction.
Model depicting the functional interactions between brPTB and Nova proteins. In

neuronal cells, the equilibrium leans towards the formation of nuclear bodies, per

aided by a third, neuron-specific co-factor, and visible by immunocytochemical met
This equilibrium state allows Nova to act in splicing activation as the addition
does not inhibit splicing in N2A cells. In non-neuronal cells, perhaps due to the
of a co-factor, transfected Nova and brPTB proteins do not co-localize and the
equilibrium is shifted, allowing brPTB to inhibit the action of Nova in splicing
as seen in assays with 293T cells.
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Representative data set of GlyR 3A/3B splicing in 293T eels after Nova and brPTB transfections
Imagequant data
transfe;ction 3A/3B

2A
3A
4A
5A
6A
7A
8A
9A
2B
3B
4B
5B
6B
7B
8B
9B

2.47218696
2.6790851
2.26062506
1.93808412
6.47917793
4.97800629
4.52765968
2.748543
2.62031864
2.30816183
2.17085283
2.76023519
5.36348234
5.60872296
4.67037842
3.0444791

Amount transfected
Nova
brPTB
2
4
6
0.5
0.5
0.5
0.5

2
4
6

Ratios
3A/3B
2.5462528
2.49362346
2.21573894
2.34915965
5.92133014
5.29336462
4.59901905
2.89651105

st. dev
0.10474492
0.26228236
0.06347855
0.5813486
0.78891592
0.44598404
0.10091739
0.20925842

Representative data set of GlyR CT Mutant 3A/3B splicing in 293T eels after Nova and brPTB transfec
Imagequant data
transfection 3A/3B
2A
3.00483025
3A
2.9125848
4A
2.97134264
5A
2.75875291
6A
4.98263266
7A
4.91065806
5.28530484
8A
6.90792117
9A
2B
2.5680186
2.86706353
3B
2.80109139
4B
2.39978879
5B
4.99776777
6B
5.01396715
7B
5.21756318
8B
3.70011208
9B
Amount transfected
Nova
brPTB
2
4
6
0.5
0.5
0.5
0.5

2
4
6

Ratios
3A/3B
st. dev
2.78642443 0.30887248
2.88982416 0.0321884
2.88621701 0.12038581
2.57927085 0.25382596
4.99020021 0.01070214
4.96231261 0.07305056
5.25143401 0.04790059
5.30401663 2.26826356

Representative data set of G A B A L/S splicing in 293T eels after Nova and brPTB transfections
Imagequant data
transfection ratio L/S
2A
0.07018442
3A
0.07679634
4A
0.04589118
5A
0.04200696
6A
0.03785201
7A
0.03770101
0.02776304
8A
9A
0.04205606
2B
0.26571511
3B
0.29708633
0.1855875
4B
5B
0.18679193
0.11622665
6B
0.12347042
7B
0.09630146
8B
0.0953829
9B
Amount transfected
brPTB
Nova

2
4
6

Average ratio
0.09247174
0.08211882
0.06148131
0.06936156
0.05112468
0.05057753
0.12632509
0.06231841
0.15713952
0.1929067
0.13945502
0.13136766
0.12114288
0.1207896
0.09309652
0.08655169

st. dev
0.00969303
0.01405035
0.01025274
0.06570757
0.05276328
0.03312425
0.01663161
0.08428605 0.01371855

L/S

2
4
6
0.5
0.5
0.5
0.5

ratio L/S
0.08088922
0.06486322
0.03766139
0.03376851
0.02807683
0.02794043
0.02497307
0.03322085
0.20089416
0.19034669
0.12331486
0.10747677
0.09152576
0.08589394
0.06896707
0.06541665

0.07788729
0.04836182
0.03887875
0.05277609
0.21734809
0.14566562
0.10984154

Representative data set of GABA GA2 Mutant L/S splicing in 293T eels after Nova and brPTB transfec
Imagequant data
transfection ratio L/S
0.04827491
2A
0.04284727
3A
4A
0.02864832
5A
0.02707616
0.02449787
6A
0.0249269
7A
0.02855375
8A
0.03288998
9A
0.11777077
2B
0.12823414
3B
0.08082518
4B
0.07634674
5B
0.0677589
6B
0.06399482
7B
0.05385417
8B
0.04747199
9B
Amount transfected
brPTB
Novai
2
4
6
0.5
0.5
0.5
0.5

2
4
6

st. dev
L/S
0.04556109 0.00383792
0.02786224 0.00111169
0.02471239 0.00030337
0.03072187 0.00306618
0.12300246 0.00739872
0.07858596 0.00316674
0.06587686 0.00266161
0.05066308 0.00451288

Representative data set of GlyR 3A/3B splicing in N2A eels after Nova and brPTB transfections
Imagequant data
transfection 3A/3B
2A
3.6877927
3A
4.302909
4A
5.42919164
5A
5.67742295
6A
6.48093565
7A
6.37372371
8A
5.99337766
9A
5.86104886
2B
7.97082414
3B
8.13739086
8.25060437
4B
5B
7.96573163
8.74927638
6B
7B
8.62804129
8.31307775
8B
8.23935339
9B

3A/3B
3.17930866
4.13476132
5.05255542
5.30093037
5.91559202
5.61386356
5.60354741
5.22499281
6.23304603
6.41826742
6.94302171
7.02109044
6.4638677
6.80258716
6.30757323
6.44061215

Amount transfected
brPTB
Nova
2
4
6
0.5
2
0.5
4
0.5
6
0.5

Ratios
3A/3B
3.82619292
5.36502509
6.09602873
5.67074169
7.18988211
7.54511204
7.66094313
7.32515413

st. dev
0.50335096
0.26041966
0.40427239
0.33838731
1.00308986
0.66124924
1.19575815
1.09994527

Representative data set of G A B A L/S splicing in N2A eels after Nova and brPTB transfections
Imagequant clata
transfection ratio L/S
2A
0.81638181
3A
0.80348118
0.59795864
4A
0.57122484
5A
6A
0.50078961
0.70576492
7A
0.49093681
8A
0.61369694
9A

ratio L/S
0.76935679
0.77464409
0.85182671
0.65319332
0.6949757
0.69464224
0.52147169

2.04846909 3.19284373

2B
3B
4B
5B
6B
7B
8B
9B

1.64791842
1.07981609
2.17325973
2.20441923
2.03290745
2.02714557
2.08181761

3.15108504
3.00035425
2.72062352
2.28523589
2.61842648
2.31050789

Amount transfected
Novci

brPTB
2
4
6

0.5
0.5
0.5
0.5

2
4
6

st. dev
L/S
0.79096597 0.02262709
0.66855088 0.12686149
0.64904312 0.09897061
0.54203515 0.0639113
2.51007907 0.78176318
2.58680699 0.58484414
2.31079652 0.29277408
2.25947439 0.26894215
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